id	sid	tid	token	lemma	pos
dpc-3121	1	1	dermatology	dermatology	NOUN
dpc-3121	1	2	:	:	PUNCT
dpc-3121	1	3	practical	practical	ADJ
dpc-3121	1	4	and	and	CCONJ
dpc-3121	1	5	conceptual	conceptual	ADJ
dpc-3121	1	6	review	review	NOUN
dpc-3121	1	7	|	|	ADV
dpc-3121	1	8	dermatol	dermatol	ADJ
dpc-3121	1	9	pract	pract	NOUN
dpc-3121	1	10	concept	concept	NOUN
dpc-3121	1	11	.	.	PUNCT
dpc-3121	2	1	2023;13(4):e2023216	2023;13(4):e2023216	NUM
dpc-3121	2	2	1	1	NUM
dpc-3121	2	3	novel	novel	NOUN
dpc-3121	2	4	vehicles	vehicle	NOUN
dpc-3121	2	5	for	for	ADP
dpc-3121	2	6	drug	drug	NOUN
dpc-3121	2	7	delivery	delivery	NOUN
dpc-3121	2	8	in	in	ADP
dpc-3121	2	9	atopic	atopic	NOUN
dpc-3121	2	10	dermatitis	dermatitis	NOUN
dpc-3121	2	11	:	:	PUNCT
dpc-3121	2	12	a	a	DET
dpc-3121	2	13	narrative	narrative	NOUN
dpc-3121	2	14	review	review	NOUN
dpc-3121	2	15	christopher	christopher	PROPN
dpc-3121	2	16	farkouh1	farkouh1	PROPN
dpc-3121	2	17	,	,	PUNCT
dpc-3121	2	18	michelle	michelle	PROPN
dpc-3121	2	19	anthony2	anthony2	PROPN
dpc-3121	2	20	,	,	PUNCT
dpc-3121	2	21	parsa	parsa	PROPN
dpc-3121	2	22	abdi	abdi	PROPN
dpc-3121	2	23	3	3	NUM
dpc-3121	2	24	,	,	PUNCT
dpc-3121	2	25	natalia	natalia	PROPN
dpc-3121	2	26	santiago4	santiago4	PROPN
dpc-3121	2	27	,	,	PUNCT
dpc-3121	2	28	matthew	matthew	PROPN
dpc-3121	2	29	 	 	SPACE
dpc-3121	2	30	farkouh5	farkouh5	PROPN
dpc-3121	2	31	1	1	NUM
dpc-3121	2	32	rush	rush	NOUN
dpc-3121	2	33	medical	medical	ADJ
dpc-3121	2	34	college	college	PROPN
dpc-3121	2	35	,	,	PUNCT
dpc-3121	2	36	chicago	chicago	PROPN
dpc-3121	2	37	,	,	PUNCT
dpc-3121	2	38	il	il	PROPN
dpc-3121	2	39	,	,	PUNCT
dpc-3121	2	40	usa	usa	PROPN
dpc-3121	2	41	2	2	NUM
dpc-3121	2	42	university	university	PROPN
dpc-3121	2	43	of	of	ADP
dpc-3121	2	44	arizona	arizona	PROPN
dpc-3121	2	45	college	college	PROPN
dpc-3121	2	46	of	of	ADP
dpc-3121	2	47	medicine	medicine	NOUN
dpc-3121	2	48	,	,	PUNCT
dpc-3121	2	49	department	department	NOUN
dpc-3121	2	50	of	of	ADP
dpc-3121	2	51	pathology	pathology	PROPN
dpc-3121	2	52	,	,	PUNCT
dpc-3121	2	53	tucson	tucson	PROPN
dpc-3121	2	54	,	,	PUNCT
dpc-3121	2	55	az	az	PROPN
dpc-3121	2	56	,	,	PUNCT
dpc-3121	2	57	usa	usa	PROPN
dpc-3121	2	58	3	3	NUM
dpc-3121	2	59	memorial	memorial	ADJ
dpc-3121	2	60	university	university	NOUN
dpc-3121	2	61	,	,	PUNCT
dpc-3121	2	62	st	st	PROPN
dpc-3121	2	63	.	.	PROPN
dpc-3121	2	64	johns	johns	PROPN
dpc-3121	2	65	,	,	PUNCT
dpc-3121	2	66	newfoundland	newfoundland	PROPN
dpc-3121	2	67	,	,	PUNCT
dpc-3121	2	68	can	can	AUX
dpc-3121	2	69	4	4	NUM
dpc-3121	2	70	universidad	universidad	PROPN
dpc-3121	2	71	autónoma	autónoma	PROPN
dpc-3121	2	72	de	de	PROPN
dpc-3121	2	73	guadalajara	guadalajara	PROPN
dpc-3121	2	74	school	school	NOUN
dpc-3121	2	75	of	of	ADP
dpc-3121	2	76	medicine	medicine	NOUN
dpc-3121	2	77	,	,	PUNCT
dpc-3121	2	78	guadalajara	guadalajara	PROPN
dpc-3121	2	79	,	,	PUNCT
dpc-3121	2	80	mex	mex	PROPN
dpc-3121	2	81	5	5	NUM
dpc-3121	2	82	ponce	ponce	PROPN
dpc-3121	2	83	health	health	PROPN
dpc-3121	2	84	sciences	sciences	PROPN
dpc-3121	2	85	university	university	PROPN
dpc-3121	2	86	,	,	PUNCT
dpc-3121	2	87	ponce	ponce	NOUN
dpc-3121	2	88	,	,	PUNCT
dpc-3121	2	89	puerto	puerto	PROPN
dpc-3121	2	90	rico	rico	PROPN
dpc-3121	2	91	,	,	PUNCT
dpc-3121	2	92	usa	usa	PROPN
dpc-3121	2	93	key	key	NOUN
dpc-3121	2	94	words	word	NOUN
dpc-3121	2	95	:	:	PUNCT
dpc-3121	2	96	atopic	atopic	NOUN
dpc-3121	2	97	dermatitis	dermatitis	NOUN
dpc-3121	2	98	,	,	PUNCT
dpc-3121	2	99	vehicle	vehicle	NOUN
dpc-3121	2	100	,	,	PUNCT
dpc-3121	2	101	crisaborole	crisaborole	NOUN
dpc-3121	2	102	,	,	PUNCT
dpc-3121	2	103	tapinarof	tapinarof	NOUN
dpc-3121	2	104	citation	citation	NOUN
dpc-3121	2	105	:	:	PUNCT
dpc-3121	2	106	farkouh	farkouh	NOUN
dpc-3121	2	107	c	c	NOUN
dpc-3121	2	108	,	,	PUNCT
dpc-3121	2	109	anthony	anthony	PROPN
dpc-3121	2	110	m	m	PROPN
dpc-3121	2	111	,	,	PUNCT
dpc-3121	2	112	abdi	abdi	PROPN
dpc-3121	2	113	p	p	PROPN
dpc-3121	2	114	,	,	PUNCT
dpc-3121	2	115	santiago	santiago	PROPN
dpc-3121	2	116	n	n	CCONJ
dpc-3121	2	117	,	,	PUNCT
dpc-3121	2	118	farkouh	farkouh	NOUN
dpc-3121	2	119	m.	m.	NOUN
dpc-3121	2	120	novel	novel	NOUN
dpc-3121	2	121	vehicles	vehicle	NOUN
dpc-3121	2	122	for	for	ADP
dpc-3121	2	123	drug	drug	NOUN
dpc-3121	2	124	delivery	delivery	NOUN
dpc-3121	2	125	in	in	ADP
dpc-3121	2	126	atopic	atopic	NOUN
dpc-3121	2	127	dermatitis	dermatitis	NOUN
dpc-3121	2	128	:	:	PUNCT
dpc-3121	2	129	a	a	DET
dpc-3121	2	130	narrative	narrative	NOUN
dpc-3121	2	131	review	review	NOUN
dpc-3121	2	132	.	.	PUNCT
dpc-3121	3	1	dermatol	dermatol	NOUN
dpc-3121	3	2	pract	pract	PROPN
dpc-3121	3	3	concept	concept	NOUN
dpc-3121	3	4	.	.	PUNCT
dpc-3121	4	1	2023;13(4):e2023216	2023;13(4):e2023216	X
dpc-3121	4	2	.	.	X
dpc-3121	4	3	doi	doi	NOUN
dpc-3121	4	4	:	:	PUNCT
dpc-3121	4	5	https://doi.org/10.5826/dpc.1304a216	https://doi.org/10.5826/dpc.1304a216	PROPN
dpc-3121	4	6	accepted	accept	VERB
dpc-3121	4	7	:	:	PUNCT
dpc-3121	4	8	april	april	PROPN
dpc-3121	4	9	24	24	NUM
dpc-3121	4	10	,	,	PUNCT
dpc-3121	4	11	2023	2023	NUM
dpc-3121	4	12	;	;	PUNCT
dpc-3121	4	13	published	publish	VERB
dpc-3121	4	14	:	:	PUNCT
dpc-3121	4	15	october	october	PROPN
dpc-3121	4	16	2023	2023	NUM
dpc-3121	4	17	copyright	copyright	NOUN
dpc-3121	4	18	:	:	PUNCT
dpc-3121	4	19	©	©	PROPN
dpc-3121	4	20	2023	2023	NUM
dpc-3121	4	21	farkouh	farkouh	NOUN
dpc-3121	4	22	et	et	PROPN
dpc-3121	4	23	al	al	PROPN
dpc-3121	4	24	.	.	PUNCT
dpc-3121	5	1	this	this	PRON
dpc-3121	5	2	is	be	AUX
dpc-3121	5	3	an	an	DET
dpc-3121	5	4	open	open	ADJ
dpc-3121	5	5	-	-	PUNCT
dpc-3121	5	6	access	access	NOUN
dpc-3121	5	7	article	article	NOUN
dpc-3121	5	8	distributed	distribute	VERB
dpc-3121	5	9	under	under	ADP
dpc-3121	5	10	the	the	DET
dpc-3121	5	11	terms	term	NOUN
dpc-3121	5	12	of	of	ADP
dpc-3121	5	13	the	the	DET
dpc-3121	5	14	creative	creative	ADJ
dpc-3121	5	15	commons	common	NOUN
dpc-3121	5	16	attribution	attribution	NOUN
dpc-3121	5	17	-	-	PUNCT
dpc-3121	5	18	noncommercial	noncommercial	ADJ
dpc-3121	5	19	license	license	NOUN
dpc-3121	5	20	(	(	PUNCT
dpc-3121	5	21	by	by	ADP
dpc-3121	5	22	-	-	PUNCT
dpc-3121	5	23	nc-4.0	nc-4.0	NOUN
dpc-3121	5	24	)	)	PUNCT
dpc-3121	5	25	,	,	PUNCT
dpc-3121	5	26	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-3121	5	27	,	,	PUNCT
dpc-3121	5	28	which	which	PRON
dpc-3121	5	29	permits	permit	VERB
dpc-3121	5	30	unrestricted	unrestricted	ADJ
dpc-3121	5	31	noncommercial	noncommercial	ADJ
dpc-3121	5	32	use	use	NOUN
dpc-3121	5	33	,	,	PUNCT
dpc-3121	5	34	distribution	distribution	NOUN
dpc-3121	5	35	,	,	PUNCT
dpc-3121	5	36	and	and	CCONJ
dpc-3121	5	37	reproduction	reproduction	NOUN
dpc-3121	5	38	in	in	ADP
dpc-3121	5	39	any	any	DET
dpc-3121	5	40	medium	medium	NOUN
dpc-3121	5	41	,	,	PUNCT
dpc-3121	5	42	provided	provide	VERB
dpc-3121	5	43	the	the	DET
dpc-3121	5	44	original	original	ADJ
dpc-3121	5	45	authors	author	NOUN
dpc-3121	5	46	and	and	CCONJ
dpc-3121	5	47	source	source	NOUN
dpc-3121	5	48	are	be	AUX
dpc-3121	5	49	credited	credit	VERB
dpc-3121	5	50	.	.	PUNCT
dpc-3121	6	1	funding	funding	NOUN
dpc-3121	6	2	:	:	PUNCT
dpc-3121	6	3	none	none	NOUN
dpc-3121	6	4	.	.	PUNCT
dpc-3121	7	1	competing	compete	VERB
dpc-3121	7	2	interests	interest	NOUN
dpc-3121	7	3	:	:	PUNCT
dpc-3121	7	4	none	none	NOUN
dpc-3121	7	5	.	.	PUNCT
dpc-3121	8	1	authorship	authorship	NOUN
dpc-3121	8	2	:	:	PUNCT
dpc-3121	8	3	all	all	DET
dpc-3121	8	4	authors	author	NOUN
dpc-3121	8	5	have	have	AUX
dpc-3121	8	6	contributed	contribute	VERB
dpc-3121	8	7	significantly	significantly	ADV
dpc-3121	8	8	to	to	ADP
dpc-3121	8	9	this	this	DET
dpc-3121	8	10	publication	publication	NOUN
dpc-3121	8	11	.	.	PUNCT
dpc-3121	9	1	corresponding	correspond	VERB
dpc-3121	9	2	author	author	NOUN
dpc-3121	9	3	:	:	PUNCT
dpc-3121	9	4	christopher	christopher	PROPN
dpc-3121	9	5	farkouh	farkouh	PROPN
dpc-3121	9	6	,	,	PUNCT
dpc-3121	9	7	bs	b	NOUN
dpc-3121	9	8	,	,	PUNCT
dpc-3121	9	9	1035	1035	NUM
dpc-3121	9	10	west	west	PROPN
dpc-3121	9	11	van	van	PROPN
dpc-3121	9	12	buren	buren	PROPN
dpc-3121	9	13	street	street	PROPN
dpc-3121	9	14	,	,	PUNCT
dpc-3121	9	15	chicago	chicago	PROPN
dpc-3121	9	16	,	,	PUNCT
dpc-3121	9	17	il	il	PROPN
dpc-3121	9	18	60607	60607	NUM
dpc-3121	9	19	.	.	PUNCT
dpc-3121	10	1	phone	phone	NOUN
dpc-3121	10	2	:	:	PUNCT
dpc-3121	10	3	(	(	PUNCT
dpc-3121	10	4	732	732	NUM
dpc-3121	10	5	)	)	PUNCT
dpc-3121	10	6	882	882	NUM
dpc-3121	10	7	-	-	SYM
dpc-3121	10	8	6414	6414	NUM
dpc-3121	10	9	email	email	NOUN
dpc-3121	10	10	:	:	PUNCT
dpc-3121	10	11	christopher_s_farkouh@rush.edu	christopher_s_farkouh@rush.edu	PROPN
dpc-3121	10	12	introduction	introduction	NOUN
dpc-3121	10	13	:	:	PUNCT
dpc-3121	10	14	atopic	atopic	NOUN
dpc-3121	10	15	dermatitis	dermatitis	NOUN
dpc-3121	10	16	(	(	PUNCT
dpc-3121	10	17	ad	ad	NOUN
dpc-3121	10	18	)	)	PUNCT
dpc-3121	10	19	causes	cause	VERB
dpc-3121	10	20	dry	dry	ADJ
dpc-3121	10	21	and	and	CCONJ
dpc-3121	10	22	itchy	itchy	ADJ
dpc-3121	10	23	skin	skin	NOUN
dpc-3121	10	24	and	and	CCONJ
dpc-3121	10	25	inflammation	inflammation	NOUN
dpc-3121	10	26	that	that	PRON
dpc-3121	10	27	severely	severely	ADV
dpc-3121	10	28	impairs	impair	VERB
dpc-3121	10	29	the	the	DET
dpc-3121	10	30	quality	quality	NOUN
dpc-3121	10	31	of	of	ADP
dpc-3121	10	32	life	life	NOUN
dpc-3121	10	33	of	of	ADP
dpc-3121	10	34	affected	affected	ADJ
dpc-3121	10	35	children	child	NOUN
dpc-3121	10	36	and	and	CCONJ
dpc-3121	10	37	adults	adult	NOUN
dpc-3121	10	38	.	.	PUNCT
dpc-3121	11	1	while	while	SCONJ
dpc-3121	11	2	topical	topical	ADJ
dpc-3121	11	3	glucocorticosteroid	glucocorticosteroid	NOUN
dpc-3121	11	4	application	application	NOUN
dpc-3121	11	5	is	be	AUX
dpc-3121	11	6	typically	typically	ADV
dpc-3121	11	7	the	the	DET
dpc-3121	11	8	first	first	ADJ
dpc-3121	11	9	-	-	PUNCT
dpc-3121	11	10	line	line	NOUN
dpc-3121	11	11	treatment	treatment	NOUN
dpc-3121	11	12	of	of	ADP
dpc-3121	11	13	choice	choice	NOUN
dpc-3121	11	14	,	,	PUNCT
dpc-3121	11	15	steroid	steroid	NOUN
dpc-3121	11	16	treatment	treatment	NOUN
dpc-3121	11	17	is	be	AUX
dpc-3121	11	18	associated	associate	VERB
dpc-3121	11	19	with	with	ADP
dpc-3121	11	20	side	side	NOUN
dpc-3121	11	21	effects	effect	NOUN
dpc-3121	11	22	and	and	CCONJ
dpc-3121	11	23	,	,	PUNCT
dpc-3121	11	24	increasingly	increasingly	ADV
dpc-3121	11	25	,	,	PUNCT
dpc-3121	11	26	patient	patient	ADJ
dpc-3121	11	27	concerns	concern	NOUN
dpc-3121	11	28	about	about	ADP
dpc-3121	11	29	prolonged	prolonged	ADJ
dpc-3121	11	30	use	use	NOUN
dpc-3121	11	31	.	.	PUNCT
dpc-3121	12	1	novel	novel	ADJ
dpc-3121	12	2	drugs	drug	NOUN
dpc-3121	12	3	and	and	CCONJ
dpc-3121	12	4	drug	drug	NOUN
dpc-3121	12	5	delivery	delivery	NOUN
dpc-3121	12	6	vehicles	vehicle	NOUN
dpc-3121	12	7	are	be	AUX
dpc-3121	12	8	required	require	VERB
dpc-3121	12	9	for	for	ADP
dpc-3121	12	10	patients	patient	NOUN
dpc-3121	12	11	with	with	ADP
dpc-3121	12	12	ad	ad	NOUN
dpc-3121	12	13	.	.	PUNCT
dpc-3121	13	1	objectives	objective	NOUN
dpc-3121	13	2	:	:	PUNCT
dpc-3121	13	3	to	to	PART
dpc-3121	13	4	summarize	summarize	VERB
dpc-3121	13	5	the	the	DET
dpc-3121	13	6	current	current	ADJ
dpc-3121	13	7	literature	literature	NOUN
dpc-3121	13	8	on	on	ADP
dpc-3121	13	9	novel	novel	ADJ
dpc-3121	13	10	topical	topical	ADJ
dpc-3121	13	11	agents	agent	NOUN
dpc-3121	13	12	for	for	ADP
dpc-3121	13	13	atopic	atopic	NOUN
dpc-3121	13	14	dermatitis	dermatitis	NOUN
dpc-3121	13	15	and	and	CCONJ
dpc-3121	13	16	novel	novel	ADJ
dpc-3121	13	17	delivery	delivery	NOUN
dpc-3121	13	18	vehicles	vehicle	NOUN
dpc-3121	13	19	.	.	PUNCT
dpc-3121	14	1	methods	method	NOUN
dpc-3121	14	2	:	:	PUNCT
dpc-3121	14	3	a	a	DET
dpc-3121	14	4	literature	literature	NOUN
dpc-3121	14	5	search	search	NOUN
dpc-3121	14	6	was	be	AUX
dpc-3121	14	7	conducted	conduct	VERB
dpc-3121	14	8	,	,	PUNCT
dpc-3121	14	9	and	and	CCONJ
dpc-3121	14	10	a	a	DET
dpc-3121	14	11	narrative	narrative	NOUN
dpc-3121	14	12	review	review	NOUN
dpc-3121	14	13	was	be	AUX
dpc-3121	14	14	compiled	compile	VERB
dpc-3121	14	15	to	to	PART
dpc-3121	14	16	summarize	summarize	VERB
dpc-3121	14	17	recent	recent	ADJ
dpc-3121	14	18	evidence	evidence	NOUN
dpc-3121	14	19	.	.	PUNCT
dpc-3121	15	1	results	result	NOUN
dpc-3121	15	2	:	:	PUNCT
dpc-3121	15	3	novel	novel	ADJ
dpc-3121	15	4	topical	topical	ADJ
dpc-3121	15	5	drugs	drug	NOUN
dpc-3121	15	6	approved	approve	VERB
dpc-3121	15	7	or	or	CCONJ
dpc-3121	15	8	in	in	ADP
dpc-3121	15	9	late	late	ADJ
dpc-3121	15	10	-	-	PUNCT
dpc-3121	15	11	phase	phase	NOUN
dpc-3121	15	12	clinical	clinical	ADJ
dpc-3121	15	13	trials	trial	NOUN
dpc-3121	15	14	for	for	ADP
dpc-3121	15	15	the	the	DET
dpc-3121	15	16	treatment	treatment	NOUN
dpc-3121	15	17	of	of	ADP
dpc-3121	15	18	ad	ad	NOUN
dpc-3121	15	19	include	include	VERB
dpc-3121	15	20	the	the	DET
dpc-3121	15	21	janus	janus	PROPN
dpc-3121	15	22	kinase	kinase	PROPN
dpc-3121	15	23	inhibitor	inhibitor	PROPN
dpc-3121	15	24	ruxolitinib	ruxolitinib	PROPN
dpc-3121	15	25	,	,	PUNCT
dpc-3121	15	26	the	the	DET
dpc-3121	15	27	phosphodiesterase-4	phosphodiesterase-4	NOUN
dpc-3121	15	28	inhibitors	inhibitor	NOUN
dpc-3121	15	29	crisaborole	crisaborole	NOUN
dpc-3121	15	30	,	,	PUNCT
dpc-3121	15	31	and	and	CCONJ
dpc-3121	15	32	roflumilast	roflumilast	NOUN
dpc-3121	15	33	,	,	PUNCT
dpc-3121	15	34	and	and	CCONJ
dpc-3121	15	35	the	the	DET
dpc-3121	15	36	aryl	aryl	NOUN
dpc-3121	15	37	hydrocarbon	hydrocarbon	NOUN
dpc-3121	15	38	receptor	receptor	NOUN
dpc-3121	15	39	activator	activator	NOUN
dpc-3121	15	40	tapinarof	tapinarof	NOUN
dpc-3121	15	41	.	.	PUNCT
dpc-3121	16	1	while	while	SCONJ
dpc-3121	16	2	current	current	ADJ
dpc-3121	16	3	topical	topical	ADJ
dpc-3121	16	4	drugs	drug	NOUN
dpc-3121	16	5	for	for	ADP
dpc-3121	16	6	ad	ad	NOUN
dpc-3121	16	7	are	be	AUX
dpc-3121	16	8	delivered	deliver	VERB
dpc-3121	16	9	via	via	ADP
dpc-3121	16	10	creams	cream	NOUN
dpc-3121	16	11	,	,	PUNCT
dpc-3121	16	12	ointments	ointment	NOUN
dpc-3121	16	13	,	,	PUNCT
dpc-3121	16	14	gels	gel	NOUN
dpc-3121	16	15	,	,	PUNCT
dpc-3121	16	16	and	and	CCONJ
dpc-3121	16	17	related	related	ADJ
dpc-3121	16	18	vehicles	vehicle	NOUN
dpc-3121	16	19	,	,	PUNCT
dpc-3121	16	20	novel	novel	ADJ
dpc-3121	16	21	delivery	delivery	NOUN
dpc-3121	16	22	approaches	approach	VERB
dpc-3121	16	23	such	such	ADJ
dpc-3121	16	24	as	as	ADP
dpc-3121	16	25	electrospun	electrospun	NOUN
dpc-3121	16	26	patches	patch	NOUN
dpc-3121	16	27	,	,	PUNCT
dpc-3121	16	28	sprays	spray	NOUN
dpc-3121	16	29	,	,	PUNCT
dpc-3121	16	30	liposomes	liposome	NOUN
dpc-3121	16	31	,	,	PUNCT
dpc-3121	16	32	nanoparticles	nanoparticle	NOUN
dpc-3121	16	33	,	,	PUNCT
dpc-3121	16	34	and	and	CCONJ
dpc-3121	16	35	lasers	laser	NOUN
dpc-3121	16	36	are	be	AUX
dpc-3121	16	37	being	be	AUX
dpc-3121	16	38	developed	develop	VERB
dpc-3121	16	39	to	to	PART
dpc-3121	16	40	enhance	enhance	VERB
dpc-3121	16	41	transdermal	transdermal	ADJ
dpc-3121	16	42	delivery	delivery	NOUN
dpc-3121	16	43	,	,	PUNCT
dpc-3121	16	44	reduce	reduce	VERB
dpc-3121	16	45	side	side	NOUN
dpc-3121	16	46	effects	effect	NOUN
dpc-3121	16	47	,	,	PUNCT
dpc-3121	16	48	and	and	CCONJ
dpc-3121	16	49	increase	increase	VERB
dpc-3121	16	50	treatment	treatment	NOUN
dpc-3121	16	51	adherence	adherence	NOUN
dpc-3121	16	52	.	.	PUNCT
dpc-3121	17	1	abstract	abstract	ADJ
dpc-3121	17	2	2	2	NUM
dpc-3121	17	3	review	review	NOUN
dpc-3121	17	4	|	|	ADV
dpc-3121	17	5	dermatol	dermatol	ADJ
dpc-3121	17	6	pract	pract	NOUN
dpc-3121	17	7	concept	concept	NOUN
dpc-3121	17	8	.	.	PUNCT
dpc-3121	18	1	2023;13(4):e2023216	2023;13(4):e2023216	NUM
dpc-3121	18	2	conclusions	conclusion	NOUN
dpc-3121	18	3	:	:	PUNCT
dpc-3121	18	4	topical	topical	ADJ
dpc-3121	18	5	application	application	NOUN
dpc-3121	18	6	of	of	ADP
dpc-3121	18	7	creams	cream	NOUN
dpc-3121	18	8	or	or	CCONJ
dpc-3121	18	9	ointments	ointment	NOUN
dpc-3121	18	10	is	be	AUX
dpc-3121	18	11	currently	currently	ADV
dpc-3121	18	12	the	the	DET
dpc-3121	18	13	predominant	predominant	ADJ
dpc-3121	18	14	vehicle	vehicle	NOUN
dpc-3121	18	15	for	for	ADP
dpc-3121	18	16	the	the	DET
dpc-3121	18	17	delivery	delivery	NOUN
dpc-3121	18	18	of	of	ADP
dpc-3121	18	19	atopic	atopic	NOUN
dpc-3121	18	20	dermatitis	dermatitis	NOUN
dpc-3121	18	21	drugs	drug	NOUN
dpc-3121	18	22	.	.	PUNCT
dpc-3121	19	1	in	in	ADP
dpc-3121	19	2	vitro	vitro	X
dpc-3121	19	3	studies	study	NOUN
dpc-3121	19	4	on	on	ADP
dpc-3121	19	5	novel	novel	ADJ
dpc-3121	19	6	vehicles	vehicle	NOUN
dpc-3121	19	7	show	show	VERB
dpc-3121	19	8	promising	promise	VERB
dpc-3121	19	9	results	result	NOUN
dpc-3121	19	10	to	to	PART
dpc-3121	19	11	overcome	overcome	VERB
dpc-3121	19	12	the	the	DET
dpc-3121	19	13	issues	issue	NOUN
dpc-3121	19	14	associated	associate	VERB
dpc-3121	19	15	with	with	ADP
dpc-3121	19	16	topical	topical	ADJ
dpc-3121	19	17	delivery	delivery	NOUN
dpc-3121	19	18	.	.	PUNCT
dpc-3121	20	1	still	still	ADV
dpc-3121	20	2	,	,	PUNCT
dpc-3121	20	3	these	these	DET
dpc-3121	20	4	findings	finding	NOUN
dpc-3121	20	5	have	have	VERB
dpc-3121	20	6	to	to	PART
dpc-3121	20	7	be	be	AUX
dpc-3121	20	8	corroborated	corroborate	VERB
dpc-3121	20	9	by	by	ADP
dpc-3121	20	10	controlled	control	VERB
dpc-3121	20	11	studies	study	NOUN
dpc-3121	20	12	with	with	ADP
dpc-3121	20	13	human	human	ADJ
dpc-3121	20	14	patients	patient	NOUN
dpc-3121	20	15	in	in	ADP
dpc-3121	20	16	the	the	DET
dpc-3121	20	17	future	future	NOUN
dpc-3121	20	18	.	.	PUNCT
dpc-3121	21	1	introduction	introduction	NOUN
dpc-3121	21	2	atopic	atopic	NOUN
dpc-3121	21	3	dermatitis	dermatitis	PROPN
dpc-3121	21	4	(	(	PUNCT
dpc-3121	21	5	ad	ad	NOUN
dpc-3121	21	6	)	)	PUNCT
dpc-3121	21	7	is	be	AUX
dpc-3121	21	8	a	a	DET
dpc-3121	21	9	chronic	chronic	ADJ
dpc-3121	21	10	cutaneous	cutaneous	ADJ
dpc-3121	21	11	disorder	disorder	NOUN
dpc-3121	21	12	that	that	PRON
dpc-3121	21	13	affects	affect	VERB
dpc-3121	21	14	up	up	ADV
dpc-3121	21	15	to	to	PART
dpc-3121	21	16	30	30	NUM
dpc-3121	21	17	%	%	NOUN
dpc-3121	21	18	of	of	ADP
dpc-3121	21	19	children	child	NOUN
dpc-3121	21	20	and	and	CCONJ
dpc-3121	21	21	20	20	NUM
dpc-3121	21	22	%	%	NOUN
dpc-3121	21	23	of	of	ADP
dpc-3121	21	24	adults	adult	NOUN
dpc-3121	21	25	depending	depend	VERB
dpc-3121	21	26	on	on	ADP
dpc-3121	21	27	the	the	DET
dpc-3121	21	28	geographical	geographical	ADJ
dpc-3121	21	29	region	region	NOUN
dpc-3121	22	1	[	[	X
dpc-3121	22	2	1,2	1,2	NUM
dpc-3121	22	3	]	]	PUNCT
dpc-3121	22	4	.	.	PUNCT
dpc-3121	23	1	this	this	DET
dpc-3121	23	2	chronic	chronic	ADJ
dpc-3121	23	3	type	type	NOUN
dpc-3121	23	4	of	of	ADP
dpc-3121	23	5	eczema	eczema	NOUN
dpc-3121	23	6	is	be	AUX
dpc-3121	23	7	characterized	characterize	VERB
dpc-3121	23	8	by	by	ADP
dpc-3121	23	9	dry	dry	ADJ
dpc-3121	23	10	skin	skin	NOUN
dpc-3121	23	11	,	,	PUNCT
dpc-3121	23	12	pruritus	pruritus	NOUN
dpc-3121	23	13	,	,	PUNCT
dpc-3121	23	14	eczematous	eczematous	ADJ
dpc-3121	23	15	lesions	lesion	NOUN
dpc-3121	23	16	,	,	PUNCT
dpc-3121	23	17	and	and	CCONJ
dpc-3121	23	18	lichenification	lichenification	NOUN
dpc-3121	24	1	[	[	X
dpc-3121	24	2	3,4	3,4	NUM
dpc-3121	24	3	]	]	PUNCT
dpc-3121	24	4	.	.	PUNCT
dpc-3121	25	1	the	the	DET
dpc-3121	25	2	multifactorial	multifactorial	ADJ
dpc-3121	25	3	etiology	etiology	NOUN
dpc-3121	25	4	of	of	ADP
dpc-3121	25	5	ad	ad	NOUN
dpc-3121	25	6	entails	entail	VERB
dpc-3121	25	7	genetic	genetic	ADJ
dpc-3121	25	8	predisposition	predisposition	NOUN
dpc-3121	25	9	,	,	PUNCT
dpc-3121	25	10	environmental	environmental	ADJ
dpc-3121	25	11	factors	factor	NOUN
dpc-3121	25	12	,	,	PUNCT
dpc-3121	25	13	and	and	CCONJ
dpc-3121	25	14	hypersensitivity	hypersensitivity	NOUN
dpc-3121	25	15	against	against	ADP
dpc-3121	25	16	certain	certain	ADJ
dpc-3121	25	17	environmental	environmental	ADJ
dpc-3121	25	18	allergens	allergen	NOUN
dpc-3121	25	19	[	[	X
dpc-3121	25	20	5	5	NUM
dpc-3121	25	21	]	]	PUNCT
dpc-3121	25	22	.	.	PUNCT
dpc-3121	26	1	the	the	DET
dpc-3121	26	2	skin	skin	NOUN
dpc-3121	26	3	barrier	barrier	NOUN
dpc-3121	26	4	is	be	AUX
dpc-3121	26	5	characterized	characterize	VERB
dpc-3121	26	6	by	by	ADP
dpc-3121	26	7	increased	increase	VERB
dpc-3121	26	8	permeability	permeability	NOUN
dpc-3121	26	9	,	,	PUNCT
dpc-3121	26	10	with	with	ADP
dpc-3121	26	11	disturbances	disturbance	NOUN
dpc-3121	26	12	in	in	ADP
dpc-3121	26	13	ceramide	ceramide	NOUN
dpc-3121	26	14	metabolism	metabolism	NOUN
dpc-3121	26	15	and	and	CCONJ
dpc-3121	26	16	composition	composition	NOUN
dpc-3121	26	17	fairly	fairly	ADV
dpc-3121	26	18	common	common	ADJ
dpc-3121	26	19	in	in	ADP
dpc-3121	26	20	ad	ad	NOUN
dpc-3121	26	21	.	.	PUNCT
dpc-3121	27	1	this	this	DET
dpc-3121	27	2	increased	increase	VERB
dpc-3121	27	3	permeability	permeability	NOUN
dpc-3121	27	4	of	of	ADP
dpc-3121	27	5	the	the	DET
dpc-3121	27	6	skin	skin	NOUN
dpc-3121	27	7	allows	allow	VERB
dpc-3121	27	8	for	for	ADP
dpc-3121	27	9	the	the	DET
dpc-3121	27	10	entry	entry	NOUN
dpc-3121	27	11	of	of	ADP
dpc-3121	27	12	irritants	irritant	NOUN
dpc-3121	27	13	,	,	PUNCT
dpc-3121	27	14	allergens	allergen	NOUN
dpc-3121	27	15	,	,	PUNCT
dpc-3121	27	16	and	and	CCONJ
dpc-3121	27	17	pathogens	pathogen	NOUN
dpc-3121	27	18	,	,	PUNCT
dpc-3121	27	19	leading	lead	VERB
dpc-3121	27	20	to	to	ADP
dpc-3121	27	21	inflammation	inflammation	NOUN
dpc-3121	27	22	[	[	X
dpc-3121	27	23	6	6	NUM
dpc-3121	27	24	]	]	PUNCT
dpc-3121	27	25	.	.	PUNCT
dpc-3121	28	1	the	the	DET
dpc-3121	28	2	clinical	clinical	ADJ
dpc-3121	28	3	diagnosis	diagnosis	NOUN
dpc-3121	28	4	follows	follow	VERB
dpc-3121	28	5	the	the	DET
dpc-3121	28	6	evaluation	evaluation	NOUN
dpc-3121	28	7	of	of	ADP
dpc-3121	28	8	essential	essential	ADJ
dpc-3121	28	9	ad	ad	NOUN
dpc-3121	28	10	features	feature	NOUN
dpc-3121	28	11	(	(	PUNCT
dpc-3121	28	12	pruritus	pruritus	PROPN
dpc-3121	28	13	,	,	PUNCT
dpc-3121	28	14	eczematous	eczematous	ADJ
dpc-3121	28	15	morphology	morphology	NOUN
dpc-3121	28	16	,	,	PUNCT
dpc-3121	28	17	chronicity	chronicity	NOUN
dpc-3121	28	18	)	)	PUNCT
dpc-3121	28	19	,	,	PUNCT
dpc-3121	28	20	crucial	crucial	ADJ
dpc-3121	28	21	features	feature	NOUN
dpc-3121	28	22	(	(	PUNCT
dpc-3121	28	23	early	early	ADJ
dpc-3121	28	24	age	age	NOUN
dpc-3121	28	25	of	of	ADP
dpc-3121	28	26	onset	onset	NOUN
dpc-3121	28	27	,	,	PUNCT
dpc-3121	28	28	xerosis	xerosis	NOUN
dpc-3121	28	29	,	,	PUNCT
dpc-3121	28	30	atopy	atopy	NOUN
dpc-3121	28	31	)	)	PUNCT
dpc-3121	28	32	,	,	PUNCT
dpc-3121	28	33	and	and	CCONJ
dpc-3121	28	34	several	several	ADJ
dpc-3121	28	35	associated	associated	ADJ
dpc-3121	28	36	features	feature	NOUN
dpc-3121	28	37	[	[	X
dpc-3121	28	38	4	4	NUM
dpc-3121	28	39	]	]	PUNCT
dpc-3121	28	40	.	.	PUNCT
dpc-3121	29	1	treatment	treatment	NOUN
dpc-3121	29	2	options	option	NOUN
dpc-3121	29	3	are	be	AUX
dpc-3121	29	4	individually	individually	ADV
dpc-3121	29	5	chosen	choose	VERB
dpc-3121	29	6	and	and	CCONJ
dpc-3121	29	7	encompass	encompass	VERB
dpc-3121	29	8	topical	topical	ADJ
dpc-3121	29	9	therapies	therapy	NOUN
dpc-3121	29	10	,	,	PUNCT
dpc-3121	29	11	phototherapy	phototherapy	NOUN
dpc-3121	29	12	,	,	PUNCT
dpc-3121	29	13	systemic	systemic	ADJ
dpc-3121	29	14	agents	agent	NOUN
dpc-3121	29	15	,	,	PUNCT
dpc-3121	29	16	or	or	CCONJ
dpc-3121	29	17	a	a	DET
dpc-3121	29	18	combination	combination	NOUN
dpc-3121	29	19	thereof	thereof	ADV
dpc-3121	29	20	[	[	X
dpc-3121	29	21	4,7	4,7	NUM
dpc-3121	29	22	]	]	PUNCT
dpc-3121	29	23	.	.	PUNCT
dpc-3121	30	1	each	each	PRON
dpc-3121	30	2	of	of	ADP
dpc-3121	30	3	these	these	DET
dpc-3121	30	4	therapeutic	therapeutic	ADJ
dpc-3121	30	5	approaches	approach	NOUN
dpc-3121	30	6	has	have	VERB
dpc-3121	30	7	risks	risk	NOUN
dpc-3121	30	8	,	,	PUNCT
dpc-3121	30	9	benefits	benefit	NOUN
dpc-3121	30	10	,	,	PUNCT
dpc-3121	30	11	and	and	CCONJ
dpc-3121	30	12	limitations	limitation	NOUN
dpc-3121	30	13	.	.	PUNCT
dpc-3121	31	1	for	for	ADP
dpc-3121	31	2	topical	topical	ADJ
dpc-3121	31	3	preparations	preparation	NOUN
dpc-3121	31	4	,	,	PUNCT
dpc-3121	31	5	the	the	DET
dpc-3121	31	6	vehicle	vehicle	NOUN
dpc-3121	31	7	by	by	ADP
dpc-3121	31	8	which	which	PRON
dpc-3121	31	9	a	a	DET
dpc-3121	31	10	drug	drug	NOUN
dpc-3121	31	11	is	be	AUX
dpc-3121	31	12	administered	administer	VERB
dpc-3121	31	13	maintains	maintain	VERB
dpc-3121	31	14	a	a	DET
dpc-3121	31	15	central	central	ADJ
dpc-3121	31	16	role	role	NOUN
dpc-3121	31	17	in	in	ADP
dpc-3121	31	18	the	the	DET
dpc-3121	31	19	treatment	treatment	NOUN
dpc-3121	31	20	outcome	outcome	NOUN
dpc-3121	31	21	because	because	SCONJ
dpc-3121	31	22	efficient	efficient	ADJ
dpc-3121	31	23	and	and	CCONJ
dpc-3121	31	24	selective	selective	ADJ
dpc-3121	31	25	delivery	delivery	NOUN
dpc-3121	31	26	of	of	ADP
dpc-3121	31	27	the	the	DET
dpc-3121	31	28	pharmacologically	pharmacologically	ADV
dpc-3121	31	29	active	active	ADJ
dpc-3121	31	30	ingredient	ingredient	NOUN
dpc-3121	31	31	to	to	ADP
dpc-3121	31	32	the	the	DET
dpc-3121	31	33	target	target	NOUN
dpc-3121	31	34	site	site	NOUN
dpc-3121	31	35	determines	determine	VERB
dpc-3121	31	36	its	its	PRON
dpc-3121	31	37	efficacy	efficacy	NOUN
dpc-3121	31	38	.	.	PUNCT
dpc-3121	32	1	simultaneously	simultaneously	ADV
dpc-3121	32	2	,	,	PUNCT
dpc-3121	32	3	the	the	DET
dpc-3121	32	4	tolerability	tolerability	NOUN
dpc-3121	32	5	of	of	ADP
dpc-3121	32	6	a	a	DET
dpc-3121	32	7	product	product	NOUN
dpc-3121	32	8	and	and	CCONJ
dpc-3121	32	9	its	its	PRON
dpc-3121	32	10	cosmetic	cosmetic	ADJ
dpc-3121	32	11	acceptability	acceptability	NOUN
dpc-3121	32	12	play	play	VERB
dpc-3121	32	13	outsized	outsized	ADJ
dpc-3121	32	14	roles	role	NOUN
dpc-3121	32	15	as	as	SCONJ
dpc-3121	32	16	it	it	PRON
dpc-3121	32	17	is	be	AUX
dpc-3121	32	18	incumbent	incumbent	ADJ
dpc-3121	32	19	upon	upon	SCONJ
dpc-3121	32	20	the	the	DET
dpc-3121	32	21	patient	patient	NOUN
dpc-3121	32	22	to	to	PART
dpc-3121	32	23	apply	apply	VERB
dpc-3121	32	24	the	the	DET
dpc-3121	32	25	treatment	treatment	NOUN
dpc-3121	32	26	for	for	SCONJ
dpc-3121	32	27	it	it	PRON
dpc-3121	32	28	to	to	PART
dpc-3121	32	29	work	work	VERB
dpc-3121	32	30	regularly	regularly	ADV
dpc-3121	32	31	.	.	PUNCT
dpc-3121	33	1	the	the	DET
dpc-3121	33	2	most	most	ADV
dpc-3121	33	3	common	common	ADJ
dpc-3121	33	4	vehicles	vehicle	NOUN
dpc-3121	33	5	for	for	ADP
dpc-3121	33	6	ad	ad	NOUN
dpc-3121	33	7	topical	topical	ADJ
dpc-3121	33	8	therapies	therapy	NOUN
dpc-3121	33	9	are	be	AUX
dpc-3121	33	10	creams	cream	NOUN
dpc-3121	33	11	or	or	CCONJ
dpc-3121	33	12	ointments	ointment	NOUN
dpc-3121	33	13	.	.	PUNCT
dpc-3121	34	1	nonetheless	nonetheless	ADV
dpc-3121	34	2	,	,	PUNCT
dpc-3121	34	3	topical	topical	ADJ
dpc-3121	34	4	and	and	CCONJ
dpc-3121	34	5	systemic	systemic	ADJ
dpc-3121	34	6	side	side	NOUN
dpc-3121	34	7	effects	effect	NOUN
dpc-3121	34	8	are	be	AUX
dpc-3121	34	9	of	of	ADP
dpc-3121	34	10	concern	concern	NOUN
dpc-3121	34	11	with	with	ADP
dpc-3121	34	12	these	these	DET
dpc-3121	34	13	vehicles	vehicle	NOUN
dpc-3121	34	14	,	,	PUNCT
dpc-3121	34	15	and	and	CCONJ
dpc-3121	34	16	their	their	PRON
dpc-3121	34	17	clinical	clinical	ADJ
dpc-3121	34	18	efficacy	efficacy	NOUN
dpc-3121	34	19	varies	vary	VERB
dpc-3121	34	20	due	due	ADJ
dpc-3121	34	21	to	to	ADP
dpc-3121	34	22	the	the	DET
dpc-3121	34	23	complete	complete	ADJ
dpc-3121	34	24	application	application	NOUN
dpc-3121	34	25	on	on	ADP
dpc-3121	34	26	the	the	DET
dpc-3121	34	27	skin	skin	NOUN
dpc-3121	34	28	[	[	X
dpc-3121	34	29	4,8	4,8	NUM
dpc-3121	34	30	]	]	PUNCT
dpc-3121	34	31	.	.	PUNCT
dpc-3121	35	1	therefore	therefore	ADV
dpc-3121	35	2	,	,	PUNCT
dpc-3121	35	3	long	long	ADJ
dpc-3121	35	4	-	-	PUNCT
dpc-3121	35	5	term	term	NOUN
dpc-3121	35	6	use	use	NOUN
dpc-3121	35	7	of	of	ADP
dpc-3121	35	8	topical	topical	ADJ
dpc-3121	35	9	agents	agent	NOUN
dpc-3121	35	10	,	,	PUNCT
dpc-3121	35	11	particularly	particularly	ADV
dpc-3121	35	12	steroidal	steroidal	NOUN
dpc-3121	35	13	drugs	drug	NOUN
dpc-3121	35	14	,	,	PUNCT
dpc-3121	35	15	is	be	AUX
dpc-3121	35	16	not	not	PART
dpc-3121	35	17	recommended	recommend	VERB
dpc-3121	35	18	,	,	PUNCT
dpc-3121	35	19	and	and	CCONJ
dpc-3121	35	20	novel	novel	NOUN
dpc-3121	35	21	or	or	CCONJ
dpc-3121	35	22	improved	improved	ADJ
dpc-3121	35	23	vehicles	vehicle	NOUN
dpc-3121	35	24	are	be	AUX
dpc-3121	35	25	developed	develop	VERB
dpc-3121	35	26	to	to	PART
dpc-3121	35	27	increase	increase	VERB
dpc-3121	35	28	the	the	DET
dpc-3121	35	29	transport	transport	NOUN
dpc-3121	35	30	of	of	ADP
dpc-3121	35	31	the	the	DET
dpc-3121	35	32	active	active	ADJ
dpc-3121	35	33	ingredient	ingredient	NOUN
dpc-3121	35	34	to	to	ADP
dpc-3121	35	35	a	a	DET
dpc-3121	35	36	specific	specific	ADJ
dpc-3121	35	37	target	target	NOUN
dpc-3121	35	38	site	site	NOUN
dpc-3121	35	39	and	and	CCONJ
dpc-3121	35	40	the	the	DET
dpc-3121	35	41	drug	drug	NOUN
dpc-3121	35	42	efficacy	efficacy	NOUN
dpc-3121	36	1	[	[	X
dpc-3121	36	2	4	4	NUM
dpc-3121	36	3	]	]	PUNCT
dpc-3121	36	4	.	.	PUNCT
dpc-3121	37	1	objectives	objective	NOUN
dpc-3121	37	2	in	in	ADP
dpc-3121	37	3	the	the	DET
dpc-3121	37	4	present	present	ADJ
dpc-3121	37	5	review	review	NOUN
dpc-3121	37	6	,	,	PUNCT
dpc-3121	37	7	the	the	DET
dpc-3121	37	8	current	current	ADJ
dpc-3121	37	9	literature	literature	NOUN
dpc-3121	37	10	on	on	ADP
dpc-3121	37	11	novel	novel	ADJ
dpc-3121	37	12	drugs	drug	NOUN
dpc-3121	37	13	against	against	ADP
dpc-3121	37	14	atopic	atopic	NOUN
dpc-3121	37	15	dermatitis	dermatitis	NOUN
dpc-3121	37	16	and	and	CCONJ
dpc-3121	37	17	their	their	PRON
dpc-3121	37	18	vehicles	vehicle	NOUN
dpc-3121	37	19	is	be	AUX
dpc-3121	37	20	synthesized	synthesize	VERB
dpc-3121	37	21	to	to	PART
dpc-3121	37	22	overview	overview	VERB
dpc-3121	37	23	available	available	ADJ
dpc-3121	37	24	evidence	evidence	NOUN
dpc-3121	37	25	and	and	CCONJ
dpc-3121	37	26	identify	identify	VERB
dpc-3121	37	27	research	research	NOUN
dpc-3121	37	28	gaps	gap	NOUN
dpc-3121	37	29	.	.	PUNCT
dpc-3121	38	1	methods	method	NOUN
dpc-3121	38	2	a	a	DET
dpc-3121	38	3	literature	literature	NOUN
dpc-3121	38	4	search	search	NOUN
dpc-3121	38	5	was	be	AUX
dpc-3121	38	6	conducted	conduct	VERB
dpc-3121	38	7	of	of	ADP
dpc-3121	38	8	the	the	DET
dpc-3121	38	9	various	various	ADJ
dpc-3121	38	10	articles	article	NOUN
dpc-3121	38	11	detailing	detail	VERB
dpc-3121	38	12	presently	presently	ADV
dpc-3121	38	13	used	use	VERB
dpc-3121	38	14	atopic	atopic	NOUN
dpc-3121	38	15	dermatitis	dermatitis	NOUN
dpc-3121	38	16	drugs	drug	NOUN
dpc-3121	38	17	and	and	CCONJ
dpc-3121	38	18	vehicles	vehicle	NOUN
dpc-3121	38	19	,	,	PUNCT
dpc-3121	38	20	and	and	CCONJ
dpc-3121	38	21	a	a	DET
dpc-3121	38	22	narrative	narrative	NOUN
dpc-3121	38	23	review	review	NOUN
dpc-3121	38	24	was	be	AUX
dpc-3121	38	25	compiled	compile	VERB
dpc-3121	38	26	to	to	PART
dpc-3121	38	27	summarize	summarize	VERB
dpc-3121	38	28	recent	recent	ADJ
dpc-3121	38	29	evidence	evidence	NOUN
dpc-3121	38	30	.	.	PUNCT
dpc-3121	39	1	results	result	VERB
dpc-3121	39	2	novel	novel	ADJ
dpc-3121	39	3	drugs	drug	NOUN
dpc-3121	39	4	against	against	ADP
dpc-3121	39	5	ad	ad	NOUN
dpc-3121	39	6	corticosteroids	corticosteroid	NOUN
dpc-3121	39	7	atopic	atopic	NOUN
dpc-3121	39	8	dermatitis	dermatitis	NOUN
dpc-3121	39	9	patients	patient	NOUN
dpc-3121	39	10	have	have	AUX
dpc-3121	39	11	been	be	AUX
dpc-3121	39	12	conventionally	conventionally	ADV
dpc-3121	39	13	treated	treat	VERB
dpc-3121	39	14	with	with	ADP
dpc-3121	39	15	topical	topical	ADJ
dpc-3121	39	16	corticosteroids	corticosteroid	NOUN
dpc-3121	39	17	as	as	ADP
dpc-3121	39	18	a	a	DET
dpc-3121	39	19	first	first	ADJ
dpc-3121	39	20	-	-	PUNCT
dpc-3121	39	21	line	line	NOUN
dpc-3121	39	22	intervention	intervention	NOUN
dpc-3121	39	23	[	[	X
dpc-3121	39	24	9	9	NUM
dpc-3121	39	25	]	]	PUNCT
dpc-3121	39	26	.	.	PUNCT
dpc-3121	40	1	the	the	DET
dpc-3121	40	2	corticosteroids	corticosteroid	NOUN
dpc-3121	40	3	prevent	prevent	VERB
dpc-3121	40	4	antigen	antigen	NOUN
dpc-3121	40	5	processing	processing	NOUN
dpc-3121	40	6	and	and	CCONJ
dpc-3121	40	7	proinflammatory	proinflammatory	ADJ
dpc-3121	40	8	cytokine	cytokine	NOUN
dpc-3121	40	9	release	release	NOUN
dpc-3121	40	10	,	,	PUNCT
dpc-3121	40	11	thereby	thereby	ADV
dpc-3121	40	12	modulating	modulate	VERB
dpc-3121	40	13	the	the	DET
dpc-3121	40	14	immune	immune	ADJ
dpc-3121	40	15	response	response	NOUN
dpc-3121	40	16	[	[	X
dpc-3121	40	17	4	4	NUM
dpc-3121	40	18	]	]	PUNCT
dpc-3121	40	19	.	.	PUNCT
dpc-3121	41	1	despite	despite	SCONJ
dpc-3121	41	2	the	the	DET
dpc-3121	41	3	efficacy	efficacy	NOUN
dpc-3121	41	4	of	of	ADP
dpc-3121	41	5	steroidal	steroidal	NOUN
dpc-3121	41	6	agents	agent	NOUN
dpc-3121	41	7	in	in	ADP
dpc-3121	41	8	reducing	reduce	VERB
dpc-3121	41	9	pruritus	pruritus	NOUN
dpc-3121	41	10	and	and	CCONJ
dpc-3121	41	11	eczematous	eczematous	ADJ
dpc-3121	41	12	lesions	lesion	NOUN
dpc-3121	41	13	,	,	PUNCT
dpc-3121	41	14	their	their	PRON
dpc-3121	41	15	safety	safety	NOUN
dpc-3121	41	16	has	have	AUX
dpc-3121	41	17	been	be	AUX
dpc-3121	41	18	questioned	question	VERB
dpc-3121	41	19	,	,	PUNCT
dpc-3121	41	20	mainly	mainly	ADV
dpc-3121	41	21	when	when	SCONJ
dpc-3121	41	22	administered	administer	VERB
dpc-3121	41	23	to	to	ADP
dpc-3121	41	24	sensitive	sensitive	ADJ
dpc-3121	41	25	body	body	NOUN
dpc-3121	41	26	areas	area	NOUN
dpc-3121	41	27	such	such	ADJ
dpc-3121	41	28	as	as	ADP
dpc-3121	41	29	the	the	DET
dpc-3121	41	30	face	face	NOUN
dpc-3121	41	31	or	or	CCONJ
dpc-3121	41	32	used	use	VERB
dpc-3121	41	33	for	for	ADP
dpc-3121	41	34	extended	extended	ADJ
dpc-3121	41	35	periods	period	NOUN
dpc-3121	41	36	 	 	SPACE
dpc-3121	41	37	[	[	PUNCT
dpc-3121	41	38	10	10	NUM
dpc-3121	41	39	]	]	PUNCT
dpc-3121	41	40	.	.	PUNCT
dpc-3121	42	1	along	along	ADP
dpc-3121	42	2	with	with	ADP
dpc-3121	42	3	these	these	DET
dpc-3121	42	4	concerns	concern	NOUN
dpc-3121	42	5	,	,	PUNCT
dpc-3121	42	6	patients	patient	NOUN
dpc-3121	42	7	’	'	PUNCT
dpc-3121	42	8	adherence	adherence	NOUN
dpc-3121	42	9	to	to	ADP
dpc-3121	42	10	the	the	DET
dpc-3121	42	11	treatment	treatment	NOUN
dpc-3121	42	12	regimen	regiman	NOUN
dpc-3121	42	13	may	may	AUX
dpc-3121	42	14	be	be	AUX
dpc-3121	42	15	suboptimal	suboptimal	ADJ
dpc-3121	42	16	,	,	PUNCT
dpc-3121	42	17	resulting	result	VERB
dpc-3121	42	18	in	in	ADP
dpc-3121	42	19	aggravation	aggravation	NOUN
dpc-3121	42	20	and	and	CCONJ
dpc-3121	42	21	extension	extension	NOUN
dpc-3121	42	22	of	of	ADP
dpc-3121	42	23	the	the	DET
dpc-3121	42	24	symptoms	symptom	NOUN
dpc-3121	42	25	[	[	X
dpc-3121	42	26	11	11	NUM
dpc-3121	42	27	]	]	PUNCT
dpc-3121	42	28	.	.	PUNCT
dpc-3121	43	1	in	in	ADP
dpc-3121	43	2	severe	severe	ADJ
dpc-3121	43	3	atopic	atopic	NOUN
dpc-3121	43	4	cases	case	NOUN
dpc-3121	43	5	,	,	PUNCT
dpc-3121	43	6	systemic	systemic	ADJ
dpc-3121	43	7	corticosteroids	corticosteroid	NOUN
dpc-3121	43	8	may	may	AUX
dpc-3121	43	9	be	be	AUX
dpc-3121	43	10	prescribed	prescribe	VERB
dpc-3121	43	11	,	,	PUNCT
dpc-3121	43	12	yet	yet	CCONJ
dpc-3121	43	13	due	due	ADP
dpc-3121	43	14	to	to	ADP
dpc-3121	43	15	side	side	ADJ
dpc-3121	43	16	effects	effect	NOUN
dpc-3121	43	17	and	and	CCONJ
dpc-3121	43	18	rebound	rebound	VERB
dpc-3121	43	19	flares	flare	NOUN
dpc-3121	43	20	with	with	ADP
dpc-3121	43	21	such	such	DET
dpc-3121	43	22	a	a	DET
dpc-3121	43	23	treatment	treatment	NOUN
dpc-3121	43	24	,	,	PUNCT
dpc-3121	43	25	their	their	PRON
dpc-3121	43	26	use	use	NOUN
dpc-3121	43	27	is	be	AUX
dpc-3121	43	28	not	not	PART
dpc-3121	43	29	recommended	recommend	VERB
dpc-3121	43	30	[	[	PUNCT
dpc-3121	43	31	12,13	12,13	NUM
dpc-3121	43	32	]	]	PUNCT
dpc-3121	43	33	.	.	PUNCT
dpc-3121	44	1	ruxolitinib	ruxolitinib	PROPN
dpc-3121	44	2	ruxolitinib	ruxolitinib	PROPN
dpc-3121	44	3	is	be	AUX
dpc-3121	44	4	an	an	DET
dpc-3121	44	5	inhibitor	inhibitor	NOUN
dpc-3121	44	6	of	of	ADP
dpc-3121	44	7	janus	janus	PROPN
dpc-3121	44	8	kinases	kinases	PROPN
dpc-3121	44	9	(	(	PUNCT
dpc-3121	44	10	jak	jak	PROPN
dpc-3121	44	11	)	)	PUNCT
dpc-3121	44	12	1	1	NUM
dpc-3121	44	13	and	and	CCONJ
dpc-3121	44	14	2	2	NUM
dpc-3121	44	15	,	,	PUNCT
dpc-3121	44	16	which	which	PRON
dpc-3121	44	17	are	be	AUX
dpc-3121	44	18	involved	involve	VERB
dpc-3121	44	19	in	in	ADP
dpc-3121	44	20	signaling	signal	VERB
dpc-3121	44	21	pathways	pathway	NOUN
dpc-3121	44	22	that	that	PRON
dpc-3121	44	23	mediate	mediate	VERB
dpc-3121	44	24	the	the	DET
dpc-3121	44	25	elevation	elevation	NOUN
dpc-3121	44	26	of	of	ADP
dpc-3121	44	27	proinflammatory	proinflammatory	ADJ
dpc-3121	44	28	cytokines	cytokine	NOUN
dpc-3121	44	29	[	[	X
dpc-3121	44	30	14	14	NUM
dpc-3121	44	31	]	]	PUNCT
dpc-3121	44	32	.	.	PUNCT
dpc-3121	45	1	oral	oral	PROPN
dpc-3121	45	2	jak	jak	PROPN
dpc-3121	45	3	inhibitors	inhibitor	NOUN
dpc-3121	45	4	have	have	AUX
dpc-3121	45	5	been	be	AUX
dpc-3121	45	6	employed	employ	VERB
dpc-3121	45	7	in	in	ADP
dpc-3121	45	8	treating	treat	VERB
dpc-3121	45	9	atopic	atopic	NOUN
dpc-3121	45	10	dermatitis	dermatitis	NOUN
dpc-3121	45	11	patients	patient	NOUN
dpc-3121	45	12	.	.	PUNCT
dpc-3121	46	1	yet	yet	CCONJ
dpc-3121	46	2	safety	safety	NOUN
dpc-3121	46	3	concerns	concern	NOUN
dpc-3121	46	4	have	have	AUX
dpc-3121	46	5	been	be	AUX
dpc-3121	46	6	raised	raise	VERB
dpc-3121	46	7	with	with	ADP
dpc-3121	46	8	this	this	DET
dpc-3121	46	9	mode	mode	NOUN
dpc-3121	46	10	of	of	ADP
dpc-3121	46	11	administration	administration	NOUN
dpc-3121	46	12	due	due	ADP
dpc-3121	46	13	to	to	ADP
dpc-3121	46	14	non	non	ADJ
dpc-3121	46	15	-	-	ADJ
dpc-3121	46	16	specific	specific	ADJ
dpc-3121	46	17	delivery	delivery	NOUN
dpc-3121	46	18	of	of	ADP
dpc-3121	46	19	the	the	DET
dpc-3121	46	20	active	active	ADJ
dpc-3121	46	21	drug	drug	NOUN
dpc-3121	46	22	and	and	CCONJ
dpc-3121	46	23	the	the	DET
dpc-3121	46	24	development	development	NOUN
dpc-3121	46	25	of	of	ADP
dpc-3121	46	26	cytopenias	cytopenia	NOUN
dpc-3121	46	27	[	[	X
dpc-3121	46	28	15	15	NUM
dpc-3121	46	29	]	]	PUNCT
dpc-3121	46	30	.	.	PUNCT
dpc-3121	47	1	theoretically	theoretically	ADV
dpc-3121	47	2	,	,	PUNCT
dpc-3121	47	3	a	a	DET
dpc-3121	47	4	topical	topical	ADJ
dpc-3121	47	5	agent	agent	NOUN
dpc-3121	47	6	targeted	target	VERB
dpc-3121	47	7	to	to	ADP
dpc-3121	47	8	specific	specific	ADJ
dpc-3121	47	9	affected	affect	VERB
dpc-3121	47	10	areas	area	NOUN
dpc-3121	47	11	could	could	AUX
dpc-3121	47	12	result	result	VERB
dpc-3121	47	13	in	in	ADP
dpc-3121	47	14	far	far	ADV
dpc-3121	47	15	less	less	ADV
dpc-3121	47	16	systemic	systemic	ADJ
dpc-3121	47	17	exposure	exposure	NOUN
dpc-3121	47	18	and	and	CCONJ
dpc-3121	47	19	,	,	PUNCT
dpc-3121	47	20	thus	thus	ADV
dpc-3121	47	21	,	,	PUNCT
dpc-3121	47	22	a	a	DET
dpc-3121	47	23	safer	safe	ADJ
dpc-3121	47	24	profile	profile	NOUN
dpc-3121	47	25	.	.	PUNCT
dpc-3121	48	1	in	in	ADP
dpc-3121	48	2	a	a	DET
dpc-3121	48	3	phase	phase	NOUN
dpc-3121	48	4	ii	ii	NOUN
dpc-3121	48	5	trial	trial	NOUN
dpc-3121	48	6	on	on	ADP
dpc-3121	48	7	patients	patient	NOUN
dpc-3121	48	8	with	with	ADP
dpc-3121	48	9	atopic	atopic	NOUN
dpc-3121	48	10	dermatitis	dermatitis	NOUN
dpc-3121	48	11	,	,	PUNCT
dpc-3121	48	12	topical	topical	ADJ
dpc-3121	48	13	administration	administration	NOUN
dpc-3121	48	14	of	of	ADP
dpc-3121	48	15	ruxolitinib	ruxolitinib	PROPN
dpc-3121	48	16	(	(	PUNCT
dpc-3121	48	17	1.5	1.5	NUM
dpc-3121	48	18	%	%	NOUN
dpc-3121	48	19	)	)	PUNCT
dpc-3121	48	20	twice	twice	DET
dpc-3121	48	21	a	a	DET
dpc-3121	48	22	day	day	NOUN
dpc-3121	48	23	significantly	significantly	ADV
dpc-3121	48	24	decreased	decrease	VERB
dpc-3121	48	25	dermatitis	dermatitis	NOUN
dpc-3121	48	26	-	-	PUNCT
dpc-3121	48	27	associated	associate	VERB
dpc-3121	48	28	pruritus	pruritus	NOUN
dpc-3121	48	29	compared	compare	VERB
dpc-3121	48	30	to	to	ADP
dpc-3121	48	31	the	the	DET
dpc-3121	48	32	empty	empty	ADJ
dpc-3121	48	33	vehicle	vehicle	NOUN
dpc-3121	48	34	control	control	NOUN
dpc-3121	48	35	after	after	ADP
dpc-3121	48	36	three	three	NUM
dpc-3121	48	37	days	day	NOUN
dpc-3121	48	38	of	of	ADP
dpc-3121	48	39	use	use	NOUN
dpc-3121	48	40	[	[	X
dpc-3121	48	41	16,17	16,17	NUM
dpc-3121	48	42	]	]	PUNCT
dpc-3121	48	43	.	.	PUNCT
dpc-3121	49	1	this	this	PRON
dpc-3121	49	2	,	,	PUNCT
dpc-3121	49	3	in	in	ADP
dpc-3121	49	4	turn	turn	NOUN
dpc-3121	49	5	,	,	PUNCT
dpc-3121	49	6	resulted	result	VERB
dpc-3121	49	7	in	in	ADP
dpc-3121	49	8	significant	significant	ADJ
dpc-3121	49	9	improvements	improvement	NOUN
dpc-3121	49	10	in	in	ADP
dpc-3121	49	11	patients	patient	NOUN
dpc-3121	49	12	life	life	NOUN
dpc-3121	49	13	quality	quality	NOUN
dpc-3121	49	14	within	within	ADP
dpc-3121	49	15	two	two	NUM
dpc-3121	49	16	weeks	week	NOUN
dpc-3121	49	17	after	after	ADP
dpc-3121	49	18	the	the	DET
dpc-3121	49	19	initiation	initiation	NOUN
dpc-3121	49	20	of	of	ADP
dpc-3121	49	21	therapy	therapy	NOUN
dpc-3121	49	22	.	.	PUNCT
dpc-3121	50	1	two	two	NUM
dpc-3121	50	2	ruxolitinib	ruxolitinib	NOUN
dpc-3121	50	3	phase	phase	NOUN
dpc-3121	50	4	iii	iii	NUM
dpc-3121	50	5	trials	trial	NOUN
dpc-3121	50	6	corroborated	corroborate	VERB
dpc-3121	50	7	these	these	DET
dpc-3121	50	8	findings	finding	NOUN
dpc-3121	50	9	,	,	PUNCT
dpc-3121	50	10	review	review	VERB
dpc-3121	50	11	|	|	ADV
dpc-3121	50	12	dermatol	dermatol	ADJ
dpc-3121	50	13	pract	pract	NOUN
dpc-3121	50	14	concept	concept	NOUN
dpc-3121	50	15	.	.	PUNCT
dpc-3121	51	1	2023;13(4):e2023216	2023;13(4):e2023216	NUM
dpc-3121	51	2	3	3	NUM
dpc-3121	51	3	where	where	SCONJ
dpc-3121	51	4	topical	topical	ADJ
dpc-3121	51	5	ruxolitinib	ruxolitinib	NOUN
dpc-3121	51	6	treatment	treatment	NOUN
dpc-3121	51	7	(	(	PUNCT
dpc-3121	51	8	0.75	0.75	NUM
dpc-3121	51	9	%	%	NOUN
dpc-3121	51	10	or	or	CCONJ
dpc-3121	51	11	1.5	1.5	NUM
dpc-3121	51	12	%	%	NOUN
dpc-3121	51	13	)	)	PUNCT
dpc-3121	51	14	was	be	AUX
dpc-3121	51	15	associated	associate	VERB
dpc-3121	51	16	with	with	ADP
dpc-3121	51	17	a	a	DET
dpc-3121	51	18	significantly	significantly	ADV
dpc-3121	51	19	more	more	ADV
dpc-3121	51	20	frequent	frequent	ADJ
dpc-3121	51	21	success	success	NOUN
dpc-3121	51	22	than	than	ADP
dpc-3121	51	23	the	the	DET
dpc-3121	51	24	vehicle	vehicle	NOUN
dpc-3121	51	25	control	control	NOUN
dpc-3121	51	26	treatment	treatment	NOUN
dpc-3121	51	27	,	,	PUNCT
dpc-3121	51	28	and	and	CCONJ
dpc-3121	51	29	less	less	ADJ
dpc-3121	51	30	than	than	ADP
dpc-3121	51	31	1	1	NUM
dpc-3121	51	32	%	%	NOUN
dpc-3121	51	33	of	of	ADP
dpc-3121	51	34	patients	patient	NOUN
dpc-3121	51	35	experienced	experience	VERB
dpc-3121	51	36	side	side	NOUN
dpc-3121	51	37	effects	effect	NOUN
dpc-3121	51	38	[	[	X
dpc-3121	51	39	18	18	NUM
dpc-3121	51	40	]	]	PUNCT
dpc-3121	51	41	.	.	PUNCT
dpc-3121	52	1	in	in	ADP
dpc-3121	52	2	a	a	DET
dpc-3121	52	3	maximum	maximum	ADJ
dpc-3121	52	4	-	-	PUNCT
dpc-3121	52	5	use	use	NOUN
dpc-3121	52	6	trial	trial	NOUN
dpc-3121	52	7	of	of	ADP
dpc-3121	52	8	ruxolitinib	ruxolitinib	NOUN
dpc-3121	52	9	(	(	PUNCT
dpc-3121	52	10	1.5	1.5	NUM
dpc-3121	52	11	%	%	NOUN
dpc-3121	52	12	cream	cream	NOUN
dpc-3121	52	13	,	,	PUNCT
dpc-3121	52	14	twice	twice	ADV
dpc-3121	52	15	daily	daily	ADV
dpc-3121	52	16	for	for	ADP
dpc-3121	52	17	28	28	NUM
dpc-3121	52	18	days	day	NOUN
dpc-3121	52	19	and	and	CCONJ
dpc-3121	52	20	as	as	SCONJ
dpc-3121	52	21	required	require	VERB
dpc-3121	52	22	during	during	ADP
dpc-3121	52	23	the	the	DET
dpc-3121	52	24	28	28	NUM
dpc-3121	52	25	days	day	NOUN
dpc-3121	52	26	thereafter	thereafter	ADV
dpc-3121	52	27	)	)	PUNCT
dpc-3121	52	28	,	,	PUNCT
dpc-3121	52	29	almost	almost	ADV
dpc-3121	52	30	a	a	DET
dpc-3121	52	31	third	third	NOUN
dpc-3121	52	32	of	of	ADP
dpc-3121	52	33	the	the	DET
dpc-3121	52	34	patients	patient	NOUN
dpc-3121	52	35	experienced	experience	VERB
dpc-3121	52	36	treatment	treatment	NOUN
dpc-3121	52	37	-	-	PUNCT
dpc-3121	52	38	related	relate	VERB
dpc-3121	52	39	adverse	adverse	ADJ
dpc-3121	52	40	events	event	NOUN
dpc-3121	52	41	[	[	X
dpc-3121	52	42	19	19	NUM
dpc-3121	52	43	]	]	PUNCT
dpc-3121	52	44	.	.	PUNCT
dpc-3121	53	1	long	long	ADJ
dpc-3121	53	2	-	-	PUNCT
dpc-3121	53	3	term	term	NOUN
dpc-3121	53	4	studies	study	NOUN
dpc-3121	53	5	on	on	ADP
dpc-3121	53	6	the	the	DET
dpc-3121	53	7	efficacy	efficacy	NOUN
dpc-3121	53	8	and	and	CCONJ
dpc-3121	53	9	safety	safety	NOUN
dpc-3121	53	10	of	of	ADP
dpc-3121	53	11	ruxolitinib	ruxolitinib	NOUN
dpc-3121	53	12	for	for	ADP
dpc-3121	53	13	atopic	atopic	NOUN
dpc-3121	53	14	dermatitis	dermatitis	NOUN
dpc-3121	53	15	treatment	treatment	NOUN
dpc-3121	53	16	are	be	AUX
dpc-3121	53	17	missing	miss	VERB
dpc-3121	53	18	to	to	ADP
dpc-3121	53	19	date	date	NOUN
dpc-3121	53	20	.	.	PUNCT
dpc-3121	54	1	crisaborole	crisaborole	PROPN
dpc-3121	54	2	crisaborole	crisaborole	PROPN
dpc-3121	54	3	is	be	AUX
dpc-3121	54	4	a	a	DET
dpc-3121	54	5	benzoxaborole	benzoxaborole	ADJ
dpc-3121	54	6	inhibitor	inhibitor	NOUN
dpc-3121	54	7	of	of	ADP
dpc-3121	54	8	phosphodiesterase-4	phosphodiesterase-4	NOUN
dpc-3121	54	9	(	(	PUNCT
dpc-3121	54	10	pde-4	pde-4	NOUN
dpc-3121	54	11	)	)	PUNCT
dpc-3121	54	12	,	,	PUNCT
dpc-3121	54	13	an	an	DET
dpc-3121	54	14	enzyme	enzyme	NOUN
dpc-3121	54	15	responsible	responsible	ADJ
dpc-3121	54	16	for	for	ADP
dpc-3121	54	17	degrading	degrade	VERB
dpc-3121	54	18	the	the	DET
dpc-3121	54	19	second	second	ADJ
dpc-3121	54	20	messenger	messenger	NOUN
dpc-3121	54	21	camp	camp	NOUN
dpc-3121	54	22	in	in	ADP
dpc-3121	54	23	immune	immune	ADJ
dpc-3121	54	24	cells	cell	NOUN
dpc-3121	54	25	[	[	X
dpc-3121	54	26	20	20	NUM
dpc-3121	54	27	]	]	PUNCT
dpc-3121	54	28	.	.	PUNCT
dpc-3121	55	1	if	if	SCONJ
dpc-3121	55	2	pde-4	pde-4	PRON
dpc-3121	55	3	is	be	AUX
dpc-3121	55	4	inhibited	inhibit	VERB
dpc-3121	55	5	,	,	PUNCT
dpc-3121	55	6	camp	camp	NOUN
dpc-3121	55	7	levels	level	NOUN
dpc-3121	55	8	rise	rise	VERB
dpc-3121	55	9	,	,	PUNCT
dpc-3121	55	10	and	and	CCONJ
dpc-3121	55	11	inflammatory	inflammatory	ADJ
dpc-3121	55	12	responses	response	NOUN
dpc-3121	55	13	are	be	AUX
dpc-3121	55	14	modulated	modulate	VERB
dpc-3121	55	15	[	[	PUNCT
dpc-3121	55	16	21	21	NUM
dpc-3121	55	17	]	]	PUNCT
dpc-3121	55	18	.	.	PUNCT
dpc-3121	56	1	in	in	ADP
dpc-3121	56	2	two	two	NUM
dpc-3121	56	3	phase	phase	NOUN
dpc-3121	56	4	iii	iii	NUM
dpc-3121	56	5	trials	trial	NOUN
dpc-3121	56	6	,	,	PUNCT
dpc-3121	56	7	the	the	DET
dpc-3121	56	8	condition	condition	NOUN
dpc-3121	56	9	of	of	ADP
dpc-3121	56	10	atopic	atopic	NOUN
dpc-3121	56	11	dermatitis	dermatitis	NOUN
dpc-3121	56	12	patients	patient	NOUN
dpc-3121	56	13	,	,	PUNCT
dpc-3121	56	14	measured	measure	VERB
dpc-3121	56	15	as	as	ADP
dpc-3121	56	16	the	the	DET
dpc-3121	56	17	investigator	investigator	NOUN
dpc-3121	56	18	static	static	ADJ
dpc-3121	56	19	global	global	ADJ
dpc-3121	56	20	assessment	assessment	NOUN
dpc-3121	56	21	score	score	NOUN
dpc-3121	56	22	,	,	PUNCT
dpc-3121	56	23	improved	improve	VERB
dpc-3121	56	24	significantly	significantly	ADV
dpc-3121	56	25	earlier	early	ADV
dpc-3121	56	26	and	and	CCONJ
dpc-3121	56	27	to	to	ADP
dpc-3121	56	28	a	a	DET
dpc-3121	56	29	greater	great	ADJ
dpc-3121	56	30	extent	extent	NOUN
dpc-3121	56	31	than	than	ADP
dpc-3121	56	32	in	in	ADP
dpc-3121	56	33	the	the	DET
dpc-3121	56	34	vehicle	vehicle	NOUN
dpc-3121	56	35	controls	control	NOUN
dpc-3121	56	36	at	at	ADP
dpc-3121	56	37	the	the	DET
dpc-3121	56	38	study	study	NOUN
dpc-3121	56	39	endpoint	endpoint	NOUN
dpc-3121	56	40	of	of	ADP
dpc-3121	56	41	28	28	NUM
dpc-3121	56	42	days	day	NOUN
dpc-3121	56	43	[	[	X
dpc-3121	56	44	22	22	NUM
dpc-3121	56	45	]	]	PUNCT
dpc-3121	56	46	.	.	PUNCT
dpc-3121	57	1	the	the	DET
dpc-3121	57	2	frequency	frequency	NOUN
dpc-3121	57	3	of	of	ADP
dpc-3121	57	4	adverse	adverse	ADJ
dpc-3121	57	5	events	event	NOUN
dpc-3121	57	6	and	and	CCONJ
dpc-3121	57	7	participant	participant	ADJ
dpc-3121	57	8	retention	retention	NOUN
dpc-3121	57	9	was	be	AUX
dpc-3121	57	10	low	low	ADJ
dpc-3121	57	11	,	,	PUNCT
dpc-3121	57	12	indicating	indicate	VERB
dpc-3121	57	13	good	good	ADJ
dpc-3121	57	14	tolerability	tolerability	NOUN
dpc-3121	57	15	of	of	ADP
dpc-3121	57	16	crisaborole	crisaborole	ADJ
dpc-3121	57	17	ointment	ointment	NOUN
dpc-3121	57	18	[	[	X
dpc-3121	57	19	22	22	NUM
dpc-3121	57	20	]	]	PUNCT
dpc-3121	57	21	.	.	PUNCT
dpc-3121	58	1	information	information	NOUN
dpc-3121	58	2	on	on	ADP
dpc-3121	58	3	the	the	DET
dpc-3121	58	4	benefits	benefit	NOUN
dpc-3121	58	5	of	of	ADP
dpc-3121	58	6	crisaborole	crisaborole	ADJ
dpc-3121	58	7	treatment	treatment	NOUN
dpc-3121	58	8	for	for	ADP
dpc-3121	58	9	infants	infant	NOUN
dpc-3121	58	10	and	and	CCONJ
dpc-3121	58	11	toddlers	toddler	NOUN
dpc-3121	58	12	is	be	AUX
dpc-3121	58	13	yet	yet	ADV
dpc-3121	58	14	lacking	lacking	ADJ
dpc-3121	58	15	,	,	PUNCT
dpc-3121	58	16	albeit	albeit	SCONJ
dpc-3121	58	17	atopic	atopic	NOUN
dpc-3121	58	18	dermatitis	dermatitis	NOUN
dpc-3121	58	19	frequently	frequently	ADV
dpc-3121	58	20	develops	develop	VERB
dpc-3121	58	21	soon	soon	ADV
dpc-3121	58	22	after	after	ADP
dpc-3121	58	23	birth	birth	NOUN
dpc-3121	58	24	.	.	PUNCT
dpc-3121	59	1	hence	hence	ADV
dpc-3121	59	2	,	,	PUNCT
dpc-3121	59	3	future	future	ADJ
dpc-3121	59	4	investigations	investigation	NOUN
dpc-3121	59	5	with	with	ADP
dpc-3121	59	6	this	this	DET
dpc-3121	59	7	patient	patient	ADJ
dpc-3121	59	8	group	group	NOUN
dpc-3121	59	9	are	be	AUX
dpc-3121	59	10	relevant	relevant	ADJ
dpc-3121	59	11	.	.	PUNCT
dpc-3121	60	1	roflumilast	roflumilast	PROPN
dpc-3121	60	2	roflumilast	roflumilast	PROPN
dpc-3121	60	3	is	be	AUX
dpc-3121	60	4	another	another	DET
dpc-3121	60	5	pde-4	pde-4	ADJ
dpc-3121	60	6	inhibitor	inhibitor	NOUN
dpc-3121	60	7	with	with	ADP
dpc-3121	60	8	anti	anti	ADJ
dpc-3121	60	9	inflammatory	inflammatory	ADJ
dpc-3121	60	10	properties	property	NOUN
dpc-3121	60	11	[	[	X
dpc-3121	60	12	23	23	NUM
dpc-3121	60	13	]	]	PUNCT
dpc-3121	60	14	.	.	PUNCT
dpc-3121	61	1	while	while	SCONJ
dpc-3121	61	2	this	this	DET
dpc-3121	61	3	drug	drug	NOUN
dpc-3121	61	4	has	have	AUX
dpc-3121	61	5	demonstrated	demonstrate	VERB
dpc-3121	61	6	efficacy	efficacy	NOUN
dpc-3121	61	7	in	in	ADP
dpc-3121	61	8	treating	treat	VERB
dpc-3121	61	9	chronic	chronic	ADJ
dpc-3121	61	10	obstructive	obstructive	ADJ
dpc-3121	61	11	pulmonary	pulmonary	ADJ
dpc-3121	61	12	disease	disease	NOUN
dpc-3121	61	13	(	(	PUNCT
dpc-3121	61	14	copd	copd	NOUN
dpc-3121	61	15	)	)	PUNCT
dpc-3121	61	16	and	and	CCONJ
dpc-3121	61	17	asthma	asthma	NOUN
dpc-3121	62	1	[	[	X
dpc-3121	62	2	24,25	24,25	NUM
dpc-3121	62	3	]	]	PUNCT
dpc-3121	62	4	,	,	PUNCT
dpc-3121	62	5	clinical	clinical	ADJ
dpc-3121	62	6	trials	trial	NOUN
dpc-3121	62	7	on	on	ADP
dpc-3121	62	8	its	its	PRON
dpc-3121	62	9	effectiveness	effectiveness	NOUN
dpc-3121	62	10	in	in	ADP
dpc-3121	62	11	treating	treat	VERB
dpc-3121	62	12	atopic	atopic	NOUN
dpc-3121	62	13	dermatitis	dermatitis	NOUN
dpc-3121	62	14	are	be	AUX
dpc-3121	62	15	ongoing	ongoing	ADJ
dpc-3121	62	16	.	.	PUNCT
dpc-3121	63	1	the	the	DET
dpc-3121	63	2	integument	integument	PROPN
dpc-3121	63	3	-	-	PUNCT
dpc-3121	63	4	i	i	PRON
dpc-3121	63	5	phase	phase	NOUN
dpc-3121	63	6	iii	iii	NOUN
dpc-3121	63	7	trial	trial	NOUN
dpc-3121	63	8	(	(	PUNCT
dpc-3121	63	9	clinicaltrials.gov	clinicaltrials.gov	X
dpc-3121	63	10	identifier	identifier	X
dpc-3121	63	11	nct04773587	nct04773587	ADJ
dpc-3121	63	12	)	)	PUNCT
dpc-3121	63	13	tested	test	VERB
dpc-3121	63	14	the	the	DET
dpc-3121	63	15	safety	safety	NOUN
dpc-3121	63	16	and	and	CCONJ
dpc-3121	63	17	efficacy	efficacy	NOUN
dpc-3121	63	18	of	of	ADP
dpc-3121	63	19	a	a	DET
dpc-3121	63	20	0.15	0.15	NUM
dpc-3121	63	21	%	%	NOUN
dpc-3121	63	22	roflumilast	roflumilast	NOUN
dpc-3121	63	23	cream	cream	NOUN
dpc-3121	63	24	,	,	PUNCT
dpc-3121	63	25	administered	administer	VERB
dpc-3121	63	26	for	for	ADP
dpc-3121	63	27	four	four	NUM
dpc-3121	63	28	weeks	week	NOUN
dpc-3121	63	29	,	,	PUNCT
dpc-3121	63	30	compared	compare	VERB
dpc-3121	63	31	to	to	ADP
dpc-3121	63	32	vehicle	vehicle	NOUN
dpc-3121	63	33	control	control	NOUN
dpc-3121	63	34	.	.	PUNCT
dpc-3121	64	1	the	the	DET
dpc-3121	64	2	trial	trial	NOUN
dpc-3121	64	3	has	have	AUX
dpc-3121	64	4	been	be	AUX
dpc-3121	64	5	completed	complete	VERB
dpc-3121	64	6	,	,	PUNCT
dpc-3121	64	7	but	but	CCONJ
dpc-3121	64	8	the	the	DET
dpc-3121	64	9	results	result	NOUN
dpc-3121	64	10	are	be	AUX
dpc-3121	64	11	yet	yet	ADV
dpc-3121	64	12	to	to	PART
dpc-3121	64	13	be	be	AUX
dpc-3121	64	14	published	publish	VERB
dpc-3121	64	15	[	[	X
dpc-3121	64	16	26	26	NUM
dpc-3121	64	17	]	]	PUNCT
dpc-3121	64	18	.	.	PUNCT
dpc-3121	65	1	tapinarof	tapinarof	NOUN
dpc-3121	65	2	(	(	PUNCT
dpc-3121	65	3	vtama	vtama	PROPN
dpc-3121	65	4	)	)	PUNCT
dpc-3121	65	5	tapinarof	tapinarof	NOUN
dpc-3121	65	6	activates	activate	VERB
dpc-3121	65	7	the	the	DET
dpc-3121	65	8	aryl	aryl	NOUN
dpc-3121	65	9	hydrocarbon	hydrocarbon	NOUN
dpc-3121	65	10	receptor	receptor	NOUN
dpc-3121	65	11	(	(	PUNCT
dpc-3121	65	12	ahr	ahr	PROPN
dpc-3121	65	13	)	)	PUNCT
dpc-3121	65	14	.	.	PUNCT
dpc-3121	66	1	ahr	ahr	PROPN
dpc-3121	66	2	is	be	AUX
dpc-3121	66	3	a	a	DET
dpc-3121	66	4	transcription	transcription	NOUN
dpc-3121	66	5	factor	factor	NOUN
dpc-3121	66	6	for	for	ADP
dpc-3121	66	7	pro	pro	ADJ
dpc-3121	66	8	-	-	ADJ
dpc-3121	66	9	inflammatory	inflammatory	ADJ
dpc-3121	66	10	cytokines	cytokine	NOUN
dpc-3121	66	11	,	,	PUNCT
dpc-3121	66	12	which	which	PRON
dpc-3121	66	13	are	be	AUX
dpc-3121	66	14	downregulated	downregulate	VERB
dpc-3121	66	15	upon	upon	SCONJ
dpc-3121	66	16	ahr	ahr	PROPN
dpc-3121	66	17	activation	activation	NOUN
dpc-3121	66	18	 	 	SPACE
dpc-3121	67	1	[	[	X
dpc-3121	67	2	27	27	NUM
dpc-3121	67	3	]	]	PUNCT
dpc-3121	67	4	.	.	PUNCT
dpc-3121	68	1	tapinarof	tapinarof	PROPN
dpc-3121	68	2	,	,	PUNCT
dpc-3121	68	3	therefore	therefore	ADV
dpc-3121	68	4	,	,	PUNCT
dpc-3121	68	5	acts	act	VERB
dpc-3121	68	6	as	as	ADP
dpc-3121	68	7	an	an	DET
dpc-3121	68	8	immune	immune	NOUN
dpc-3121	68	9	-	-	PUNCT
dpc-3121	68	10	modulator	modulator	NOUN
dpc-3121	68	11	,	,	PUNCT
dpc-3121	68	12	anti	anti	ADJ
dpc-3121	68	13	-	-	ADJ
dpc-3121	68	14	oxidative	oxidative	ADJ
dpc-3121	68	15	,	,	PUNCT
dpc-3121	68	16	and	and	CCONJ
dpc-3121	68	17	anti	anti	ADJ
dpc-3121	68	18	-	-	ADJ
dpc-3121	68	19	inflammatory	inflammatory	ADJ
dpc-3121	68	20	treatment	treatment	NOUN
dpc-3121	68	21	.	.	PUNCT
dpc-3121	69	1	in	in	ADP
dpc-3121	69	2	a	a	DET
dpc-3121	69	3	recent	recent	ADJ
dpc-3121	69	4	phase	phase	NOUN
dpc-3121	69	5	iib	iib	NOUN
dpc-3121	69	6	trial	trial	NOUN
dpc-3121	69	7	,	,	PUNCT
dpc-3121	69	8	topical	topical	ADJ
dpc-3121	69	9	administration	administration	NOUN
dpc-3121	69	10	of	of	ADP
dpc-3121	69	11	tapinarof	tapinarof	PROPN
dpc-3121	69	12	cream	cream	PROPN
dpc-3121	69	13	(	(	PUNCT
dpc-3121	69	14	0.5	0.5	NUM
dpc-3121	69	15	%	%	NOUN
dpc-3121	69	16	or	or	CCONJ
dpc-3121	69	17	1	1	NUM
dpc-3121	69	18	%	%	NOUN
dpc-3121	69	19	)	)	PUNCT
dpc-3121	69	20	for	for	ADP
dpc-3121	69	21	12	12	NUM
dpc-3121	69	22	weeks	week	NOUN
dpc-3121	69	23	resulted	result	VERB
dpc-3121	69	24	in	in	ADP
dpc-3121	69	25	a	a	DET
dpc-3121	69	26	greater	great	ADJ
dpc-3121	69	27	improvement	improvement	NOUN
dpc-3121	69	28	of	of	ADP
dpc-3121	69	29	eczema	eczema	NOUN
dpc-3121	69	30	and	and	CCONJ
dpc-3121	69	31	a	a	DET
dpc-3121	69	32	reduced	reduce	VERB
dpc-3121	69	33	affected	affected	ADJ
dpc-3121	69	34	body	body	NOUN
dpc-3121	69	35	area	area	NOUN
dpc-3121	69	36	than	than	ADP
dpc-3121	69	37	in	in	ADP
dpc-3121	69	38	the	the	DET
dpc-3121	69	39	vehicle	vehicle	NOUN
dpc-3121	69	40	control	control	NOUN
dpc-3121	69	41	group	group	NOUN
dpc-3121	69	42	[	[	X
dpc-3121	69	43	28	28	NUM
dpc-3121	69	44	]	]	PUNCT
dpc-3121	69	45	.	.	PUNCT
dpc-3121	70	1	in	in	ADP
dpc-3121	70	2	dose	dose	NOUN
dpc-3121	70	3	-	-	PUNCT
dpc-3121	70	4	finding	find	VERB
dpc-3121	70	5	studies	study	NOUN
dpc-3121	70	6	and	and	CCONJ
dpc-3121	70	7	phase	phase	NOUN
dpc-3121	70	8	ii	ii	PROPN
dpc-3121	70	9	trials	trial	NOUN
dpc-3121	70	10	,	,	PUNCT
dpc-3121	70	11	adverse	adverse	ADJ
dpc-3121	70	12	events	event	NOUN
dpc-3121	70	13	were	be	AUX
dpc-3121	70	14	rare	rare	ADJ
dpc-3121	70	15	and	and	CCONJ
dpc-3121	70	16	of	of	ADP
dpc-3121	70	17	low	low	ADJ
dpc-3121	70	18	or	or	CCONJ
dpc-3121	70	19	moderate	moderate	ADJ
dpc-3121	70	20	intensity	intensity	NOUN
dpc-3121	70	21	[	[	X
dpc-3121	70	22	28,29	28,29	NUM
dpc-3121	70	23	]	]	PUNCT
dpc-3121	70	24	.	.	PUNCT
dpc-3121	71	1	novel	novel	ADJ
dpc-3121	71	2	vehicles	vehicle	NOUN
dpc-3121	71	3	for	for	ADP
dpc-3121	71	4	delivery	delivery	NOUN
dpc-3121	71	5	of	of	ADP
dpc-3121	71	6	ad	ad	NOUN
dpc-3121	71	7	drugs	drug	NOUN
dpc-3121	71	8	topical	topical	ADJ
dpc-3121	71	9	delivery	delivery	NOUN
dpc-3121	71	10	the	the	DET
dpc-3121	71	11	traditional	traditional	ADJ
dpc-3121	71	12	administration	administration	NOUN
dpc-3121	71	13	of	of	ADP
dpc-3121	71	14	atopic	atopic	NOUN
dpc-3121	71	15	dermatitis	dermatitis	NOUN
dpc-3121	71	16	treatments	treatment	NOUN
dpc-3121	71	17	is	be	AUX
dpc-3121	71	18	the	the	DET
dpc-3121	71	19	application	application	NOUN
dpc-3121	71	20	of	of	ADP
dpc-3121	71	21	a	a	DET
dpc-3121	71	22	cream	cream	NOUN
dpc-3121	71	23	or	or	CCONJ
dpc-3121	71	24	ointment	ointment	NOUN
dpc-3121	71	25	directly	directly	ADV
dpc-3121	71	26	on	on	ADP
dpc-3121	71	27	the	the	DET
dpc-3121	71	28	affected	affected	ADJ
dpc-3121	71	29	skin	skin	NOUN
dpc-3121	71	30	area	area	NOUN
dpc-3121	71	31	.	.	PUNCT
dpc-3121	72	1	current	current	ADJ
dpc-3121	72	2	guidelines	guideline	NOUN
dpc-3121	72	3	recommend	recommend	VERB
dpc-3121	72	4	the	the	DET
dpc-3121	72	5	topical	topical	ADJ
dpc-3121	72	6	administration	administration	NOUN
dpc-3121	72	7	of	of	ADP
dpc-3121	72	8	glucocorticosteroid	glucocorticosteroid	PROPN
dpc-3121	72	9	class	class	PROPN
dpc-3121	72	10	ii	ii	NOUN
dpc-3121	72	11	creams	cream	NOUN
dpc-3121	72	12	for	for	ADP
dpc-3121	72	13	mild	mild	ADJ
dpc-3121	72	14	or	or	CCONJ
dpc-3121	72	15	transient	transient	ADJ
dpc-3121	72	16	eczema	eczema	NOUN
dpc-3121	72	17	and	and	CCONJ
dpc-3121	72	18	class	class	NOUN
dpc-3121	72	19	iii	iii	NOUN
dpc-3121	72	20	creams	cream	NOUN
dpc-3121	72	21	for	for	ADP
dpc-3121	72	22	moderate	moderate	ADJ
dpc-3121	72	23	or	or	CCONJ
dpc-3121	72	24	recurrent	recurrent	ADJ
dpc-3121	72	25	eczema	eczema	NOUN
dpc-3121	72	26	[	[	X
dpc-3121	72	27	30	30	NUM
dpc-3121	72	28	]	]	PUNCT
dpc-3121	72	29	.	.	PUNCT
dpc-3121	73	1	nonetheless	nonetheless	ADV
dpc-3121	73	2	,	,	PUNCT
dpc-3121	73	3	such	such	ADJ
dpc-3121	73	4	topical	topical	ADJ
dpc-3121	73	5	administration	administration	NOUN
dpc-3121	73	6	may	may	AUX
dpc-3121	73	7	not	not	PART
dpc-3121	73	8	ensure	ensure	VERB
dpc-3121	73	9	complete	complete	ADJ
dpc-3121	73	10	absorption	absorption	NOUN
dpc-3121	73	11	of	of	ADP
dpc-3121	73	12	the	the	DET
dpc-3121	73	13	pharmaceutically	pharmaceutically	ADV
dpc-3121	73	14	active	active	ADJ
dpc-3121	73	15	ingredient	ingredient	NOUN
dpc-3121	73	16	and	and	CCONJ
dpc-3121	73	17	diminish	diminish	VERB
dpc-3121	73	18	the	the	DET
dpc-3121	73	19	pharmacokinetic	pharmacokinetic	ADJ
dpc-3121	73	20	capacity	capacity	NOUN
dpc-3121	73	21	of	of	ADP
dpc-3121	73	22	the	the	DET
dpc-3121	73	23	drug	drug	NOUN
dpc-3121	73	24	.	.	PUNCT
dpc-3121	74	1	moreover	moreover	ADV
dpc-3121	74	2	,	,	PUNCT
dpc-3121	74	3	long	long	ADJ
dpc-3121	74	4	-	-	PUNCT
dpc-3121	74	5	term	term	NOUN
dpc-3121	74	6	administration	administration	NOUN
dpc-3121	74	7	of	of	ADP
dpc-3121	74	8	steroidal	steroidal	NOUN
dpc-3121	74	9	creams	cream	NOUN
dpc-3121	74	10	is	be	AUX
dpc-3121	74	11	not	not	PART
dpc-3121	74	12	recommended	recommend	VERB
dpc-3121	74	13	due	due	ADJ
dpc-3121	74	14	to	to	ADP
dpc-3121	74	15	side	side	ADJ
dpc-3121	74	16	effects	effect	NOUN
dpc-3121	74	17	associated	associate	VERB
dpc-3121	74	18	with	with	ADP
dpc-3121	74	19	chronic	chronic	ADJ
dpc-3121	74	20	exposure	exposure	NOUN
dpc-3121	74	21	to	to	ADP
dpc-3121	74	22	the	the	DET
dpc-3121	74	23	compound	compound	NOUN
dpc-3121	74	24	,	,	PUNCT
dpc-3121	74	25	including	include	VERB
dpc-3121	74	26	skin	skin	NOUN
dpc-3121	74	27	atrophy	atrophy	NOUN
dpc-3121	74	28	,	,	PUNCT
dpc-3121	74	29	telangiectasia	telangiectasia	NOUN
dpc-3121	74	30	,	,	PUNCT
dpc-3121	74	31	and	and	CCONJ
dpc-3121	74	32	striae	striae	PROPN
dpc-3121	74	33	distensae	distensae	NOUN
dpc-3121	74	34	[	[	X
dpc-3121	74	35	30	30	NUM
dpc-3121	74	36	]	]	PUNCT
dpc-3121	74	37	.	.	PUNCT
dpc-3121	75	1	some	some	DET
dpc-3121	75	2	novel	novel	ADJ
dpc-3121	75	3	atopic	atopic	NOUN
dpc-3121	75	4	dermatitis	dermatitis	NOUN
dpc-3121	75	5	drugs	drug	NOUN
dpc-3121	75	6	,	,	PUNCT
dpc-3121	75	7	eg	eg	NOUN
dpc-3121	75	8	crisaborole	crisaborole	NOUN
dpc-3121	75	9	,	,	PUNCT
dpc-3121	75	10	are	be	AUX
dpc-3121	75	11	again	again	ADV
dpc-3121	75	12	delivered	deliver	VERB
dpc-3121	75	13	by	by	ADP
dpc-3121	75	14	topical	topical	ADJ
dpc-3121	75	15	application	application	NOUN
dpc-3121	75	16	[	[	X
dpc-3121	75	17	22,31	22,31	NOUN
dpc-3121	75	18	+	+	NOUN
dpc-3121	75	19	.	.	PUNCT
dpc-3121	76	1	with	with	ADP
dpc-3121	76	2	currently	currently	ADV
dpc-3121	76	3	limited	limit	VERB
dpc-3121	76	4	evidence	evidence	NOUN
dpc-3121	76	5	for	for	ADP
dpc-3121	76	6	their	their	PRON
dpc-3121	76	7	efficacy	efficacy	NOUN
dpc-3121	76	8	in	in	ADP
dpc-3121	76	9	comparison	comparison	NOUN
dpc-3121	76	10	with	with	ADP
dpc-3121	76	11	established	establish	VERB
dpc-3121	76	12	glucocorticoids	glucocorticoid	NOUN
dpc-3121	76	13	and	and	CCONJ
dpc-3121	76	14	calcineurin	calcineurin	ADJ
dpc-3121	76	15	inhibitors	inhibitor	NOUN
dpc-3121	76	16	such	such	ADJ
dpc-3121	76	17	as	as	ADP
dpc-3121	76	18	tacrolimus	tacrolimus	NOUN
dpc-3121	76	19	,	,	PUNCT
dpc-3121	76	20	they	they	PRON
dpc-3121	76	21	are	be	AUX
dpc-3121	76	22	,	,	PUNCT
dpc-3121	76	23	at	at	ADP
dpc-3121	76	24	present	present	ADJ
dpc-3121	76	25	,	,	PUNCT
dpc-3121	76	26	particularly	particularly	ADV
dpc-3121	76	27	recommended	recommend	VERB
dpc-3121	76	28	for	for	ADP
dpc-3121	76	29	those	those	DET
dpc-3121	76	30	patients	patient	NOUN
dpc-3121	76	31	for	for	ADP
dpc-3121	76	32	whom	whom	PRON
dpc-3121	76	33	steroid	steroid	NOUN
dpc-3121	76	34	treatment	treatment	NOUN
dpc-3121	76	35	is	be	AUX
dpc-3121	76	36	contraindicated	contraindicate	VERB
dpc-3121	76	37	or	or	CCONJ
dpc-3121	76	38	for	for	ADP
dpc-3121	76	39	those	those	PRON
dpc-3121	76	40	who	who	PRON
dpc-3121	76	41	are	be	AUX
dpc-3121	76	42	recalcitrant	recalcitrant	ADJ
dpc-3121	76	43	and	and	CCONJ
dpc-3121	76	44	hence	hence	ADV
dpc-3121	76	45	can	can	AUX
dpc-3121	76	46	not	not	PART
dpc-3121	76	47	be	be	AUX
dpc-3121	76	48	treated	treat	VERB
dpc-3121	76	49	with	with	ADP
dpc-3121	76	50	calcineurin	calcineurin	ADJ
dpc-3121	76	51	inhibitors	inhibitor	NOUN
dpc-3121	76	52	[	[	X
dpc-3121	76	53	32	32	NUM
dpc-3121	76	54	]	]	PUNCT
dpc-3121	76	55	.	.	PUNCT
dpc-3121	77	1	in	in	ADP
dpc-3121	77	2	a	a	DET
dpc-3121	77	3	recent	recent	ADJ
dpc-3121	77	4	study	study	NOUN
dpc-3121	77	5	by	by	ADP
dpc-3121	77	6	thom	thom	PROPN
dpc-3121	77	7	et	et	PROPN
dpc-3121	77	8	al	al	PROPN
dpc-3121	77	9	,	,	PUNCT
dpc-3121	77	10	the	the	DET
dpc-3121	77	11	efficacy	efficacy	NOUN
dpc-3121	77	12	of	of	ADP
dpc-3121	77	13	crisaborole	crisaborole	PROPN
dpc-3121	77	14	ointment	ointment	NOUN
dpc-3121	77	15	was	be	AUX
dpc-3121	77	16	compared	compare	VERB
dpc-3121	77	17	to	to	ADP
dpc-3121	77	18	that	that	PRON
dpc-3121	77	19	of	of	ADP
dpc-3121	77	20	the	the	DET
dpc-3121	77	21	calcineurin	calcineurin	ADJ
dpc-3121	77	22	inhibitors	inhibitor	NOUN
dpc-3121	77	23	tacrolimus	tacrolimus	VERB
dpc-3121	77	24	and	and	CCONJ
dpc-3121	77	25	pimecrolimus	pimecrolimus	NOUN
dpc-3121	77	26	based	base	VERB
dpc-3121	77	27	on	on	ADP
dpc-3121	77	28	patient	patient	ADJ
dpc-3121	77	29	data	datum	NOUN
dpc-3121	77	30	from	from	ADP
dpc-3121	77	31	randomized	randomized	ADJ
dpc-3121	77	32	controlled	control	VERB
dpc-3121	77	33	trials	trial	NOUN
dpc-3121	77	34	that	that	PRON
dpc-3121	77	35	tested	test	VERB
dpc-3121	77	36	either	either	CCONJ
dpc-3121	77	37	crisaborole	crisaborole	NOUN
dpc-3121	77	38	or	or	CCONJ
dpc-3121	77	39	the	the	DET
dpc-3121	77	40	calcineurin	calcineurin	ADJ
dpc-3121	77	41	inhibitors	inhibitor	NOUN
dpc-3121	77	42	[	[	X
dpc-3121	77	43	33	33	NUM
dpc-3121	77	44	]	]	PUNCT
dpc-3121	77	45	.	.	PUNCT
dpc-3121	78	1	based	base	VERB
dpc-3121	78	2	on	on	ADP
dpc-3121	78	3	this	this	DET
dpc-3121	78	4	indirect	indirect	ADJ
dpc-3121	78	5	comparison	comparison	NOUN
dpc-3121	78	6	,	,	PUNCT
dpc-3121	78	7	crisaborole	crisaborole	PROPN
dpc-3121	78	8	was	be	AUX
dpc-3121	78	9	superior	superior	ADJ
dpc-3121	78	10	to	to	ADP
dpc-3121	78	11	both	both	DET
dpc-3121	78	12	calcineurin	calcineurin	ADJ
dpc-3121	78	13	inhibitors	inhibitor	NOUN
dpc-3121	78	14	in	in	ADP
dpc-3121	78	15	improving	improve	VERB
dpc-3121	78	16	the	the	DET
dpc-3121	78	17	investigator	investigator	NOUN
dpc-3121	78	18	static	static	ADJ
dpc-3121	78	19	global	global	ADJ
dpc-3121	78	20	assessment	assessment	NOUN
dpc-3121	78	21	scores	score	NOUN
dpc-3121	78	22	[	[	X
dpc-3121	78	23	33	33	NUM
dpc-3121	78	24	]	]	PUNCT
dpc-3121	78	25	.	.	PUNCT
dpc-3121	79	1	in	in	ADP
dpc-3121	79	2	this	this	DET
dpc-3121	79	3	context	context	NOUN
dpc-3121	79	4	,	,	PUNCT
dpc-3121	79	5	prospective	prospective	ADJ
dpc-3121	79	6	trials	trial	NOUN
dpc-3121	79	7	directly	directly	ADV
dpc-3121	79	8	comparing	compare	VERB
dpc-3121	79	9	both	both	DET
dpc-3121	79	10	agents	agent	NOUN
dpc-3121	79	11	within	within	ADP
dpc-3121	79	12	the	the	DET
dpc-3121	79	13	same	same	ADJ
dpc-3121	79	14	study	study	NOUN
dpc-3121	79	15	setting	setting	NOUN
dpc-3121	79	16	are	be	AUX
dpc-3121	79	17	required	require	VERB
dpc-3121	79	18	to	to	PART
dpc-3121	79	19	judge	judge	VERB
dpc-3121	79	20	the	the	DET
dpc-3121	79	21	superiority	superiority	NOUN
dpc-3121	79	22	of	of	ADP
dpc-3121	79	23	crisaborole	crisaborole	NOUN
dpc-3121	79	24	over	over	ADP
dpc-3121	79	25	established	establish	VERB
dpc-3121	79	26	calcineurin	calcineurin	NOUN
dpc-3121	79	27	agents	agent	NOUN
dpc-3121	79	28	conclusively	conclusively	ADV
dpc-3121	79	29	.	.	PUNCT
dpc-3121	80	1	one	one	NUM
dpc-3121	80	2	such	such	ADJ
dpc-3121	80	3	trial	trial	NOUN
dpc-3121	80	4	with	with	ADP
dpc-3121	80	5	a	a	DET
dpc-3121	80	6	comparatively	comparatively	ADV
dpc-3121	80	7	small	small	ADJ
dpc-3121	80	8	study	study	NOUN
dpc-3121	80	9	cohort	cohort	NOUN
dpc-3121	80	10	(	(	PUNCT
dpc-3121	80	11	n	n	NOUN
dpc-3121	80	12	=	=	SYM
dpc-3121	80	13	235	235	NUM
dpc-3121	80	14	in	in	ADP
dpc-3121	80	15	four	four	NUM
dpc-3121	80	16	patient	patient	ADJ
dpc-3121	80	17	groups	group	NOUN
dpc-3121	80	18	)	)	PUNCT
dpc-3121	80	19	was	be	AUX
dpc-3121	80	20	conducted	conduct	VERB
dpc-3121	80	21	but	but	CCONJ
dpc-3121	80	22	terminated	terminate	VERB
dpc-3121	80	23	early	early	ADV
dpc-3121	80	24	due	due	ADP
dpc-3121	80	25	to	to	ADP
dpc-3121	80	26	a	a	DET
dpc-3121	80	27	business	business	NOUN
dpc-3121	80	28	decision	decision	NOUN
dpc-3121	80	29	,	,	PUNCT
dpc-3121	80	30	yet	yet	CCONJ
dpc-3121	80	31	initial	initial	ADJ
dpc-3121	80	32	results	result	NOUN
dpc-3121	80	33	were	be	AUX
dpc-3121	80	34	obtained	obtain	VERB
dpc-3121	80	35	(	(	PUNCT
dpc-3121	80	36	clinicaltrials.gov	clinicaltrials.gov	X
dpc-3121	80	37	identifier	identifier	NOUN
dpc-3121	80	38	nct03539601	nct03539601	NOUN
dpc-3121	80	39	)	)	PUNCT
dpc-3121	80	40	.	.	PUNCT
dpc-3121	81	1	within	within	ADP
dpc-3121	81	2	the	the	DET
dpc-3121	81	3	four	four	NUM
dpc-3121	81	4	study	study	NOUN
dpc-3121	81	5	groups	group	NOUN
dpc-3121	81	6	(	(	PUNCT
dpc-3121	81	7	vehicle	vehicle	NOUN
dpc-3121	81	8	control	control	NOUN
dpc-3121	81	9	,	,	PUNCT
dpc-3121	81	10	crisaborole	crisaborole	NOUN
dpc-3121	81	11	,	,	PUNCT
dpc-3121	81	12	hydrocortisone	hydrocortisone	NOUN
dpc-3121	81	13	butyrate	butyrate	NOUN
dpc-3121	81	14	,	,	PUNCT
dpc-3121	81	15	pimecrolimus	pimecrolimus	NOUN
dpc-3121	81	16	)	)	PUNCT
dpc-3121	81	17	,	,	PUNCT
dpc-3121	81	18	the	the	DET
dpc-3121	81	19	largest	large	ADJ
dpc-3121	81	20	improvement	improvement	NOUN
dpc-3121	81	21	was	be	AUX
dpc-3121	81	22	seen	see	VERB
dpc-3121	81	23	for	for	ADP
dpc-3121	81	24	patients	patient	NOUN
dpc-3121	81	25	treated	treat	VERB
dpc-3121	81	26	with	with	ADP
dpc-3121	81	27	hydrocortisone	hydrocortisone	PROPN
dpc-3121	81	28	,	,	PUNCT
dpc-3121	81	29	yet	yet	CCONJ
dpc-3121	81	30	the	the	DET
dpc-3121	81	31	organizers	organizer	NOUN
dpc-3121	81	32	acknowledged	acknowledge	VERB
dpc-3121	81	33	that	that	SCONJ
dpc-3121	81	34	the	the	DET
dpc-3121	81	35	subgroups	subgroup	NOUN
dpc-3121	81	36	were	be	AUX
dpc-3121	81	37	too	too	ADV
dpc-3121	81	38	small	small	ADJ
dpc-3121	81	39	to	to	PART
dpc-3121	81	40	conduct	conduct	VERB
dpc-3121	81	41	reliable	reliable	ADJ
dpc-3121	81	42	statistical	statistical	ADJ
dpc-3121	81	43	analysis	analysis	NOUN
dpc-3121	82	1	[	[	X
dpc-3121	82	2	34	34	NUM
dpc-3121	82	3	]	]	PUNCT
dpc-3121	82	4	.	.	PUNCT
dpc-3121	83	1	it	it	PRON
dpc-3121	83	2	is	be	AUX
dpc-3121	83	3	also	also	ADV
dpc-3121	83	4	yet	yet	ADV
dpc-3121	83	5	unclear	unclear	ADJ
dpc-3121	83	6	to	to	ADP
dpc-3121	83	7	what	what	DET
dpc-3121	83	8	extent	extent	NOUN
dpc-3121	83	9	crisaborole	crisaborole	VERB
dpc-3121	83	10	creams	cream	NOUN
dpc-3121	83	11	or	or	CCONJ
dpc-3121	83	12	ointments	ointment	NOUN
dpc-3121	83	13	can	can	AUX
dpc-3121	83	14	overcome	overcome	VERB
dpc-3121	83	15	the	the	DET
dpc-3121	83	16	side	side	NOUN
dpc-3121	83	17	effects	effect	NOUN
dpc-3121	83	18	raised	raise	VERB
dpc-3121	83	19	with	with	ADP
dpc-3121	83	20	glucocorticoid	glucocorticoid	ADJ
dpc-3121	83	21	treatment	treatment	NOUN
dpc-3121	83	22	,	,	PUNCT
dpc-3121	83	23	and	and	CCONJ
dpc-3121	83	24	their	their	PRON
dpc-3121	83	25	suitability	suitability	NOUN
dpc-3121	83	26	for	for	ADP
dpc-3121	83	27	long	long	ADJ
dpc-3121	83	28	-	-	PUNCT
dpc-3121	83	29	term	term	NOUN
dpc-3121	83	30	treatment	treatment	NOUN
dpc-3121	83	31	must	must	AUX
dpc-3121	83	32	be	be	AUX
dpc-3121	83	33	validated	validate	VERB
dpc-3121	83	34	.	.	PUNCT
dpc-3121	84	1	patches	patch	NOUN
dpc-3121	84	2	are	be	AUX
dpc-3121	84	3	an	an	DET
dpc-3121	84	4	alternative	alternative	ADJ
dpc-3121	84	5	vehicle	vehicle	NOUN
dpc-3121	84	6	for	for	ADP
dpc-3121	84	7	the	the	DET
dpc-3121	84	8	topical	topical	ADJ
dpc-3121	84	9	application	application	NOUN
dpc-3121	84	10	of	of	ADP
dpc-3121	84	11	an	an	DET
dpc-3121	84	12	atopic	atopic	NOUN
dpc-3121	84	13	dermatitis	dermatitis	NOUN
dpc-3121	84	14	drug	drug	NOUN
dpc-3121	84	15	[	[	X
dpc-3121	84	16	35	35	NUM
dpc-3121	84	17	-	-	SYM
dpc-3121	84	18	37	37	NUM
dpc-3121	84	19	]	]	PUNCT
dpc-3121	84	20	.	.	PUNCT
dpc-3121	85	1	these	these	PRON
dpc-3121	85	2	have	have	AUX
dpc-3121	85	3	been	be	AUX
dpc-3121	85	4	developed	develop	VERB
dpc-3121	85	5	for	for	ADP
dpc-3121	85	6	the	the	DET
dpc-3121	85	7	administration	administration	NOUN
dpc-3121	85	8	of	of	ADP
dpc-3121	85	9	urea	urea	NOUN
dpc-3121	85	10	and	and	CCONJ
dpc-3121	85	11	pioglitazone	pioglitazone	NOUN
dpc-3121	86	1	[	[	X
dpc-3121	86	2	35,36	35,36	NUM
dpc-3121	86	3	]	]	PUNCT
dpc-3121	86	4	.	.	PUNCT
dpc-3121	87	1	the	the	DET
dpc-3121	87	2	urea	urea	NOUN
dpc-3121	87	3	patch	patch	NOUN
dpc-3121	87	4	is	be	AUX
dpc-3121	87	5	produced	produce	VERB
dpc-3121	87	6	as	as	ADP
dpc-3121	87	7	a	a	DET
dpc-3121	87	8	combination	combination	NOUN
dpc-3121	87	9	of	of	ADP
dpc-3121	87	10	electrospinning	electrospinne	VERB
dpc-3121	87	11	of	of	ADP
dpc-3121	87	12	poly(vinyl	poly(vinyl	ADJ
dpc-3121	87	13	butyral	butyral	ADJ
dpc-3121	87	14	-	-	PUNCT
dpc-3121	87	15	co	co	NOUN
dpc-3121	87	16	-	-	ADJ
dpc-3121	87	17	vinyl	vinyl	ADJ
dpc-3121	87	18	alcohol	alcohol	NOUN
dpc-3121	87	19	-	-	PUNCT
dpc-3121	87	20	co	co	NOUN
dpc-3121	87	21	-	-	ADJ
dpc-3121	87	22	vinyl	vinyl	ADJ
dpc-3121	87	23	acetate	acetate	NOUN
dpc-3121	87	24	)	)	PUNCT
dpc-3121	87	25	fibers	fiber	NOUN
dpc-3121	87	26	to	to	PART
dpc-3121	87	27	generate	generate	VERB
dpc-3121	87	28	a	a	DET
dpc-3121	87	29	membrane	membrane	NOUN
dpc-3121	87	30	and	and	CCONJ
dpc-3121	87	31	electrospraying	electrospraye	VERB
dpc-3121	87	32	4	4	NUM
dpc-3121	87	33	review	review	NOUN
dpc-3121	87	34	|	|	ADV
dpc-3121	87	35	dermatol	dermatol	ADJ
dpc-3121	87	36	pract	pract	NOUN
dpc-3121	87	37	concept	concept	NOUN
dpc-3121	87	38	.	.	PUNCT
dpc-3121	88	1	2023;13(4):e2023216	2023;13(4):e2023216	NUM
dpc-3121	88	2	ingredient	ingredient	NOUN
dpc-3121	88	3	efficacy	efficacy	NOUN
dpc-3121	88	4	and	and	CCONJ
dpc-3121	88	5	ensure	ensure	VERB
dpc-3121	88	6	its	its	PRON
dpc-3121	88	7	delivery	delivery	NOUN
dpc-3121	88	8	to	to	ADP
dpc-3121	88	9	the	the	DET
dpc-3121	88	10	target	target	NOUN
dpc-3121	88	11	site	site	NOUN
dpc-3121	88	12	.	.	PUNCT
dpc-3121	89	1	they	they	PRON
dpc-3121	89	2	typically	typically	ADV
dpc-3121	89	3	target	target	VERB
dpc-3121	89	4	the	the	DET
dpc-3121	89	5	entire	entire	ADJ
dpc-3121	89	6	immune	immune	ADJ
dpc-3121	89	7	system	system	NOUN
dpc-3121	89	8	and	and	CCONJ
dpc-3121	89	9	the	the	DET
dpc-3121	89	10	release	release	NOUN
dpc-3121	89	11	of	of	ADP
dpc-3121	89	12	pro	pro	ADJ
dpc-3121	89	13	-	-	ADJ
dpc-3121	89	14	inflammatory	inflammatory	ADJ
dpc-3121	89	15	cytokines	cytokine	NOUN
dpc-3121	89	16	rather	rather	ADV
dpc-3121	89	17	than	than	ADP
dpc-3121	89	18	the	the	DET
dpc-3121	89	19	isolated	isolate	VERB
dpc-3121	89	20	inflamed	inflame	VERB
dpc-3121	89	21	skin	skin	NOUN
dpc-3121	89	22	area	area	NOUN
dpc-3121	89	23	.	.	PUNCT
dpc-3121	90	1	importantly	importantly	ADV
dpc-3121	90	2	,	,	PUNCT
dpc-3121	90	3	due	due	ADP
dpc-3121	90	4	to	to	ADP
dpc-3121	90	5	the	the	DET
dpc-3121	90	6	risk	risk	NOUN
dpc-3121	90	7	of	of	ADP
dpc-3121	90	8	side	side	NOUN
dpc-3121	90	9	effects	effect	NOUN
dpc-3121	90	10	of	of	ADP
dpc-3121	90	11	systemic	systemic	ADJ
dpc-3121	90	12	drugs	drug	NOUN
dpc-3121	90	13	,	,	PUNCT
dpc-3121	90	14	the	the	DET
dpc-3121	90	15	dose	dose	NOUN
dpc-3121	90	16	should	should	AUX
dpc-3121	90	17	be	be	AUX
dpc-3121	90	18	relatively	relatively	ADV
dpc-3121	90	19	low	low	ADJ
dpc-3121	90	20	and	and	CCONJ
dpc-3121	90	21	be	be	AUX
dpc-3121	90	22	oriented	orient	VERB
dpc-3121	90	23	on	on	ADP
dpc-3121	90	24	the	the	DET
dpc-3121	90	25	effective	effective	ADJ
dpc-3121	90	26	topical	topical	ADJ
dpc-3121	90	27	concentration	concentration	NOUN
dpc-3121	91	1	[	[	X
dpc-3121	91	2	43	43	NUM
dpc-3121	91	3	]	]	PUNCT
dpc-3121	91	4	.	.	PUNCT
dpc-3121	92	1	purohit	purohit	PROPN
dpc-3121	92	2	et	et	PROPN
dpc-3121	92	3	al	al	PROPN
dpc-3121	92	4	report	report	PROPN
dpc-3121	92	5	on	on	ADP
dpc-3121	92	6	their	their	PRON
dpc-3121	92	7	analysis	analysis	NOUN
dpc-3121	92	8	to	to	PART
dpc-3121	92	9	determine	determine	VERB
dpc-3121	92	10	the	the	DET
dpc-3121	92	11	systemic	systemic	ADJ
dpc-3121	92	12	tofacitinib	tofacitinib	PROPN
dpc-3121	92	13	concentration	concentration	NOUN
dpc-3121	92	14	based	base	VERB
dpc-3121	92	15	on	on	ADP
dpc-3121	92	16	the	the	DET
dpc-3121	92	17	concentration	concentration	NOUN
dpc-3121	92	18	of	of	ADP
dpc-3121	92	19	tofacitinib	tofacitinib	NOUN
dpc-3121	92	20	ointment	ointment	NOUN
dpc-3121	92	21	and	and	CCONJ
dpc-3121	92	22	systemic	systemic	ADJ
dpc-3121	92	23	exposure	exposure	NOUN
dpc-3121	92	24	after	after	ADP
dpc-3121	92	25	crisaborole	crisaborole	NOUN
dpc-3121	92	26	ointment	ointment	NOUN
dpc-3121	92	27	application	application	NOUN
dpc-3121	92	28	[	[	X
dpc-3121	92	29	43,44	43,44	X
dpc-3121	92	30	]	]	X
dpc-3121	92	31	.	.	PUNCT
dpc-3121	93	1	their	their	PRON
dpc-3121	93	2	findings	finding	NOUN
dpc-3121	93	3	indicate	indicate	VERB
dpc-3121	93	4	a	a	DET
dpc-3121	93	5	proportional	proportional	ADJ
dpc-3121	93	6	systemic	systemic	ADJ
dpc-3121	93	7	exposure	exposure	NOUN
dpc-3121	93	8	of	of	ADP
dpc-3121	93	9	both	both	DET
dpc-3121	93	10	drugs	drug	NOUN
dpc-3121	93	11	according	accord	VERB
dpc-3121	93	12	to	to	ADP
dpc-3121	93	13	the	the	DET
dpc-3121	93	14	body	body	NOUN
dpc-3121	93	15	surface	surface	NOUN
dpc-3121	93	16	area	area	NOUN
dpc-3121	93	17	treated	treat	VERB
dpc-3121	93	18	.	.	PUNCT
dpc-3121	94	1	nanoparticles	nanoparticle	NOUN
dpc-3121	94	2	loading	load	VERB
dpc-3121	94	3	an	an	DET
dpc-3121	94	4	active	active	ADJ
dpc-3121	94	5	pharmacological	pharmacological	ADJ
dpc-3121	94	6	substance	substance	NOUN
dpc-3121	94	7	onto	onto	ADP
dpc-3121	94	8	nanoparticles	nanoparticle	NOUN
dpc-3121	94	9	has	have	AUX
dpc-3121	94	10	proven	prove	VERB
dpc-3121	94	11	efficient	efficient	ADJ
dpc-3121	94	12	for	for	ADP
dpc-3121	94	13	delivering	deliver	VERB
dpc-3121	94	14	numerous	numerous	ADJ
dpc-3121	94	15	drugs	drug	NOUN
dpc-3121	94	16	across	across	ADP
dpc-3121	94	17	distinct	distinct	ADJ
dpc-3121	94	18	indications	indication	NOUN
dpc-3121	94	19	.	.	PUNCT
dpc-3121	95	1	for	for	ADP
dpc-3121	95	2	the	the	DET
dpc-3121	95	3	treatment	treatment	NOUN
dpc-3121	95	4	of	of	ADP
dpc-3121	95	5	atopic	atopic	NOUN
dpc-3121	95	6	dermatitis	dermatitis	NOUN
dpc-3121	95	7	,	,	PUNCT
dpc-3121	95	8	such	such	ADJ
dpc-3121	95	9	nanoparticles	nanoparticle	NOUN
dpc-3121	95	10	are	be	AUX
dpc-3121	95	11	being	be	AUX
dpc-3121	95	12	developed	develop	VERB
dpc-3121	95	13	to	to	PART
dpc-3121	95	14	enhance	enhance	VERB
dpc-3121	95	15	the	the	DET
dpc-3121	95	16	efficient	efficient	ADJ
dpc-3121	95	17	delivery	delivery	NOUN
dpc-3121	95	18	of	of	ADP
dpc-3121	95	19	the	the	DET
dpc-3121	95	20	active	active	ADJ
dpc-3121	95	21	substance	substance	NOUN
dpc-3121	95	22	to	to	ADP
dpc-3121	95	23	the	the	DET
dpc-3121	95	24	target	target	NOUN
dpc-3121	95	25	site	site	NOUN
dpc-3121	96	1	[	[	X
dpc-3121	96	2	45,46	45,46	NOUN
dpc-3121	96	3	]	]	PUNCT
dpc-3121	96	4	.	.	PUNCT
dpc-3121	97	1	these	these	PRON
dpc-3121	97	2	have	have	AUX
dpc-3121	97	3	shown	show	VERB
dpc-3121	97	4	efficacy	efficacy	NOUN
dpc-3121	97	5	in	in	ADP
dpc-3121	97	6	vitro	vitro	X
dpc-3121	97	7	for	for	ADP
dpc-3121	97	8	the	the	DET
dpc-3121	97	9	delivery	delivery	NOUN
dpc-3121	97	10	of	of	ADP
dpc-3121	97	11	conventional	conventional	ADJ
dpc-3121	97	12	atopic	atopic	NOUN
dpc-3121	97	13	dermatitis	dermatitis	NOUN
dpc-3121	97	14	drugs	drug	NOUN
dpc-3121	97	15	such	such	ADJ
dpc-3121	97	16	as	as	ADP
dpc-3121	97	17	betamethasone	betamethasone	PROPN
dpc-3121	97	18	,	,	PUNCT
dpc-3121	97	19	hydrocortisone	hydrocortisone	PROPN
dpc-3121	97	20	,	,	PUNCT
dpc-3121	97	21	dexamethasone	dexamethasone	NOUN
dpc-3121	97	22	,	,	PUNCT
dpc-3121	97	23	and	and	CCONJ
dpc-3121	97	24	tacrolimus	tacrolimus	NOUN
dpc-3121	98	1	[	[	X
dpc-3121	98	2	47	47	NUM
dpc-3121	98	3	-	-	SYM
dpc-3121	98	4	53	53	NUM
dpc-3121	98	5	]	]	PUNCT
dpc-3121	98	6	.	.	PUNCT
dpc-3121	99	1	no	no	DET
dpc-3121	99	2	studies	study	NOUN
dpc-3121	99	3	have	have	AUX
dpc-3121	99	4	yet	yet	ADV
dpc-3121	99	5	investigated	investigate	VERB
dpc-3121	99	6	the	the	DET
dpc-3121	99	7	use	use	NOUN
dpc-3121	99	8	of	of	ADP
dpc-3121	99	9	nanoparticles	nanoparticle	NOUN
dpc-3121	99	10	for	for	ADP
dpc-3121	99	11	the	the	DET
dpc-3121	99	12	delivery	delivery	NOUN
dpc-3121	99	13	of	of	ADP
dpc-3121	99	14	novel	novel	ADJ
dpc-3121	99	15	atopic	atopic	NOUN
dpc-3121	99	16	dermatitis	dermatitis	NOUN
dpc-3121	99	17	drugs	drug	NOUN
dpc-3121	99	18	.	.	PUNCT
dpc-3121	100	1	of	of	ADP
dpc-3121	100	2	note	note	NOUN
dpc-3121	100	3	,	,	PUNCT
dpc-3121	100	4	the	the	DET
dpc-3121	100	5	use	use	NOUN
dpc-3121	100	6	of	of	ADP
dpc-3121	100	7	nanoparticles	nanoparticle	NOUN
dpc-3121	100	8	for	for	ADP
dpc-3121	100	9	the	the	DET
dpc-3121	100	10	delivery	delivery	NOUN
dpc-3121	100	11	of	of	ADP
dpc-3121	100	12	atopic	atopic	NOUN
dpc-3121	100	13	dermatitis	dermatitis	NOUN
dpc-3121	100	14	drugs	drug	NOUN
dpc-3121	100	15	must	must	AUX
dpc-3121	100	16	consider	consider	VERB
dpc-3121	100	17	the	the	DET
dpc-3121	100	18	potential	potential	NOUN
dpc-3121	100	19	for	for	ADP
dpc-3121	100	20	induction	induction	NOUN
dpc-3121	100	21	of	of	ADP
dpc-3121	100	22	anti	anti	ADJ
dpc-3121	100	23	-	-	ADJ
dpc-3121	100	24	inflammatory	inflammatory	ADJ
dpc-3121	100	25	reactions	reaction	NOUN
dpc-3121	100	26	[	[	X
dpc-3121	100	27	54	54	NUM
dpc-3121	100	28	]	]	PUNCT
dpc-3121	100	29	.	.	PUNCT
dpc-3121	101	1	choi	choi	PROPN
dpc-3121	101	2	et	et	PROPN
dpc-3121	101	3	al	al	PROPN
dpc-3121	101	4	demonstrated	demonstrate	VERB
dpc-3121	101	5	that	that	SCONJ
dpc-3121	101	6	the	the	DET
dpc-3121	101	7	material	material	NOUN
dpc-3121	101	8	and	and	CCONJ
dpc-3121	101	9	protein	protein	NOUN
dpc-3121	101	10	corona	corona	NOUN
dpc-3121	101	11	around	around	ADP
dpc-3121	101	12	the	the	DET
dpc-3121	101	13	nanoparticles	nanoparticle	NOUN
dpc-3121	101	14	determines	determine	VERB
dpc-3121	101	15	their	their	PRON
dpc-3121	101	16	inflammatory	inflammatory	ADJ
dpc-3121	101	17	potential	potential	NOUN
dpc-3121	101	18	,	,	PUNCT
dpc-3121	101	19	which	which	PRON
dpc-3121	101	20	is	be	AUX
dpc-3121	101	21	relevant	relevant	ADJ
dpc-3121	101	22	for	for	ADP
dpc-3121	101	23	inflammatory	inflammatory	ADJ
dpc-3121	101	24	skin	skin	NOUN
dpc-3121	101	25	conditions	condition	NOUN
dpc-3121	101	26	[	[	X
dpc-3121	101	27	54	54	NUM
dpc-3121	101	28	]	]	PUNCT
dpc-3121	101	29	.	.	PUNCT
dpc-3121	102	1	colloidal	colloidal	NOUN
dpc-3121	102	2	silica	silica	NOUN
dpc-3121	102	3	nanoparticles	nanoparticle	NOUN
dpc-3121	102	4	were	be	AUX
dpc-3121	102	5	found	find	VERB
dpc-3121	102	6	to	to	PART
dpc-3121	102	7	be	be	AUX
dpc-3121	102	8	superior	superior	ADJ
dpc-3121	102	9	to	to	ADP
dpc-3121	102	10	mesoporous	mesoporous	ADJ
dpc-3121	102	11	silica	silica	NOUN
dpc-3121	102	12	nanoparticles	nanoparticle	NOUN
dpc-3121	102	13	in	in	ADP
dpc-3121	102	14	terms	term	NOUN
dpc-3121	102	15	of	of	ADP
dpc-3121	102	16	the	the	DET
dpc-3121	102	17	inflammatory	inflammatory	ADJ
dpc-3121	102	18	reactions	reaction	NOUN
dpc-3121	102	19	in	in	ADP
dpc-3121	102	20	the	the	DET
dpc-3121	102	21	skin	skin	NOUN
dpc-3121	102	22	following	follow	VERB
dpc-3121	102	23	treatment	treatment	NOUN
dpc-3121	102	24	and	and	CCONJ
dpc-3121	102	25	the	the	DET
dpc-3121	102	26	induction	induction	NOUN
dpc-3121	102	27	of	of	ADP
dpc-3121	102	28	pro	pro	ADJ
dpc-3121	102	29	-	-	ADJ
dpc-3121	102	30	inflammatory	inflammatory	ADJ
dpc-3121	102	31	cytokines	cytokine	NOUN
dpc-3121	102	32	and	and	CCONJ
dpc-3121	102	33	dermatitis	dermatitis	NOUN
dpc-3121	102	34	-	-	PUNCT
dpc-3121	102	35	associated	associate	VERB
dpc-3121	102	36	immunoglobulins	immunoglobulin	NOUN
dpc-3121	102	37	[	[	X
dpc-3121	102	38	54	54	NUM
dpc-3121	102	39	]	]	PUNCT
dpc-3121	102	40	.	.	PUNCT
dpc-3121	103	1	iontophoresis	iontophoresis	NOUN
dpc-3121	103	2	iontophoresis	iontophoresis	NOUN
dpc-3121	103	3	entails	entail	VERB
dpc-3121	103	4	the	the	DET
dpc-3121	103	5	application	application	NOUN
dpc-3121	103	6	of	of	ADP
dpc-3121	103	7	a	a	DET
dpc-3121	103	8	low	low	ADJ
dpc-3121	103	9	-	-	PUNCT
dpc-3121	103	10	voltage	voltage	NOUN
dpc-3121	103	11	current	current	NOUN
dpc-3121	103	12	to	to	ADP
dpc-3121	103	13	the	the	DET
dpc-3121	103	14	skin	skin	NOUN
dpc-3121	103	15	to	to	PART
dpc-3121	103	16	stimulate	stimulate	VERB
dpc-3121	103	17	the	the	DET
dpc-3121	103	18	transdermal	transdermal	ADJ
dpc-3121	103	19	delivery	delivery	NOUN
dpc-3121	103	20	of	of	ADP
dpc-3121	103	21	a	a	DET
dpc-3121	103	22	pharmacological	pharmacological	ADJ
dpc-3121	103	23	agent	agent	NOUN
dpc-3121	103	24	[	[	X
dpc-3121	103	25	55	55	NUM
dpc-3121	103	26	]	]	PUNCT
dpc-3121	103	27	.	.	PUNCT
dpc-3121	104	1	this	this	DET
dpc-3121	104	2	method	method	NOUN
dpc-3121	104	3	has	have	AUX
dpc-3121	104	4	proven	prove	VERB
dpc-3121	104	5	efficient	efficient	ADJ
dpc-3121	104	6	for	for	ADP
dpc-3121	104	7	the	the	DET
dpc-3121	104	8	administering	administer	VERB
dpc-3121	104	9	corticosteroids	corticosteroid	NOUN
dpc-3121	104	10	for	for	ADP
dpc-3121	104	11	various	various	ADJ
dpc-3121	104	12	indications	indication	NOUN
dpc-3121	104	13	,	,	PUNCT
dpc-3121	104	14	including	include	VERB
dpc-3121	104	15	skin	skin	NOUN
dpc-3121	104	16	diseases	disease	NOUN
dpc-3121	104	17	[	[	X
dpc-3121	104	18	56	56	NUM
dpc-3121	104	19	]	]	PUNCT
dpc-3121	104	20	.	.	PUNCT
dpc-3121	105	1	there	there	PRON
dpc-3121	105	2	are	be	VERB
dpc-3121	105	3	currently	currently	ADV
dpc-3121	105	4	no	no	DET
dpc-3121	105	5	controlled	control	VERB
dpc-3121	105	6	clinical	clinical	ADJ
dpc-3121	105	7	studies	study	NOUN
dpc-3121	105	8	with	with	ADP
dpc-3121	105	9	human	human	ADJ
dpc-3121	105	10	patients	patient	NOUN
dpc-3121	105	11	that	that	PRON
dpc-3121	105	12	assessed	assess	VERB
dpc-3121	105	13	the	the	DET
dpc-3121	105	14	suitability	suitability	NOUN
dpc-3121	105	15	of	of	ADP
dpc-3121	105	16	this	this	DET
dpc-3121	105	17	method	method	NOUN
dpc-3121	105	18	for	for	ADP
dpc-3121	105	19	atopic	atopic	NOUN
dpc-3121	105	20	dermatitis	dermatitis	NOUN
dpc-3121	105	21	drugs	drug	NOUN
dpc-3121	105	22	.	.	PUNCT
dpc-3121	106	1	in	in	ADP
dpc-3121	106	2	vitro	vitro	X
dpc-3121	106	3	data	datum	NOUN
dpc-3121	106	4	using	use	VERB
dpc-3121	106	5	human	human	ADJ
dpc-3121	106	6	skin	skin	NOUN
dpc-3121	106	7	preparations	preparation	NOUN
dpc-3121	106	8	revealed	reveal	VERB
dpc-3121	106	9	transdermal	transdermal	ADJ
dpc-3121	106	10	delivery	delivery	NOUN
dpc-3121	106	11	of	of	ADP
dpc-3121	106	12	hydrocortisone	hydrocortisone	NOUN
dpc-3121	106	13	,	,	PUNCT
dpc-3121	106	14	albeit	albeit	SCONJ
dpc-3121	106	15	similar	similar	ADJ
dpc-3121	106	16	efficacy	efficacy	NOUN
dpc-3121	106	17	was	be	AUX
dpc-3121	106	18	obtained	obtain	VERB
dpc-3121	106	19	by	by	ADP
dpc-3121	106	20	passive	passive	ADJ
dpc-3121	106	21	diffusion	diffusion	NOUN
dpc-3121	106	22	when	when	SCONJ
dpc-3121	106	23	healthy	healthy	ADJ
dpc-3121	106	24	skin	skin	NOUN
dpc-3121	106	25	was	be	AUX
dpc-3121	106	26	tested	test	VERB
dpc-3121	106	27	[	[	PUNCT
dpc-3121	106	28	57	57	NUM
dpc-3121	106	29	]	]	PUNCT
dpc-3121	106	30	.	.	PUNCT
dpc-3121	107	1	however	however	ADV
dpc-3121	107	2	,	,	PUNCT
dpc-3121	107	3	iontophoresis	iontophoresis	NOUN
dpc-3121	107	4	resulted	result	VERB
dpc-3121	107	5	in	in	ADP
dpc-3121	107	6	significantly	significantly	ADV
dpc-3121	107	7	higher	high	ADJ
dpc-3121	107	8	absorbance	absorbance	NOUN
dpc-3121	107	9	of	of	ADP
dpc-3121	107	10	hydrocortisone	hydrocortisone	NOUN
dpc-3121	107	11	than	than	ADP
dpc-3121	107	12	passive	passive	ADJ
dpc-3121	107	13	diffusion	diffusion	NOUN
dpc-3121	107	14	when	when	SCONJ
dpc-3121	107	15	eczematous	eczematous	ADJ
dpc-3121	107	16	skin	skin	NOUN
dpc-3121	107	17	and	and	CCONJ
dpc-3121	107	18	psoriatic	psoriatic	ADJ
dpc-3121	107	19	skin	skin	NOUN
dpc-3121	107	20	were	be	AUX
dpc-3121	107	21	tested	test	VERB
dpc-3121	107	22	[	[	PUNCT
dpc-3121	107	23	58	58	NUM
dpc-3121	107	24	]	]	PUNCT
dpc-3121	107	25	.	.	PUNCT
dpc-3121	108	1	the	the	DET
dpc-3121	108	2	clinical	clinical	ADJ
dpc-3121	108	3	use	use	NOUN
dpc-3121	108	4	of	of	ADP
dpc-3121	108	5	this	this	DET
dpc-3121	108	6	method	method	NOUN
dpc-3121	108	7	has	have	VERB
dpc-3121	108	8	yet	yet	ADV
dpc-3121	108	9	to	to	PART
dpc-3121	108	10	be	be	AUX
dpc-3121	108	11	established	establish	VERB
dpc-3121	108	12	for	for	ADP
dpc-3121	108	13	atopic	atopic	NOUN
dpc-3121	108	14	dermatitis	dermatitis	NOUN
dpc-3121	108	15	patients	patient	NOUN
dpc-3121	108	16	.	.	PUNCT
dpc-3121	109	1	a	a	DET
dpc-3121	109	2	summary	summary	NOUN
dpc-3121	109	3	of	of	ADP
dpc-3121	109	4	the	the	PRON
dpc-3121	109	5	of	of	ADP
dpc-3121	109	6	the	the	DET
dpc-3121	109	7	fibers	fiber	NOUN
dpc-3121	109	8	with	with	ADP
dpc-3121	109	9	urea	urea	NOUN
dpc-3121	109	10	to	to	PART
dpc-3121	109	11	soak	soak	VERB
dpc-3121	109	12	the	the	DET
dpc-3121	109	13	fibers	fiber	NOUN
dpc-3121	109	14	in	in	ADP
dpc-3121	109	15	the	the	DET
dpc-3121	109	16	active	active	ADJ
dpc-3121	109	17	substance	substance	NOUN
dpc-3121	109	18	[	[	X
dpc-3121	109	19	35	35	NUM
dpc-3121	109	20	]	]	PUNCT
dpc-3121	109	21	.	.	PUNCT
dpc-3121	110	1	the	the	DET
dpc-3121	110	2	idea	idea	NOUN
dpc-3121	110	3	behind	behind	ADP
dpc-3121	110	4	such	such	DET
dpc-3121	110	5	a	a	DET
dpc-3121	110	6	patch	patch	NOUN
dpc-3121	110	7	is	be	AUX
dpc-3121	110	8	to	to	PART
dpc-3121	110	9	enable	enable	VERB
dpc-3121	110	10	the	the	DET
dpc-3121	110	11	controlled	control	VERB
dpc-3121	110	12	release	release	NOUN
dpc-3121	110	13	of	of	ADP
dpc-3121	110	14	the	the	DET
dpc-3121	110	15	active	active	ADJ
dpc-3121	110	16	substance	substance	NOUN
dpc-3121	110	17	,	,	PUNCT
dpc-3121	110	18	in	in	ADP
dpc-3121	110	19	this	this	DET
dpc-3121	110	20	case	case	NOUN
dpc-3121	110	21	,	,	PUNCT
dpc-3121	110	22	urea	urea	NOUN
dpc-3121	110	23	,	,	PUNCT
dpc-3121	110	24	and	and	CCONJ
dpc-3121	110	25	enhance	enhance	VERB
dpc-3121	110	26	its	its	PRON
dpc-3121	110	27	transdermal	transdermal	ADJ
dpc-3121	110	28	delivery	delivery	NOUN
dpc-3121	110	29	.	.	PUNCT
dpc-3121	111	1	at	at	ADP
dpc-3121	111	2	present	present	ADJ
dpc-3121	111	3	,	,	PUNCT
dpc-3121	111	4	there	there	PRON
dpc-3121	111	5	is	be	VERB
dpc-3121	111	6	no	no	DET
dpc-3121	111	7	study	study	NOUN
dpc-3121	111	8	assessing	assess	VERB
dpc-3121	111	9	the	the	DET
dpc-3121	111	10	efficacy	efficacy	NOUN
dpc-3121	111	11	of	of	ADP
dpc-3121	111	12	such	such	ADJ
dpc-3121	111	13	urea	urea	NOUN
dpc-3121	111	14	patches	patch	NOUN
dpc-3121	111	15	in	in	ADP
dpc-3121	111	16	human	human	ADJ
dpc-3121	111	17	subjects	subject	NOUN
dpc-3121	111	18	.	.	PUNCT
dpc-3121	112	1	obaidat	obaidat	NOUN
dpc-3121	112	2	et	et	PROPN
dpc-3121	112	3	al	al	PROPN
dpc-3121	112	4	report	report	VERB
dpc-3121	112	5	the	the	DET
dpc-3121	112	6	generation	generation	NOUN
dpc-3121	112	7	of	of	ADP
dpc-3121	112	8	polyvinylpyrrolidone	polyvinylpyrrolidone	NOUN
dpc-3121	112	9	fiber	fiber	NOUN
dpc-3121	112	10	patches	patch	NOUN
dpc-3121	112	11	by	by	ADP
dpc-3121	112	12	electrospinning	electrospinne	VERB
dpc-3121	112	13	for	for	ADP
dpc-3121	112	14	the	the	DET
dpc-3121	112	15	transdermal	transdermal	ADJ
dpc-3121	112	16	delivery	delivery	NOUN
dpc-3121	112	17	of	of	ADP
dpc-3121	112	18	pioglitazone	pioglitazone	NOUN
dpc-3121	112	19	[	[	X
dpc-3121	112	20	36	36	NUM
dpc-3121	112	21	]	]	PUNCT
dpc-3121	112	22	.	.	PUNCT
dpc-3121	113	1	the	the	DET
dpc-3121	113	2	results	result	NOUN
dpc-3121	113	3	of	of	ADP
dpc-3121	113	4	in	in	ADP
dpc-3121	113	5	vitro	vitro	X
dpc-3121	113	6	experiments	experiment	NOUN
dpc-3121	113	7	demonstrated	demonstrate	VERB
dpc-3121	113	8	delivery	delivery	NOUN
dpc-3121	113	9	and	and	CCONJ
dpc-3121	113	10	retention	retention	NOUN
dpc-3121	113	11	of	of	ADP
dpc-3121	113	12	the	the	DET
dpc-3121	113	13	drug	drug	NOUN
dpc-3121	113	14	in	in	ADP
dpc-3121	113	15	the	the	DET
dpc-3121	113	16	skin	skin	NOUN
dpc-3121	113	17	[	[	X
dpc-3121	113	18	36	36	NUM
dpc-3121	113	19	]	]	PUNCT
dpc-3121	113	20	.	.	PUNCT
dpc-3121	114	1	investigations	investigation	NOUN
dpc-3121	114	2	on	on	ADP
dpc-3121	114	3	the	the	DET
dpc-3121	114	4	efficacy	efficacy	NOUN
dpc-3121	114	5	and	and	CCONJ
dpc-3121	114	6	safety	safety	NOUN
dpc-3121	114	7	of	of	ADP
dpc-3121	114	8	such	such	ADJ
dpc-3121	114	9	patches	patch	NOUN
dpc-3121	114	10	in	in	ADP
dpc-3121	114	11	human	human	ADJ
dpc-3121	114	12	patients	patient	NOUN
dpc-3121	114	13	are	be	AUX
dpc-3121	114	14	yet	yet	ADV
dpc-3121	114	15	to	to	PART
dpc-3121	114	16	be	be	AUX
dpc-3121	114	17	conducted	conduct	VERB
dpc-3121	114	18	.	.	PUNCT
dpc-3121	115	1	another	another	DET
dpc-3121	115	2	topical	topical	ADJ
dpc-3121	115	3	treatment	treatment	NOUN
dpc-3121	115	4	was	be	AUX
dpc-3121	115	5	developed	develop	VERB
dpc-3121	115	6	to	to	PART
dpc-3121	115	7	apply	apply	VERB
dpc-3121	115	8	botanicals	botanical	NOUN
dpc-3121	115	9	in	in	ADP
dpc-3121	115	10	adults	adult	NOUN
dpc-3121	115	11	suffering	suffer	VERB
dpc-3121	115	12	from	from	ADP
dpc-3121	115	13	atopic	atopic	NOUN
dpc-3121	115	14	dermatitis	dermatitis	NOUN
dpc-3121	115	15	[	[	X
dpc-3121	115	16	37	37	NUM
dpc-3121	115	17	-	-	SYM
dpc-3121	115	18	39	39	NUM
dpc-3121	115	19	]	]	PUNCT
dpc-3121	115	20	.	.	PUNCT
dpc-3121	116	1	compared	compare	VERB
dpc-3121	116	2	to	to	ADP
dpc-3121	116	3	the	the	DET
dpc-3121	116	4	vehicle	vehicle	NOUN
dpc-3121	116	5	,	,	PUNCT
dpc-3121	116	6	the	the	DET
dpc-3121	116	7	botanical	botanical	ADJ
dpc-3121	116	8	product	product	NOUN
dpc-3121	116	9	yielded	yield	VERB
dpc-3121	116	10	superior	superior	ADJ
dpc-3121	116	11	results	result	NOUN
dpc-3121	116	12	in	in	ADP
dpc-3121	116	13	improving	improve	VERB
dpc-3121	116	14	the	the	DET
dpc-3121	116	15	investigator	investigator	NOUN
dpc-3121	116	16	global	global	ADJ
dpc-3121	116	17	assessment	assessment	NOUN
dpc-3121	116	18	scores	score	NOUN
dpc-3121	116	19	and	and	CCONJ
dpc-3121	116	20	the	the	DET
dpc-3121	116	21	affected	affected	ADJ
dpc-3121	116	22	body	body	NOUN
dpc-3121	116	23	area	area	NOUN
dpc-3121	117	1	[	[	X
dpc-3121	117	2	38,39	38,39	NOUN
dpc-3121	117	3	]	]	X
dpc-3121	117	4	.	.	PUNCT
dpc-3121	118	1	unfortunately	unfortunately	ADV
dpc-3121	118	2	,	,	PUNCT
dpc-3121	118	3	no	no	DET
dpc-3121	118	4	details	detail	NOUN
dpc-3121	118	5	on	on	ADP
dpc-3121	118	6	the	the	DET
dpc-3121	118	7	product	product	NOUN
dpc-3121	118	8	particular	particular	ADJ
dpc-3121	118	9	characteristics	characteristic	NOUN
dpc-3121	118	10	or	or	CCONJ
dpc-3121	118	11	its	its	PRON
dpc-3121	118	12	performance	performance	NOUN
dpc-3121	118	13	in	in	ADP
dpc-3121	118	14	direct	direct	ADJ
dpc-3121	118	15	comparison	comparison	NOUN
dpc-3121	118	16	with	with	ADP
dpc-3121	118	17	a	a	DET
dpc-3121	118	18	competitor	competitor	NOUN
dpc-3121	118	19	product	product	NOUN
dpc-3121	118	20	were	be	AUX
dpc-3121	118	21	provided	provide	VERB
dpc-3121	118	22	.	.	PUNCT
dpc-3121	119	1	hogue	hogue	PROPN
dpc-3121	119	2	et	et	PROPN
dpc-3121	119	3	al	al	PROPN
dpc-3121	119	4	.	.	PROPN
dpc-3121	119	5	tested	test	VERB
dpc-3121	119	6	whether	whether	SCONJ
dpc-3121	119	7	applying	apply	VERB
dpc-3121	119	8	corticosteroids	corticosteroid	NOUN
dpc-3121	119	9	in	in	ADP
dpc-3121	119	10	a	a	DET
dpc-3121	119	11	spray	spray	NOUN
dpc-3121	119	12	rather	rather	ADV
dpc-3121	119	13	than	than	ADP
dpc-3121	119	14	a	a	DET
dpc-3121	119	15	cream	cream	NOUN
dpc-3121	119	16	could	could	AUX
dpc-3121	119	17	overcome	overcome	VERB
dpc-3121	119	18	the	the	DET
dpc-3121	119	19	adherence	adherence	NOUN
dpc-3121	119	20	issues	issue	NOUN
dpc-3121	119	21	observed	observe	VERB
dpc-3121	119	22	with	with	ADP
dpc-3121	119	23	conventional	conventional	ADJ
dpc-3121	119	24	corticosteroid	corticosteroid	ADJ
dpc-3121	119	25	treatments	treatment	NOUN
dpc-3121	120	1	[	[	X
dpc-3121	120	2	40	40	NUM
dpc-3121	120	3	]	]	PUNCT
dpc-3121	120	4	.	.	PUNCT
dpc-3121	121	1	patients	patient	NOUN
dpc-3121	121	2	with	with	ADP
dpc-3121	121	3	a	a	DET
dpc-3121	121	4	history	history	NOUN
dpc-3121	121	5	of	of	ADP
dpc-3121	121	6	failed	fail	VERB
dpc-3121	121	7	corticosteroid	corticosteroid	NOUN
dpc-3121	121	8	therapy	therapy	NOUN
dpc-3121	121	9	were	be	AUX
dpc-3121	121	10	recruited	recruit	VERB
dpc-3121	121	11	and	and	CCONJ
dpc-3121	121	12	asked	ask	VERB
dpc-3121	121	13	to	to	PART
dpc-3121	121	14	apply	apply	VERB
dpc-3121	121	15	desoximetasone	desoximetasone	NOUN
dpc-3121	121	16	in	in	ADP
dpc-3121	121	17	spray	spray	NOUN
dpc-3121	121	18	form	form	NOUN
dpc-3121	121	19	.	.	PUNCT
dpc-3121	122	1	a	a	DET
dpc-3121	122	2	subgroup	subgroup	NOUN
dpc-3121	122	3	of	of	ADP
dpc-3121	122	4	the	the	DET
dpc-3121	122	5	patients	patient	NOUN
dpc-3121	122	6	was	be	AUX
dpc-3121	122	7	reminded	remind	VERB
dpc-3121	122	8	by	by	ADP
dpc-3121	122	9	phone	phone	NOUN
dpc-3121	122	10	calls	call	NOUN
dpc-3121	122	11	to	to	PART
dpc-3121	122	12	use	use	VERB
dpc-3121	122	13	the	the	DET
dpc-3121	122	14	spray	spray	NOUN
dpc-3121	122	15	daily	daily	ADV
dpc-3121	122	16	.	.	PUNCT
dpc-3121	123	1	the	the	DET
dpc-3121	123	2	results	result	NOUN
dpc-3121	123	3	revealed	reveal	VERB
dpc-3121	123	4	an	an	DET
dpc-3121	123	5	effect	effect	NOUN
dpc-3121	123	6	of	of	ADP
dpc-3121	123	7	the	the	DET
dpc-3121	123	8	spray	spray	NOUN
dpc-3121	123	9	vehicle	vehicle	NOUN
dpc-3121	123	10	and	and	CCONJ
dpc-3121	123	11	the	the	DET
dpc-3121	123	12	phone	phone	NOUN
dpc-3121	123	13	call	call	NOUN
dpc-3121	123	14	reminders	reminder	NOUN
dpc-3121	123	15	on	on	ADP
dpc-3121	123	16	treatment	treatment	NOUN
dpc-3121	123	17	adherence	adherence	NOUN
dpc-3121	123	18	[	[	X
dpc-3121	123	19	40	40	NUM
dpc-3121	123	20	]	]	PUNCT
dpc-3121	123	21	.	.	PUNCT
dpc-3121	124	1	these	these	DET
dpc-3121	124	2	findings	finding	NOUN
dpc-3121	124	3	point	point	VERB
dpc-3121	124	4	towards	towards	ADP
dpc-3121	124	5	spray	spray	VERB
dpc-3121	124	6	preparations	preparation	NOUN
dpc-3121	124	7	as	as	ADP
dpc-3121	124	8	alternative	alternative	ADJ
dpc-3121	124	9	vehicles	vehicle	NOUN
dpc-3121	124	10	for	for	ADP
dpc-3121	124	11	those	those	DET
dpc-3121	124	12	patients	patient	NOUN
dpc-3121	124	13	who	who	PRON
dpc-3121	124	14	consider	consider	VERB
dpc-3121	124	15	the	the	DET
dpc-3121	124	16	messiness	messiness	NOUN
dpc-3121	124	17	of	of	ADP
dpc-3121	124	18	ointment	ointment	NOUN
dpc-3121	124	19	or	or	CCONJ
dpc-3121	124	20	cream	cream	NOUN
dpc-3121	124	21	vehicles	vehicle	NOUN
dpc-3121	124	22	as	as	ADP
dpc-3121	124	23	an	an	DET
dpc-3121	124	24	obstacle	obstacle	NOUN
dpc-3121	124	25	for	for	ADP
dpc-3121	124	26	their	their	PRON
dpc-3121	124	27	regular	regular	ADJ
dpc-3121	124	28	application	application	NOUN
dpc-3121	124	29	[	[	X
dpc-3121	124	30	41	41	NUM
dpc-3121	124	31	]	]	PUNCT
dpc-3121	124	32	.	.	PUNCT
dpc-3121	125	1	nanoliposomes	nanoliposome	NOUN
dpc-3121	125	2	are	be	AUX
dpc-3121	125	3	developed	develop	VERB
dpc-3121	125	4	that	that	PRON
dpc-3121	125	5	enclose	enclose	VERB
dpc-3121	125	6	the	the	DET
dpc-3121	125	7	active	active	ADJ
dpc-3121	125	8	ingredient	ingredient	NOUN
dpc-3121	125	9	within	within	ADP
dpc-3121	125	10	a	a	DET
dpc-3121	125	11	lipid	lipid	NOUN
dpc-3121	125	12	layer	layer	NOUN
dpc-3121	125	13	and	and	CCONJ
dpc-3121	125	14	thereby	thereby	ADV
dpc-3121	125	15	prevent	prevent	VERB
dpc-3121	125	16	its	its	PRON
dpc-3121	125	17	premature	premature	ADJ
dpc-3121	125	18	solution	solution	NOUN
dpc-3121	125	19	to	to	PART
dpc-3121	125	20	improve	improve	VERB
dpc-3121	125	21	transdermal	transdermal	ADJ
dpc-3121	125	22	delivery	delivery	NOUN
dpc-3121	125	23	of	of	ADP
dpc-3121	125	24	the	the	DET
dpc-3121	125	25	drug	drug	NOUN
dpc-3121	125	26	to	to	ADP
dpc-3121	125	27	its	its	PRON
dpc-3121	125	28	target	target	NOUN
dpc-3121	125	29	site	site	NOUN
dpc-3121	125	30	.	.	PUNCT
dpc-3121	126	1	naeimifar	naeimifar	ADV
dpc-3121	126	2	et	et	PROPN
dpc-3121	126	3	al	al	PROPN
dpc-3121	126	4	developed	develop	VERB
dpc-3121	126	5	a	a	DET
dpc-3121	126	6	ruxolitinib	ruxolitinib	NOUN
dpc-3121	126	7	emulgel	emulgel	NOUN
dpc-3121	126	8	with	with	ADP
dpc-3121	126	9	nanoliposomes	nanoliposome	NOUN
dpc-3121	126	10	and	and	CCONJ
dpc-3121	126	11	tested	test	VERB
dpc-3121	126	12	its	its	PRON
dpc-3121	126	13	efficacy	efficacy	NOUN
dpc-3121	126	14	on	on	ADP
dpc-3121	126	15	patients	patient	NOUN
dpc-3121	126	16	with	with	ADP
dpc-3121	126	17	mild	mild	ADJ
dpc-3121	126	18	atopic	atopic	NOUN
dpc-3121	126	19	dermatitis	dermatitis	NOUN
dpc-3121	126	20	[	[	X
dpc-3121	126	21	42	42	NUM
dpc-3121	126	22	]	]	PUNCT
dpc-3121	126	23	.	.	PUNCT
dpc-3121	127	1	in	in	ADP
dpc-3121	127	2	addition	addition	NOUN
dpc-3121	127	3	to	to	ADP
dpc-3121	127	4	improving	improve	VERB
dpc-3121	127	5	dermatitis	dermatitis	NOUN
dpc-3121	127	6	-	-	PUNCT
dpc-3121	127	7	associated	associate	VERB
dpc-3121	127	8	symptoms	symptom	NOUN
dpc-3121	127	9	such	such	ADJ
dpc-3121	127	10	as	as	ADP
dpc-3121	127	11	itching	itching	NOUN
dpc-3121	127	12	and	and	CCONJ
dpc-3121	127	13	the	the	DET
dpc-3121	127	14	local	local	ADJ
dpc-3121	127	15	scoring	scoring	NOUN
dpc-3121	127	16	atopic	atopic	NOUN
dpc-3121	127	17	dermatitis	dermatitis	NOUN
dpc-3121	127	18	score	score	NOUN
dpc-3121	127	19	,	,	PUNCT
dpc-3121	127	20	the	the	DET
dpc-3121	127	21	skin	skin	NOUN
dpc-3121	127	22	condition	condition	NOUN
dpc-3121	127	23	at	at	ADP
dpc-3121	127	24	the	the	DET
dpc-3121	127	25	application	application	NOUN
dpc-3121	127	26	site	site	NOUN
dpc-3121	127	27	was	be	AUX
dpc-3121	127	28	evaluated	evaluate	VERB
dpc-3121	127	29	.	.	PUNCT
dpc-3121	128	1	symptoms	symptom	NOUN
dpc-3121	128	2	significantly	significantly	ADV
dpc-3121	128	3	improved	improve	VERB
dpc-3121	128	4	after	after	ADP
dpc-3121	128	5	a	a	DET
dpc-3121	128	6	four	four	NUM
dpc-3121	128	7	-	-	PUNCT
dpc-3121	128	8	week	week	NOUN
dpc-3121	128	9	use	use	NOUN
dpc-3121	128	10	of	of	ADP
dpc-3121	128	11	the	the	DET
dpc-3121	128	12	nanoliposomal	nanoliposomal	ADJ
dpc-3121	128	13	emulgel	emulgel	NOUN
dpc-3121	128	14	,	,	PUNCT
dpc-3121	128	15	and	and	CCONJ
dpc-3121	128	16	so	so	ADV
dpc-3121	128	17	did	do	VERB
dpc-3121	128	18	the	the	DET
dpc-3121	128	19	skin	skin	NOUN
dpc-3121	128	20	’s	’s	PART
dpc-3121	128	21	condition	condition	NOUN
dpc-3121	128	22	regarding	regard	VERB
dpc-3121	128	23	hydration	hydration	NOUN
dpc-3121	128	24	,	,	PUNCT
dpc-3121	128	25	melanin	melanin	NOUN
dpc-3121	128	26	content	content	NOUN
dpc-3121	128	27	,	,	PUNCT
dpc-3121	128	28	and	and	CCONJ
dpc-3121	128	29	erythema	erythema	ADJ
dpc-3121	129	1	[	[	X
dpc-3121	129	2	42	42	NUM
dpc-3121	129	3	]	]	PUNCT
dpc-3121	129	4	.	.	PUNCT
dpc-3121	130	1	systemic	systemic	ADJ
dpc-3121	130	2	delivery	delivery	NOUN
dpc-3121	130	3	systemic	systemic	ADJ
dpc-3121	130	4	treatment	treatment	NOUN
dpc-3121	130	5	is	be	AUX
dpc-3121	130	6	currently	currently	ADV
dpc-3121	130	7	only	only	ADV
dpc-3121	130	8	recommended	recommend	VERB
dpc-3121	130	9	for	for	ADP
dpc-3121	130	10	those	those	PRON
dpc-3121	130	11	with	with	ADP
dpc-3121	130	12	severe	severe	ADJ
dpc-3121	130	13	scored	scored	NOUN
dpc-3121	130	14	or	or	CCONJ
dpc-3121	130	15	persistent	persistent	ADJ
dpc-3121	130	16	eczema	eczema	NOUN
dpc-3121	131	1	[	[	X
dpc-3121	131	2	30	30	NUM
dpc-3121	131	3	]	]	PUNCT
dpc-3121	131	4	.	.	PUNCT
dpc-3121	132	1	recommended	recommend	VERB
dpc-3121	132	2	oral	oral	ADJ
dpc-3121	132	3	systemic	systemic	ADJ
dpc-3121	132	4	drugs	drug	NOUN
dpc-3121	132	5	for	for	ADP
dpc-3121	132	6	such	such	ADJ
dpc-3121	132	7	cases	case	NOUN
dpc-3121	132	8	are	be	AUX
dpc-3121	132	9	glucocorticoids	glucocorticoid	NOUN
dpc-3121	132	10	,	,	PUNCT
dpc-3121	132	11	dupilumab	dupilumab	NOUN
dpc-3121	132	12	,	,	PUNCT
dpc-3121	132	13	methotrexate	methotrexate	NOUN
dpc-3121	132	14	,	,	PUNCT
dpc-3121	132	15	azathioprine	azathioprine	NOUN
dpc-3121	132	16	,	,	PUNCT
dpc-3121	132	17	and	and	CCONJ
dpc-3121	132	18	mycophenolate	mycophenolate	VERB
dpc-3121	132	19	mofetil	mofetil	NOUN
dpc-3121	132	20	[	[	X
dpc-3121	132	21	30	30	NUM
dpc-3121	132	22	]	]	PUNCT
dpc-3121	132	23	.	.	PUNCT
dpc-3121	133	1	the	the	DET
dpc-3121	133	2	incentive	incentive	NOUN
dpc-3121	133	3	for	for	ADP
dpc-3121	133	4	developing	develop	VERB
dpc-3121	133	5	systemic	systemic	ADJ
dpc-3121	133	6	vehicles	vehicle	NOUN
dpc-3121	133	7	rather	rather	ADV
dpc-3121	133	8	than	than	ADP
dpc-3121	133	9	topical	topical	ADJ
dpc-3121	133	10	vehicles	vehicle	NOUN
dpc-3121	133	11	is	be	AUX
dpc-3121	133	12	to	to	PART
dpc-3121	133	13	enhance	enhance	VERB
dpc-3121	133	14	the	the	DET
dpc-3121	133	15	active	active	ADJ
dpc-3121	133	16	review	review	NOUN
dpc-3121	133	17	|	|	ADV
dpc-3121	133	18	dermatol	dermatol	ADJ
dpc-3121	133	19	pract	pract	NOUN
dpc-3121	133	20	concept	concept	NOUN
dpc-3121	133	21	.	.	PUNCT
dpc-3121	134	1	2023;13(4):e2023216	2023;13(4):e2023216	NUM
dpc-3121	134	2	5	5	NUM
dpc-3121	134	3	treatment	treatment	NOUN
dpc-3121	134	4	targets	target	NOUN
dpc-3121	134	5	with	with	ADP
dpc-3121	134	6	vehicles	vehicle	NOUN
dpc-3121	134	7	that	that	PRON
dpc-3121	134	8	allow	allow	VERB
dpc-3121	134	9	a	a	DET
dpc-3121	134	10	more	more	ADV
dpc-3121	134	11	reliable	reliable	ADJ
dpc-3121	134	12	delivery	delivery	NOUN
dpc-3121	134	13	of	of	ADP
dpc-3121	134	14	the	the	DET
dpc-3121	134	15	active	active	ADJ
dpc-3121	134	16	drug	drug	NOUN
dpc-3121	134	17	ingredient	ingredient	NOUN
dpc-3121	134	18	to	to	ADP
dpc-3121	134	19	the	the	DET
dpc-3121	134	20	target	target	NOUN
dpc-3121	134	21	site	site	NOUN
dpc-3121	134	22	.	.	PUNCT
dpc-3121	135	1	references	reference	NOUN
dpc-3121	135	2	1	1	NUM
dpc-3121	135	3	.	.	PUNCT
dpc-3121	136	1	urban	urban	PROPN
dpc-3121	136	2	k	k	PROPN
dpc-3121	136	3	,	,	PUNCT
dpc-3121	136	4	chu	chu	PROPN
dpc-3121	136	5	s	s	PROPN
dpc-3121	136	6	,	,	PUNCT
dpc-3121	136	7	giesey	giesey	ADJ
dpc-3121	136	8	rl	rl	X
dpc-3121	136	9	,	,	PUNCT
dpc-3121	136	10	mehrmal	mehrmal	PROPN
dpc-3121	136	11	s	s	PROPN
dpc-3121	136	12	,	,	PUNCT
dpc-3121	136	13	et	et	PROPN
dpc-3121	136	14	al	al	PROPN
dpc-3121	136	15	.	.	PUNCT
dpc-3121	137	1	the	the	DET
dpc-3121	137	2	global	global	ADJ
dpc-3121	137	3	,	,	PUNCT
dpc-3121	137	4	regional	regional	ADJ
dpc-3121	137	5	,	,	PUNCT
dpc-3121	137	6	and	and	CCONJ
dpc-3121	137	7	national	national	ADJ
dpc-3121	137	8	burden	burden	NOUN
dpc-3121	137	9	of	of	ADP
dpc-3121	137	10	atopic	atopic	NOUN
dpc-3121	137	11	dermatitis	dermatitis	NOUN
dpc-3121	137	12	in	in	ADP
dpc-3121	137	13	195	195	NUM
dpc-3121	137	14	countries	country	NOUN
dpc-3121	137	15	and	and	CCONJ
dpc-3121	137	16	territories	territory	NOUN
dpc-3121	137	17	:	:	PUNCT
dpc-3121	137	18	an	an	DET
dpc-3121	137	19	ecological	ecological	ADJ
dpc-3121	137	20	study	study	NOUN
dpc-3121	137	21	from	from	ADP
dpc-3121	137	22	the	the	DET
dpc-3121	137	23	global	global	ADJ
dpc-3121	137	24	burden	burden	NOUN
dpc-3121	137	25	of	of	ADP
dpc-3121	137	26	disease	disease	NOUN
dpc-3121	137	27	study	study	NOUN
dpc-3121	137	28	2017	2017	NUM
dpc-3121	137	29	.	.	PUNCT
dpc-3121	138	1	jaad	jaad	NOUN
dpc-3121	138	2	int	int	PROPN
dpc-3121	138	3	.	.	PUNCT
dpc-3121	139	1	2020;2:12	2020;2:12	NUM
dpc-3121	139	2	-	-	PUNCT
dpc-3121	139	3	18	18	NUM
dpc-3121	139	4	.	.	PUNCT
dpc-3121	140	1	doi	doi	NOUN
dpc-3121	140	2	:	:	PUNCT
dpc-3121	140	3	10.1016	10.1016	NUM
dpc-3121	140	4	/	/	SYM
dpc-3121	140	5	j	j	PROPN
dpc-3121	140	6	.jdin.2020.10.002	.jdin.2020.10.002	PUNCT
dpc-3121	140	7	.	.	PUNCT
dpc-3121	141	1	pmid	pmid	NOUN
dpc-3121	141	2	:	:	PUNCT
dpc-3121	141	3	34409347	34409347	NUM
dpc-3121	141	4	.	.	PUNCT
dpc-3121	142	1	pmcid	pmcid	NOUN
dpc-3121	142	2	:	:	PUNCT
dpc-3121	142	3	pmc8362298	pmc8362298	ADJ
dpc-3121	142	4	.	.	PUNCT
dpc-3121	143	1	2	2	X
dpc-3121	143	2	.	.	X
dpc-3121	143	3	bylund	bylund	PROPN
dpc-3121	143	4	s	s	PROPN
dpc-3121	143	5	,	,	PUNCT
dpc-3121	143	6	kobyletzki	kobyletzki	VERB
dpc-3121	143	7	lb	lb	NOUN
dpc-3121	143	8	,	,	PUNCT
dpc-3121	143	9	svalstedt	svalstedt	PROPN
dpc-3121	143	10	m	m	PROPN
dpc-3121	143	11	,	,	PUNCT
dpc-3121	143	12	svensson	svensson	PROPN
dpc-3121	143	13	å	å	PROPN
dpc-3121	143	14	.	.	PUNCT
dpc-3121	144	1	prevalence	prevalence	NOUN
dpc-3121	144	2	and	and	CCONJ
dpc-3121	144	3	incidence	incidence	NOUN
dpc-3121	144	4	of	of	ADP
dpc-3121	144	5	atopic	atopic	NOUN
dpc-3121	144	6	dermatitis	dermatitis	NOUN
dpc-3121	144	7	:	:	PUNCT
dpc-3121	144	8	a	a	DET
dpc-3121	144	9	systematic	systematic	ADJ
dpc-3121	144	10	review	review	NOUN
dpc-3121	144	11	.	.	PUNCT
dpc-3121	145	1	acta	acta	PROPN
dpc-3121	145	2	derm	derm	PROPN
dpc-3121	145	3	venereol	venereol	NOUN
dpc-3121	145	4	.	.	PUNCT
dpc-3121	146	1	2020;100(12):adv00160	2020;100(12):adv00160	X
dpc-3121	146	2	.	.	PUNCT
dpc-3121	146	3	doi:10.2340/00015555	doi:10.2340/00015555	NOUN
dpc-3121	146	4	-3510	-3510	PROPN
dpc-3121	146	5	.	.	PUNCT
dpc-3121	147	1	pmid	pmid	NOUN
dpc-3121	147	2	:	:	PUNCT
dpc-3121	147	3	32412646	32412646	NUM
dpc-3121	147	4	.	.	PUNCT
dpc-3121	148	1	pmcid	pmcid	NOUN
dpc-3121	148	2	:	:	PUNCT
dpc-3121	148	3	pmc9189744	pmc9189744	VERB
dpc-3121	148	4	.	.	PUNCT
dpc-3121	149	1	3	3	X
dpc-3121	149	2	.	.	X
dpc-3121	149	3	katoh	katoh	PROPN
dpc-3121	149	4	n	n	CCONJ
dpc-3121	149	5	,	,	PUNCT
dpc-3121	149	6	ohya	ohya	PROPN
dpc-3121	149	7	y	y	PROPN
dpc-3121	149	8	,	,	PUNCT
dpc-3121	149	9	ikeda	ikeda	PROPN
dpc-3121	149	10	m	m	PROPN
dpc-3121	149	11	,	,	PUNCT
dpc-3121	149	12	et	et	PROPN
dpc-3121	149	13	al	al	PROPN
dpc-3121	149	14	.	.	PROPN
dpc-3121	150	1	clinical	clinical	ADJ
dpc-3121	150	2	practice	practice	NOUN
dpc-3121	150	3	guidelines	guideline	NOUN
dpc-3121	150	4	for	for	ADP
dpc-3121	150	5	the	the	DET
dpc-3121	150	6	management	management	NOUN
dpc-3121	150	7	of	of	ADP
dpc-3121	150	8	atopic	atopic	NOUN
dpc-3121	150	9	dermatitis	dermatitis	NOUN
dpc-3121	150	10	2018	2018	NUM
dpc-3121	150	11	.	.	PUNCT
dpc-3121	151	1	j	j	PROPN
dpc-3121	151	2	dermatol	dermatol	NOUN
dpc-3121	151	3	.	.	PUNCT
dpc-3121	152	1	019;46(12):1053	019;46(12):1053	NUM
dpc-3121	152	2	-	-	PUNCT
dpc-3121	152	3	1101	1101	NUM
dpc-3121	152	4	.	.	PUNCT
dpc-3121	153	1	doi:10.1111/1346	doi:10.1111/1346	NOUN
dpc-3121	153	2	-	-	PUNCT
dpc-3121	153	3	8138.15090	8138.15090	NOUN
dpc-3121	153	4	.	.	PUNCT
dpc-3121	154	1	pmid	pmid	NOUN
dpc-3121	154	2	:	:	PUNCT
dpc-3121	154	3	31599013	31599013	NUM
dpc-3121	154	4	.	.	PUNCT
dpc-3121	155	1	4	4	X
dpc-3121	155	2	.	.	X
dpc-3121	155	3	eichenfield	eichenfield	PROPN
dpc-3121	155	4	lf	lf	PROPN
dpc-3121	155	5	,	,	PUNCT
dpc-3121	155	6	tom	tom	PROPN
dpc-3121	155	7	wl	wl	PROPN
dpc-3121	155	8	,	,	PUNCT
dpc-3121	155	9	chamlin	chamlin	PROPN
dpc-3121	155	10	sl	sl	PROPN
dpc-3121	155	11	,	,	PUNCT
dpc-3121	155	12	et	et	PROPN
dpc-3121	155	13	al	al	PROPN
dpc-3121	155	14	.	.	PUNCT
dpc-3121	155	15	guidelines	guideline	NOUN
dpc-3121	155	16	of	of	ADP
dpc-3121	155	17	care	care	NOUN
dpc-3121	155	18	for	for	ADP
dpc-3121	155	19	the	the	DET
dpc-3121	155	20	management	management	NOUN
dpc-3121	155	21	of	of	ADP
dpc-3121	155	22	atopic	atopic	NOUN
dpc-3121	155	23	dermatitis	dermatitis	NOUN
dpc-3121	155	24	:	:	PUNCT
dpc-3121	155	25	section	section	NOUN
dpc-3121	155	26	1	1	NUM
dpc-3121	155	27	.	.	PUNCT
dpc-3121	155	28	diagnosis	diagnosis	NOUN
dpc-3121	155	29	and	and	CCONJ
dpc-3121	155	30	assessment	assessment	NOUN
dpc-3121	155	31	of	of	ADP
dpc-3121	155	32	atopic	atopic	NOUN
dpc-3121	155	33	dermatitis	dermatitis	NOUN
dpc-3121	155	34	.	.	PUNCT
dpc-3121	156	1	j	j	PROPN
dpc-3121	156	2	am	be	AUX
dpc-3121	156	3	acad	acad	ADJ
dpc-3121	156	4	dermatol	dermatol	NOUN
dpc-3121	156	5	.	.	PUNCT
dpc-3121	157	1	014;70(2):338	014;70(2):338	NOUN
dpc-3121	157	2	-	-	PUNCT
dpc-3121	157	3	351	351	NUM
dpc-3121	157	4	.	.	PUNCT
dpc-3121	158	1	doi:10.1016	doi:10.1016	PROPN
dpc-3121	158	2	/	/	SYM
dpc-3121	158	3	j.jaad.2013.10.010	j.jaad.2013.10.010	PROPN
dpc-3121	158	4	.	.	PUNCT
dpc-3121	159	1	pmid	pmid	NOUN
dpc-3121	159	2	:	:	PUNCT
dpc-3121	159	3	24290431	24290431	NUM
dpc-3121	159	4	.	.	PUNCT
dpc-3121	160	1	pmcid	pmcid	NOUN
dpc-3121	160	2	:	:	PUNCT
dpc-3121	160	3	pmc4410183	pmc4410183	ADJ
dpc-3121	160	4	.	.	PUNCT
dpc-3121	161	1	5	5	X
dpc-3121	161	2	.	.	X
dpc-3121	161	3	katta	katta	PROPN
dpc-3121	161	4	r	r	PROPN
dpc-3121	161	5	,	,	PUNCT
dpc-3121	161	6	schlichte	schlichte	VERB
dpc-3121	161	7	m.	m.	NOUN
dpc-3121	161	8	diet	diet	PROPN
dpc-3121	161	9	and	and	CCONJ
dpc-3121	161	10	dermatitis	dermatitis	NOUN
dpc-3121	161	11	:	:	PUNCT
dpc-3121	161	12	food	food	NOUN
dpc-3121	161	13	triggers	trigger	NOUN
dpc-3121	161	14	.	.	PUNCT
dpc-3121	162	1	j	j	PROPN
dpc-3121	162	2	clin	clin	PROPN
dpc-3121	162	3	aesthet	aesthet	PROPN
dpc-3121	162	4	dermatol	dermatol	PROPN
dpc-3121	162	5	.	.	PUNCT
dpc-3121	163	1	2014;7(3):30	2014;7(3):30	NUM
dpc-3121	163	2	-	-	SYM
dpc-3121	163	3	36	36	NUM
dpc-3121	163	4	.	.	PUNCT
dpc-3121	164	1	pmid	pmid	NOUN
dpc-3121	164	2	:	:	PUNCT
dpc-3121	164	3	24688624	24688624	NUM
dpc-3121	164	4	.	.	PUNCT
dpc-3121	165	1	pmcid	pmcid	ADJ
dpc-3121	165	2	:	:	PUNCT
dpc-3121	165	3	pmc3970830	pmc3970830	NOUN
dpc-3121	165	4	.	.	PUNCT
dpc-3121	166	1	6	6	NUM
dpc-3121	166	2	.	.	X
dpc-3121	166	3	fujii	fujii	PROPN
dpc-3121	166	4	m.	m.	VERB
dpc-3121	166	5	the	the	DET
dpc-3121	166	6	pathogenic	pathogenic	ADJ
dpc-3121	166	7	and	and	CCONJ
dpc-3121	166	8	therapeutic	therapeutic	ADJ
dpc-3121	166	9	implications	implication	NOUN
dpc-3121	166	10	of	of	ADP
dpc-3121	166	11	ceramide	ceramide	NOUN
dpc-3121	166	12	abnormalities	abnormality	NOUN
dpc-3121	166	13	in	in	ADP
dpc-3121	166	14	atopic	atopic	NOUN
dpc-3121	166	15	dermatitis	dermatitis	NOUN
dpc-3121	166	16	.	.	PUNCT
dpc-3121	167	1	cells	cell	NOUN
dpc-3121	167	2	.	.	PUNCT
dpc-3121	168	1	2021;10(9	2021;10(9	NUM
dpc-3121	168	2	):	):	PUNCT
dpc-3121	168	3	2386	2386	NUM
dpc-3121	168	4	.	.	PUNCT
dpc-3121	169	1	doi:10.3390	doi:10.3390	NOUN
dpc-3121	169	2	/	/	SYM
dpc-3121	169	3	cells10092386	cells10092386	PROPN
dpc-3121	169	4	.	.	PUNCT
dpc-3121	170	1	pmid	pmid	NOUN
dpc-3121	170	2	:	:	PUNCT
dpc-3121	170	3	34572035	34572035	NUM
dpc-3121	170	4	.	.	PUNCT
dpc-3121	171	1	pmcid	pmcid	NOUN
dpc-3121	171	2	:	:	PUNCT
dpc-3121	171	3	pmc8468445	pmc8468445	ADJ
dpc-3121	171	4	.	.	PUNCT
dpc-3121	172	1	7	7	X
dpc-3121	172	2	.	.	X
dpc-3121	172	3	davis	davis	PROPN
dpc-3121	172	4	dmr	dmr	PROPN
dpc-3121	172	5	,	,	PUNCT
dpc-3121	172	6	drucker	drucker	NOUN
dpc-3121	172	7	am	be	AUX
dpc-3121	172	8	,	,	PUNCT
dpc-3121	172	9	alikhan	alikhan	ADV
dpc-3121	172	10	a	a	PRON
dpc-3121	172	11	,	,	PUNCT
dpc-3121	172	12	et	et	PROPN
dpc-3121	172	13	al	al	PROPN
dpc-3121	172	14	.	.	PROPN
dpc-3121	173	1	american	american	PROPN
dpc-3121	173	2	academy	academy	PROPN
dpc-3121	173	3	of	of	ADP
dpc-3121	173	4	dermatology	dermatology	NOUN
dpc-3121	173	5	guidelines	guideline	NOUN
dpc-3121	173	6	:	:	PUNCT
dpc-3121	173	7	awareness	awareness	NOUN
dpc-3121	173	8	of	of	ADP
dpc-3121	173	9	comorbidities	comorbiditie	NOUN
dpc-3121	173	10	associated	associate	VERB
dpc-3121	173	11	with	with	ADP
dpc-3121	173	12	atopic	atopic	NOUN
dpc-3121	173	13	dermatitis	dermatitis	NOUN
dpc-3121	173	14	in	in	ADP
dpc-3121	173	15	adults	adult	NOUN
dpc-3121	173	16	.	.	PUNCT
dpc-3121	174	1	j	j	PROPN
dpc-3121	174	2	am	be	AUX
dpc-3121	174	3	acad	acad	ADJ
dpc-3121	174	4	dermatol	dermatol	NOUN
dpc-3121	174	5	.	.	PUNCT
dpc-3121	175	1	2022;86(6):1335	2022;86(6):1335	NUM
dpc-3121	175	2	-	-	PUNCT
dpc-3121	175	3	1336.e18	1336.e18	NUM
dpc-3121	175	4	.	.	PUNCT
dpc-3121	176	1	doi	doi	NOUN
dpc-3121	176	2	:	:	PUNCT
dpc-3121	176	3	10.1016	10.1016	NUM
dpc-3121	176	4	/	/	SYM
dpc-3121	176	5	j.jaad.2022.01.009	j.jaad.2022.01.009	PROPN
dpc-3121	176	6	.	.	PUNCT
dpc-3121	177	1	pmid	pmid	NOUN
dpc-3121	177	2	:	:	PUNCT
dpc-3121	177	3	35085682	35085682	NUM
dpc-3121	177	4	.	.	PUNCT
dpc-3121	178	1	8	8	X
dpc-3121	178	2	.	.	PUNCT
dpc-3121	179	1	müller	müller	PROPN
dpc-3121	179	2	sm	sm	PROPN
dpc-3121	179	3	,	,	PUNCT
dpc-3121	179	4	tomaschett	tomaschett	NOUN
dpc-3121	179	5	d	d	PROPN
dpc-3121	179	6	,	,	PUNCT
dpc-3121	179	7	euler	euler	PROPN
dpc-3121	179	8	s	s	PROPN
dpc-3121	179	9	,	,	PUNCT
dpc-3121	179	10	vogt	vogt	PROPN
dpc-3121	179	11	dr	dr	PROPN
dpc-3121	179	12	,	,	PUNCT
dpc-3121	179	13	herzog	herzog	PROPN
dpc-3121	179	14	l	l	PROPN
dpc-3121	179	15	,	,	PUNCT
dpc-3121	179	16	itin	itin	ADJ
dpc-3121	179	17	p.	p.	NOUN
dpc-3121	179	18	topical	topical	ADJ
dpc-3121	179	19	corticosteroid	corticosteroid	ADJ
dpc-3121	179	20	concerns	concern	NOUN
dpc-3121	179	21	in	in	ADP
dpc-3121	179	22	dermatological	dermatological	ADJ
dpc-3121	179	23	outpatients	outpatient	NOUN
dpc-3121	179	24	:	:	PUNCT
dpc-3121	179	25	a	a	DET
dpc-3121	179	26	cross	cross	ADJ
dpc-3121	179	27	-	-	ADJ
dpc-3121	179	28	sectional	sectional	ADJ
dpc-3121	179	29	and	and	CCONJ
dpc-3121	179	30	interventional	interventional	ADJ
dpc-3121	179	31	study	study	NOUN
dpc-3121	179	32	.	.	PUNCT
dpc-3121	180	1	dermatology	dermatology	NOUN
dpc-3121	180	2	.	.	PUNCT
dpc-3121	181	1	2016;232(4):444	2016;232(4):444	NUM
dpc-3121	181	2	-	-	SYM
dpc-3121	181	3	452	452	NUM
dpc-3121	181	4	.	.	PUNCT
dpc-3121	181	5	doi:10.1159/000446068	doi:10.1159/000446068	PROPN
dpc-3121	181	6	.	.	PUNCT
dpc-3121	182	1	pmid	pmid	NOUN
dpc-3121	182	2	:	:	PUNCT
dpc-3121	182	3	27322385	27322385	NUM
dpc-3121	182	4	.	.	PUNCT
dpc-3121	183	1	novel	novel	ADJ
dpc-3121	183	2	drugs	drug	NOUN
dpc-3121	183	3	against	against	ADP
dpc-3121	183	4	atopic	atopic	NOUN
dpc-3121	183	5	dermatitis	dermatitis	NOUN
dpc-3121	183	6	and	and	CCONJ
dpc-3121	183	7	their	their	PRON
dpc-3121	183	8	vehicles	vehicle	NOUN
dpc-3121	183	9	for	for	ADP
dpc-3121	183	10	delivery	delivery	NOUN
dpc-3121	183	11	can	can	AUX
dpc-3121	183	12	be	be	AUX
dpc-3121	183	13	found	find	VERB
dpc-3121	183	14	below	below	ADP
dpc-3121	183	15	in	in	ADP
dpc-3121	183	16	table	table	NOUN
dpc-3121	183	17	1	1	NUM
dpc-3121	183	18	.	.	PUNCT
dpc-3121	184	1	conclusions	conclusion	NOUN
dpc-3121	184	2	current	current	ADJ
dpc-3121	184	3	recommendations	recommendation	NOUN
dpc-3121	184	4	for	for	ADP
dpc-3121	184	5	treating	treat	VERB
dpc-3121	184	6	atopic	atopic	NOUN
dpc-3121	184	7	dermatitis	dermatitis	NOUN
dpc-3121	184	8	currently	currently	ADV
dpc-3121	184	9	focus	focus	VERB
dpc-3121	184	10	on	on	ADP
dpc-3121	184	11	topical	topical	ADJ
dpc-3121	184	12	or	or	CCONJ
dpc-3121	184	13	systemic	systemic	ADJ
dpc-3121	184	14	administration	administration	NOUN
dpc-3121	184	15	of	of	ADP
dpc-3121	184	16	glucocorticoids	glucocorticoids	PROPN
dpc-3121	184	17	.	.	PUNCT
dpc-3121	185	1	in	in	ADP
dpc-3121	185	2	light	light	NOUN
dpc-3121	185	3	of	of	ADP
dpc-3121	185	4	their	their	PRON
dpc-3121	185	5	known	know	VERB
dpc-3121	185	6	side	side	NOUN
dpc-3121	185	7	effects	effect	NOUN
dpc-3121	185	8	,	,	PUNCT
dpc-3121	185	9	their	their	PRON
dpc-3121	185	10	limit	limit	NOUN
dpc-3121	185	11	to	to	ADP
dpc-3121	185	12	short	short	ADJ
dpc-3121	185	13	-	-	PUNCT
dpc-3121	185	14	term	term	NOUN
dpc-3121	185	15	application	application	NOUN
dpc-3121	185	16	,	,	PUNCT
dpc-3121	185	17	intolerant	intolerant	ADJ
dpc-3121	185	18	patients	patient	NOUN
dpc-3121	185	19	,	,	PUNCT
dpc-3121	185	20	and	and	CCONJ
dpc-3121	185	21	diminished	diminish	VERB
dpc-3121	185	22	patient	patient	NOUN
dpc-3121	185	23	adherence	adherence	NOUN
dpc-3121	185	24	,	,	PUNCT
dpc-3121	185	25	novel	novel	ADJ
dpc-3121	185	26	drugs	drug	NOUN
dpc-3121	185	27	are	be	AUX
dpc-3121	185	28	being	be	AUX
dpc-3121	185	29	developed	develop	VERB
dpc-3121	185	30	that	that	PRON
dpc-3121	185	31	may	may	AUX
dpc-3121	185	32	overcome	overcome	VERB
dpc-3121	185	33	the	the	DET
dpc-3121	185	34	limitations	limitation	NOUN
dpc-3121	185	35	of	of	ADP
dpc-3121	185	36	steroidal	steroidal	NOUN
dpc-3121	185	37	medications	medication	NOUN
dpc-3121	185	38	.	.	PUNCT
dpc-3121	186	1	in	in	ADP
dpc-3121	186	2	addition	addition	NOUN
dpc-3121	186	3	,	,	PUNCT
dpc-3121	186	4	novel	novel	ADJ
dpc-3121	186	5	vehicles	vehicle	NOUN
dpc-3121	186	6	may	may	AUX
dpc-3121	186	7	increase	increase	VERB
dpc-3121	186	8	the	the	DET
dpc-3121	186	9	transdermal	transdermal	ADJ
dpc-3121	186	10	delivery	delivery	NOUN
dpc-3121	186	11	of	of	ADP
dpc-3121	186	12	an	an	DET
dpc-3121	186	13	atopic	atopic	NOUN
dpc-3121	186	14	dermatitis	dermatitis	NOUN
dpc-3121	186	15	drug	drug	NOUN
dpc-3121	186	16	and	and	CCONJ
dpc-3121	186	17	overcome	overcome	VERB
dpc-3121	186	18	side	side	NOUN
dpc-3121	186	19	effects	effect	NOUN
dpc-3121	186	20	associated	associate	VERB
dpc-3121	186	21	with	with	ADP
dpc-3121	186	22	conventional	conventional	ADJ
dpc-3121	186	23	topical	topical	ADJ
dpc-3121	186	24	administration	administration	NOUN
dpc-3121	186	25	.	.	PUNCT
dpc-3121	187	1	these	these	DET
dpc-3121	187	2	novel	novel	ADJ
dpc-3121	187	3	vehicles	vehicle	NOUN
dpc-3121	187	4	are	be	AUX
dpc-3121	187	5	currently	currently	ADV
dpc-3121	187	6	under	under	ADP
dpc-3121	187	7	development	development	NOUN
dpc-3121	187	8	,	,	PUNCT
dpc-3121	187	9	and	and	CCONJ
dpc-3121	187	10	their	their	PRON
dpc-3121	187	11	suitability	suitability	NOUN
dpc-3121	187	12	for	for	ADP
dpc-3121	187	13	a	a	DET
dpc-3121	187	14	broad	broad	ADJ
dpc-3121	187	15	clinical	clinical	ADJ
dpc-3121	187	16	application	application	NOUN
dpc-3121	187	17	is	be	AUX
dpc-3121	187	18	yet	yet	ADV
dpc-3121	187	19	to	to	PART
dpc-3121	187	20	be	be	AUX
dpc-3121	187	21	tested	test	VERB
dpc-3121	187	22	in	in	ADP
dpc-3121	187	23	controlled	control	VERB
dpc-3121	187	24	clinical	clinical	ADJ
dpc-3121	187	25	trials	trial	NOUN
dpc-3121	187	26	.	.	PUNCT
dpc-3121	188	1	of	of	ADP
dpc-3121	188	2	note	note	NOUN
dpc-3121	188	3	,	,	PUNCT
dpc-3121	188	4	modern	modern	ADJ
dpc-3121	188	5	drug	drug	NOUN
dpc-3121	188	6	delivery	delivery	NOUN
dpc-3121	188	7	vehicles	vehicle	NOUN
dpc-3121	188	8	such	such	ADJ
dpc-3121	188	9	as	as	ADP
dpc-3121	188	10	nanoparticles	nanoparticle	NOUN
dpc-3121	188	11	are	be	AUX
dpc-3121	188	12	being	be	AUX
dpc-3121	188	13	tested	test	VERB
dpc-3121	188	14	based	base	VERB
dpc-3121	188	15	on	on	ADP
dpc-3121	188	16	the	the	DET
dpc-3121	188	17	delivery	delivery	NOUN
dpc-3121	188	18	of	of	ADP
dpc-3121	188	19	conventional	conventional	ADJ
dpc-3121	188	20	drugs	drug	NOUN
dpc-3121	188	21	such	such	ADJ
dpc-3121	188	22	as	as	ADP
dpc-3121	188	23	glucocorticosteroids	glucocorticosteroid	NOUN
dpc-3121	188	24	,	,	PUNCT
dpc-3121	188	25	for	for	ADP
dpc-3121	188	26	which	which	PRON
dpc-3121	188	27	more	more	ADV
dpc-3121	188	28	pharmacokinetic	pharmacokinetic	ADJ
dpc-3121	188	29	data	datum	NOUN
dpc-3121	188	30	is	be	AUX
dpc-3121	188	31	available	available	ADJ
dpc-3121	188	32	than	than	ADP
dpc-3121	188	33	for	for	ADP
dpc-3121	188	34	novel	novel	ADJ
dpc-3121	188	35	drugs	drug	NOUN
dpc-3121	188	36	with	with	ADP
dpc-3121	188	37	different	different	ADJ
dpc-3121	188	38	molecular	molecular	ADJ
dpc-3121	188	39	targets	target	NOUN
dpc-3121	188	40	and	and	CCONJ
dpc-3121	188	41	biochemical	biochemical	ADJ
dpc-3121	188	42	approaches	approach	NOUN
dpc-3121	188	43	.	.	PUNCT
dpc-3121	189	1	therefore	therefore	ADV
dpc-3121	189	2	,	,	PUNCT
dpc-3121	189	3	most	most	ADJ
dpc-3121	189	4	in	in	ADP
dpc-3121	189	5	vitro	vitro	X
dpc-3121	189	6	studies	study	NOUN
dpc-3121	189	7	on	on	ADP
dpc-3121	189	8	such	such	ADJ
dpc-3121	189	9	novel	novel	ADJ
dpc-3121	189	10	vehicles	vehicle	NOUN
dpc-3121	189	11	test	test	VERB
dpc-3121	189	12	the	the	DET
dpc-3121	189	13	transdermal	transdermal	ADJ
dpc-3121	189	14	crossing	crossing	NOUN
dpc-3121	189	15	and	and	CCONJ
dpc-3121	189	16	the	the	DET
dpc-3121	189	17	accumulation	accumulation	NOUN
dpc-3121	189	18	of	of	ADP
dpc-3121	189	19	steroids	steroid	NOUN
dpc-3121	189	20	in	in	ADP
dpc-3121	189	21	the	the	DET
dpc-3121	189	22	epidermis	epidermis	NOUN
dpc-3121	189	23	.	.	PUNCT
dpc-3121	190	1	likewise	likewise	ADV
dpc-3121	190	2	,	,	PUNCT
dpc-3121	190	3	efficacy	efficacy	NOUN
dpc-3121	190	4	and	and	CCONJ
dpc-3121	190	5	safety	safety	NOUN
dpc-3121	190	6	data	datum	NOUN
dpc-3121	190	7	on	on	ADP
dpc-3121	190	8	novel	novel	ADJ
dpc-3121	190	9	drugs	drug	NOUN
dpc-3121	190	10	such	such	ADJ
dpc-3121	190	11	as	as	ADP
dpc-3121	190	12	crisaborole	crisaborole	NOUN
dpc-3121	190	13	and	and	CCONJ
dpc-3121	190	14	ruxolitinib	ruxolitinib	NOUN
dpc-3121	190	15	are	be	AUX
dpc-3121	190	16	just	just	ADV
dpc-3121	190	17	emerging	emerge	VERB
dpc-3121	190	18	from	from	ADP
dpc-3121	190	19	phase	phase	NOUN
dpc-3121	190	20	ii	ii	PROPN
dpc-3121	190	21	and	and	CCONJ
dpc-3121	190	22	iii	iii	NUM
dpc-3121	190	23	clinical	clinical	ADJ
dpc-3121	190	24	trials	trial	NOUN
dpc-3121	190	25	,	,	PUNCT
dpc-3121	190	26	and	and	CCONJ
dpc-3121	190	27	conventional	conventional	ADJ
dpc-3121	190	28	,	,	PUNCT
dpc-3121	190	29	topical	topical	ADJ
dpc-3121	190	30	delivery	delivery	NOUN
dpc-3121	190	31	is	be	AUX
dpc-3121	190	32	chosen	choose	VERB
dpc-3121	190	33	for	for	ADP
dpc-3121	190	34	these	these	DET
dpc-3121	190	35	drugs	drug	NOUN
dpc-3121	190	36	as	as	SCONJ
dpc-3121	190	37	it	it	PRON
dpc-3121	190	38	is	be	AUX
dpc-3121	190	39	known	know	VERB
dpc-3121	190	40	to	to	PART
dpc-3121	190	41	result	result	VERB
dpc-3121	190	42	in	in	ADP
dpc-3121	190	43	improvement	improvement	NOUN
dpc-3121	190	44	of	of	ADP
dpc-3121	190	45	atopic	atopic	NOUN
dpc-3121	190	46	dermatitis	dermatitis	NOUN
dpc-3121	190	47	-	-	PUNCT
dpc-3121	190	48	associated	associate	VERB
dpc-3121	190	49	symptoms	symptom	NOUN
dpc-3121	190	50	in	in	ADP
dpc-3121	190	51	topical	topical	ADJ
dpc-3121	190	52	steroid	steroid	NOUN
dpc-3121	190	53	application	application	NOUN
dpc-3121	190	54	.	.	PUNCT
dpc-3121	191	1	hence	hence	ADV
dpc-3121	191	2	,	,	PUNCT
dpc-3121	191	3	the	the	DET
dpc-3121	191	4	development	development	NOUN
dpc-3121	191	5	of	of	ADP
dpc-3121	191	6	novel	novel	ADJ
dpc-3121	191	7	atopic	atopic	NOUN
dpc-3121	191	8	dermatitis	dermatitis	NOUN
dpc-3121	191	9	drugs	drug	NOUN
dpc-3121	191	10	and	and	CCONJ
dpc-3121	191	11	novel	novel	ADJ
dpc-3121	191	12	delivery	delivery	NOUN
dpc-3121	191	13	vehicles	vehicle	NOUN
dpc-3121	191	14	currently	currently	ADV
dpc-3121	191	15	happens	happen	VERB
dpc-3121	191	16	in	in	ADP
dpc-3121	191	17	parallel	parallel	NOUN
dpc-3121	191	18	.	.	PUNCT
dpc-3121	192	1	in	in	ADP
dpc-3121	192	2	contrast	contrast	NOUN
dpc-3121	192	3	,	,	PUNCT
dpc-3121	192	4	novel	novel	ADJ
dpc-3121	192	5	drugs	drug	NOUN
dpc-3121	192	6	have	have	AUX
dpc-3121	192	7	not	not	PART
dpc-3121	192	8	been	be	AUX
dpc-3121	192	9	tested	test	VERB
dpc-3121	192	10	to	to	PART
dpc-3121	192	11	establish	establish	VERB
dpc-3121	192	12	novel	novel	ADJ
dpc-3121	192	13	vehicles	vehicle	NOUN
dpc-3121	192	14	.	.	PUNCT
dpc-3121	193	1	therefore	therefore	ADV
dpc-3121	193	2	,	,	PUNCT
dpc-3121	193	3	future	future	ADJ
dpc-3121	193	4	studies	study	NOUN
dpc-3121	193	5	must	must	AUX
dpc-3121	193	6	elucidate	elucidate	VERB
dpc-3121	193	7	whether	whether	SCONJ
dpc-3121	193	8	the	the	DET
dpc-3121	193	9	highest	high	ADJ
dpc-3121	193	10	efficacy	efficacy	NOUN
dpc-3121	193	11	and	and	CCONJ
dpc-3121	193	12	safety	safety	NOUN
dpc-3121	193	13	of	of	ADP
dpc-3121	193	14	atopic	atopic	NOUN
dpc-3121	193	15	dermatitis	dermatitis	NOUN
dpc-3121	193	16	drugs	drug	NOUN
dpc-3121	193	17	may	may	AUX
dpc-3121	193	18	be	be	AUX
dpc-3121	193	19	achieved	achieve	VERB
dpc-3121	193	20	by	by	ADP
dpc-3121	193	21	combining	combine	VERB
dpc-3121	193	22	drugs	drug	NOUN
dpc-3121	193	23	against	against	ADP
dpc-3121	193	24	novel	novel	ADJ
dpc-3121	193	25	table	table	NOUN
dpc-3121	193	26	1	1	NUM
dpc-3121	193	27	.	.	PUNCT
dpc-3121	193	28	novel	novel	ADJ
dpc-3121	193	29	drugs	drug	NOUN
dpc-3121	193	30	against	against	ADP
dpc-3121	193	31	atopic	atopic	NOUN
dpc-3121	193	32	dermatitis	dermatitis	NOUN
dpc-3121	193	33	and	and	CCONJ
dpc-3121	193	34	their	their	PRON
dpc-3121	193	35	vehicles	vehicle	NOUN
dpc-3121	193	36	for	for	ADP
dpc-3121	193	37	delivery	delivery	NOUN
dpc-3121	193	38	.	.	PUNCT
dpc-3121	194	1	drug	drug	NOUN
dpc-3121	194	2	target	target	NOUN
dpc-3121	194	3	/	/	SYM
dpc-3121	194	4	proposed	propose	VERB
dpc-3121	194	5	effect	effect	NOUN
dpc-3121	194	6	available	available	ADJ
dpc-3121	194	7	vehicles	vehicle	NOUN
dpc-3121	194	8	references	reference	NOUN
dpc-3121	194	9	#	#	NOUN
dpc-3121	194	10	glucocorticoids	glucocorticoid	NOUN
dpc-3121	194	11	prevention	prevention	NOUN
dpc-3121	194	12	of	of	ADP
dpc-3121	194	13	antigen	antigen	ADJ
dpc-3121	194	14	processing	processing	NOUN
dpc-3121	194	15	and	and	CCONJ
dpc-3121	194	16	proinflammatory	proinflammatory	ADJ
dpc-3121	194	17	cytokine	cytokine	NOUN
dpc-3121	194	18	release	release	NOUN
dpc-3121	194	19	topical	topical	ADJ
dpc-3121	194	20	/	/	SYM
dpc-3121	194	21	cream	cream	NOUN
dpc-3121	194	22	or	or	CCONJ
dpc-3121	194	23	spray	spray	VERB
dpc-3121	194	24	systemic	systemic	ADJ
dpc-3121	194	25	/	/	SYM
dpc-3121	194	26	oral	oral	ADJ
dpc-3121	194	27	nanoparticles	nanoparticle	NOUN
dpc-3121	194	28	,	,	PUNCT
dpc-3121	194	29	iontophoresis	iontophoresis	NOUN
dpc-3121	194	30	4	4	NUM
dpc-3121	194	31	,	,	PUNCT
dpc-3121	194	32	30	30	NUM
dpc-3121	194	33	,	,	PUNCT
dpc-3121	194	34	40	40	NUM
dpc-3121	194	35	,	,	PUNCT
dpc-3121	194	36	47	47	NUM
dpc-3121	194	37	-	-	SYM
dpc-3121	194	38	51	51	NUM
dpc-3121	194	39	,	,	PUNCT
dpc-3121	194	40	57	57	NUM
dpc-3121	194	41	crisaborole	crisaborole	NOUN
dpc-3121	194	42	phosphodiesterase-4	phosphodiesterase-4	NOUN
dpc-3121	194	43	inhibitor	inhibitor	NOUN
dpc-3121	194	44	topical	topical	ADJ
dpc-3121	194	45	/	/	SYM
dpc-3121	194	46	cream	cream	NOUN
dpc-3121	194	47	or	or	CCONJ
dpc-3121	194	48	ointment	ointment	NOUN
dpc-3121	194	49	20	20	NUM
dpc-3121	194	50	,	,	PUNCT
dpc-3121	194	51	34	34	NUM
dpc-3121	194	52	,	,	PUNCT
dpc-3121	194	53	58	58	NUM
dpc-3121	194	54	-	-	SYM
dpc-3121	194	55	67	67	NUM
dpc-3121	194	56	ruxolitinib	ruxolitinib	PROPN
dpc-3121	194	57	janus	janus	PROPN
dpc-3121	194	58	kinases	kinase	NOUN
dpc-3121	194	59	1	1	NUM
dpc-3121	194	60	and	and	CCONJ
dpc-3121	194	61	2	2	NUM
dpc-3121	194	62	topical	topical	ADJ
dpc-3121	194	63	/	/	SYM
dpc-3121	194	64	cream	cream	NOUN
dpc-3121	194	65	or	or	CCONJ
dpc-3121	194	66	nanoliposomes	nanoliposomes	ADV
dpc-3121	194	67	42	42	NUM
dpc-3121	194	68	tapinarof	tapinarof	NOUN
dpc-3121	194	69	activation	activation	NOUN
dpc-3121	194	70	of	of	ADP
dpc-3121	194	71	hydrocarbon	hydrocarbon	NOUN
dpc-3121	194	72	receptor	receptor	NOUN
dpc-3121	194	73	and	and	CCONJ
dpc-3121	194	74	downregulation	downregulation	NOUN
dpc-3121	194	75	of	of	ADP
dpc-3121	194	76	pro	pro	ADJ
dpc-3121	194	77	-	-	ADJ
dpc-3121	194	78	inflammatory	inflammatory	ADJ
dpc-3121	194	79	cytokines	cytokine	VERB
dpc-3121	194	80	topical	topical	ADJ
dpc-3121	194	81	/	/	SYM
dpc-3121	194	82	cream	cream	NOUN
dpc-3121	194	83	28	28	NUM
dpc-3121	194	84	,	,	PUNCT
dpc-3121	194	85	29	29	NUM
dpc-3121	194	86	,	,	PUNCT
dpc-3121	194	87	68	68	NUM
dpc-3121	194	88	,	,	PUNCT
dpc-3121	194	89	69	69	NUM
dpc-3121	194	90	roflumilast	roflumilast	NOUN
dpc-3121	194	91	phosphodiesterase-4	phosphodiesterase-4	NOUN
dpc-3121	194	92	inhibitor	inhibitor	NOUN
dpc-3121	194	93	topical	topical	ADJ
dpc-3121	194	94	/	/	SYM
dpc-3121	194	95	cream	cream	NOUN
dpc-3121	194	96	23	23	NUM
dpc-3121	194	97	botanicals	botanical	NOUN
dpc-3121	194	98	unknown	unknown	ADJ
dpc-3121	194	99	topical	topical	ADJ
dpc-3121	194	100	/	/	SYM
dpc-3121	194	101	cream	cream	NOUN
dpc-3121	194	102	38	38	NUM
dpc-3121	194	103	,	,	PUNCT
dpc-3121	194	104	39	39	NUM
dpc-3121	194	105	pioglitazone	pioglitazone	NOUN
dpc-3121	194	106	reduction	reduction	NOUN
dpc-3121	194	107	of	of	ADP
dpc-3121	194	108	pro	pro	ADJ
dpc-3121	194	109	-	-	ADJ
dpc-3121	194	110	inflammatory	inflammatory	ADJ
dpc-3121	194	111	cytokines	cytokine	VERB
dpc-3121	194	112	topical	topical	ADJ
dpc-3121	194	113	/	/	SYM
dpc-3121	194	114	patch	patch	NOUN
dpc-3121	194	115	36	36	NUM
dpc-3121	194	116	urea	urea	NOUN
dpc-3121	194	117	emollient	emollient	NOUN
dpc-3121	194	118	,	,	PUNCT
dpc-3121	194	119	keratolytic	keratolytic	ADJ
dpc-3121	194	120	topical	topical	ADJ
dpc-3121	194	121	/	/	SYM
dpc-3121	194	122	patch	patch	NOUN
dpc-3121	194	123	35	35	NUM
dpc-3121	194	124	6	6	NUM
dpc-3121	194	125	review	review	NOUN
dpc-3121	194	126	|	|	ADV
dpc-3121	194	127	dermatol	dermatol	ADJ
dpc-3121	194	128	pract	pract	NOUN
dpc-3121	194	129	concept	concept	NOUN
dpc-3121	194	130	.	.	PUNCT
dpc-3121	195	1	2023;13(4):e2023216	2023;13(4):e2023216	NUM
dpc-3121	195	2	acad	acad	NOUN
dpc-3121	195	3	dermatol	dermatol	NOUN
dpc-3121	195	4	.	.	PUNCT
dpc-3121	195	5	  	  	SPACE
dpc-3121	196	1	2016;75(3):494	2016;75(3):494	NUM
dpc-3121	196	2	-	-	SYM
dpc-3121	196	3	503.e6	503.e6	NUM
dpc-3121	196	4	.	.	PUNCT
dpc-3121	197	1	doi:10.1016	doi:10.1016	PROPN
dpc-3121	197	2	/	/	SYM
dpc-3121	197	3	j.	j.	PROPN
dpc-3121	197	4	jaad.2016.05.046	jaad.2016.05.046	PROPN
dpc-3121	197	5	.	.	PUNCT
dpc-3121	198	1	pmid	pmid	NOUN
dpc-3121	198	2	:	:	PUNCT
dpc-3121	198	3	27417017	27417017	NUM
dpc-3121	198	4	.	.	PUNCT
dpc-3121	199	1	23	23	NUM
dpc-3121	199	2	.	.	PUNCT
dpc-3121	200	1	heo	heo	PROPN
dpc-3121	200	2	jy	jy	PROPN
dpc-3121	200	3	,	,	PUNCT
dpc-3121	200	4	cho	cho	PROPN
dpc-3121	200	5	ys	ys	PROPN
dpc-3121	200	6	,	,	PUNCT
dpc-3121	200	7	cheon	cheon	PROPN
dpc-3121	200	8	hg	hg	PROPN
dpc-3121	200	9	.	.	PUNCT
dpc-3121	200	10	topical	topical	ADJ
dpc-3121	200	11	effects	effect	NOUN
dpc-3121	200	12	of	of	ADP
dpc-3121	200	13	roflumilast	roflumilast	NOUN
dpc-3121	200	14	on	on	ADP
dpc-3121	200	15	1	1	NUM
dpc-3121	200	16	-	-	PUNCT
dpc-3121	200	17	chloro-2,4	chloro-2,4	NOUN
dpc-3121	200	18	-	-	PUNCT
dpc-3121	200	19	dinitrobenzene	dinitrobenzene	NOUN
dpc-3121	200	20	-	-	PUNCT
dpc-3121	200	21	induced	induce	VERB
dpc-3121	200	22	atopic	atopic	NOUN
dpc-3121	200	23	dermatitis	dermatitis	NOUN
dpc-3121	200	24	-	-	PUNCT
dpc-3121	200	25	like	like	ADJ
dpc-3121	200	26	skin	skin	NOUN
dpc-3121	200	27	lesions	lesion	NOUN
dpc-3121	200	28	in	in	ADP
dpc-3121	200	29	nc	nc	PROPN
dpc-3121	200	30	/	/	SYM
dpc-3121	200	31	nga	nga	NOUN
dpc-3121	200	32	mice	mouse	NOUN
dpc-3121	200	33	.	.	PUNCT
dpc-3121	201	1	pharmazie	pharmazie	NOUN
dpc-3121	201	2	.	.	PUNCT
dpc-3121	202	1	2010;65(12):906	2010;65(12):906	NUM
dpc-3121	202	2	-	-	SYM
dpc-3121	202	3	912	912	NUM
dpc-3121	202	4	.	.	PUNCT
dpc-3121	203	1	pmid	pmid	NOUN
dpc-3121	203	2	:	:	PUNCT
dpc-3121	203	3	21284261	21284261	NUM
dpc-3121	203	4	.	.	PUNCT
dpc-3121	204	1	24	24	NUM
dpc-3121	204	2	.	.	PUNCT
dpc-3121	205	1	shen	shen	PROPN
dpc-3121	205	2	lf	lf	PROPN
dpc-3121	205	3	,	,	PUNCT
dpc-3121	205	4	lv	lv	PROPN
dpc-3121	205	5	xd	xd	PROPN
dpc-3121	205	6	,	,	PUNCT
dpc-3121	205	7	chen	chen	PROPN
dpc-3121	205	8	wy	wy	PROPN
dpc-3121	205	9	,	,	PUNCT
dpc-3121	205	10	yang	yang	PROPN
dpc-3121	205	11	q	q	PROPN
dpc-3121	205	12	,	,	PUNCT
dpc-3121	205	13	fang	fang	X
dpc-3121	205	14	zx	zx	NUM
dpc-3121	205	15	,	,	PUNCT
dpc-3121	205	16	lu	lu	PROPN
dpc-3121	205	17	wf	wf	PROPN
dpc-3121	205	18	.	.	PUNCT
dpc-3121	205	19	effect	effect	NOUN
dpc-3121	205	20	of	of	ADP
dpc-3121	205	21	roflumilast	roflumilast	NOUN
dpc-3121	205	22	on	on	ADP
dpc-3121	205	23	chronic	chronic	ADJ
dpc-3121	205	24	obstructive	obstructive	ADJ
dpc-3121	205	25	pulmonary	pulmonary	ADJ
dpc-3121	205	26	disease	disease	NOUN
dpc-3121	205	27	:	:	PUNCT
dpc-3121	205	28	a	a	DET
dpc-3121	205	29	systematic	systematic	ADJ
dpc-3121	205	30	review	review	NOUN
dpc-3121	205	31	and	and	CCONJ
dpc-3121	205	32	meta	meta	ADJ
dpc-3121	205	33	-	-	PUNCT
dpc-3121	205	34	analysis	analysis	NOUN
dpc-3121	205	35	.	.	PUNCT
dpc-3121	206	1	ir	ir	PROPN
dpc-3121	206	2	j	j	PROPN
dpc-3121	206	3	med	med	PROPN
dpc-3121	206	4	sci	sci	PROPN
dpc-3121	206	5	.	.	PUNCT
dpc-3121	207	1	2018;187(3):731	2018;187(3):731	X
dpc-3121	207	2	-	-	SYM
dpc-3121	207	3	738	738	NUM
dpc-3121	207	4	.	.	PUNCT
dpc-3121	208	1	doi:10.1007	doi:10.1007	PROPN
dpc-3121	208	2	/	/	SYM
dpc-3121	208	3	s11845	s11845	PROPN
dpc-3121	208	4	-	-	PUNCT
dpc-3121	208	5	018	018	NUM
dpc-3121	208	6	-	-	PUNCT
dpc-3121	208	7	1738	1738	NUM
dpc-3121	208	8	-	-	SYM
dpc-3121	208	9	9	9	NUM
dpc-3121	208	10	pmid	pmid	NOUN
dpc-3121	208	11	:	:	PUNCT
dpc-3121	208	12	29397527	29397527	NUM
dpc-3121	208	13	.	.	PUNCT
dpc-3121	209	1	25	25	NUM
dpc-3121	209	2	.	.	PUNCT
dpc-3121	209	3	bateman	bateman	PROPN
dpc-3121	209	4	ed	ed	PROPN
dpc-3121	209	5	,	,	PUNCT
dpc-3121	209	6	izquierdo	izquierdo	PROPN
dpc-3121	209	7	jl	jl	PROPN
dpc-3121	209	8	,	,	PUNCT
dpc-3121	209	9	harnest	harn	ADJ
dpc-3121	209	10	u	u	NOUN
dpc-3121	209	11	,	,	PUNCT
dpc-3121	209	12	et	et	PROPN
dpc-3121	209	13	al	al	PROPN
dpc-3121	209	14	.	.	PROPN
dpc-3121	209	15	efficacy	efficacy	NOUN
dpc-3121	209	16	and	and	CCONJ
dpc-3121	209	17	safety	safety	NOUN
dpc-3121	209	18	of	of	ADP
dpc-3121	209	19	roflumilast	roflumilast	NOUN
dpc-3121	209	20	in	in	ADP
dpc-3121	209	21	the	the	DET
dpc-3121	209	22	treatment	treatment	NOUN
dpc-3121	209	23	of	of	ADP
dpc-3121	209	24	asthma	asthma	NOUN
dpc-3121	209	25	.	.	PUNCT
dpc-3121	210	1	ann	ann	PROPN
dpc-3121	210	2	allergy	allergy	PROPN
dpc-3121	210	3	asthma	asthma	PROPN
dpc-3121	210	4	immunol	immunol	PROPN
dpc-3121	210	5	.	.	PUNCT
dpc-3121	211	1	2006;96(5):679	2006;96(5):679	NOUN
dpc-3121	211	2	-	-	PUNCT
dpc-3121	211	3	686	686	NUM
dpc-3121	211	4	.	.	PUNCT
dpc-3121	212	1	doi:10.1016	doi:10.1016	PROPN
dpc-3121	212	2	/	/	SYM
dpc-3121	212	3	s1081	s1081	PROPN
dpc-3121	212	4	-1206(10)61065	-1206(10)61065	NOUN
dpc-3121	212	5	-	-	PUNCT
dpc-3121	212	6	4	4	NUM
dpc-3121	212	7	.	.	PUNCT
dpc-3121	213	1	pmid	pmid	NOUN
dpc-3121	213	2	:	:	PUNCT
dpc-3121	213	3	16729780	16729780	NUM
dpc-3121	213	4	.	.	PUNCT
dpc-3121	214	1	26	26	NUM
dpc-3121	214	2	.	.	PUNCT
dpc-3121	215	1	arcutis	arcutis	ADJ
dpc-3121	215	2	biotherapeutics	biotherapeutic	NOUN
dpc-3121	215	3	,	,	PUNCT
dpc-3121	215	4	inc.a	inc.a	PROPN
dpc-3121	215	5	.	.	NOUN
dpc-3121	215	6	phase	phase	NOUN
dpc-3121	215	7	3	3	NUM
dpc-3121	215	8	,	,	PUNCT
dpc-3121	215	9	4	4	NUM
dpc-3121	215	10	-	-	PUNCT
dpc-3121	215	11	week	week	NOUN
dpc-3121	215	12	,	,	PUNCT
dpc-3121	215	13	parallel	parallel	ADJ
dpc-3121	215	14	group	group	NOUN
dpc-3121	215	15	,	,	PUNCT
dpc-3121	215	16	double	double	ADV
dpc-3121	215	17	blind	blind	ADJ
dpc-3121	215	18	,	,	PUNCT
dpc-3121	215	19	vehicle	vehicle	NOUN
dpc-3121	215	20	-	-	PUNCT
dpc-3121	215	21	controlled	control	VERB
dpc-3121	215	22	study	study	NOUN
dpc-3121	215	23	of	of	ADP
dpc-3121	215	24	the	the	DET
dpc-3121	215	25	safety	safety	NOUN
dpc-3121	215	26	and	and	CCONJ
dpc-3121	215	27	efficacy	efficacy	NOUN
dpc-3121	215	28	of	of	ADP
dpc-3121	215	29	arq-151	arq-151	PROPN
dpc-3121	215	30	cream	cream	NOUN
dpc-3121	215	31	0.15	0.15	NUM
dpc-3121	215	32	%	%	NOUN
dpc-3121	215	33	administered	administer	VERB
dpc-3121	215	34	qd	qd	NOUN
dpc-3121	215	35	in	in	ADP
dpc-3121	215	36	subjects	subject	NOUN
dpc-3121	215	37	with	with	ADP
dpc-3121	215	38	atopic	atopic	NOUN
dpc-3121	215	39	dermatitis	dermatitis	NOUN
dpc-3121	215	40	.	.	PUNCT
dpc-3121	216	1	clinicaltrials.gov	clinicaltrials.gov	NOUN
dpc-3121	216	2	identifier	identifier	NOUN
dpc-3121	216	3	:	:	PUNCT
dpc-3121	216	4	nct04773587	nct04773587	ADJ
dpc-3121	216	5	.	.	PUNCT
dpc-3121	217	1	updated	update	VERB
dpc-3121	217	2	septemberl	septemberl	NOUN
dpc-3121	217	3	14	14	NUM
dpc-3121	217	4	,	,	PUNCT
dpc-3121	217	5	2022	2022	NUM
dpc-3121	217	6	.	.	PUNCT
dpc-3121	218	1	available	available	ADJ
dpc-3121	218	2	from	from	ADP
dpc-3121	218	3	:	:	PUNCT
dpc-3121	218	4	https://clinicaltrials	https://clinicaltrial	NOUN
dpc-3121	218	5	.gov	.gov	ADJ
dpc-3121	218	6	/	/	SYM
dpc-3121	218	7	ct2	ct2	PROPN
dpc-3121	218	8	/	/	SYM
dpc-3121	218	9	show	show	NOUN
dpc-3121	218	10	/	/	SYM
dpc-3121	218	11	nct04773587,accessed	nct04773587,accesse	VERB
dpc-3121	218	12	december	december	PROPN
dpc-3121	218	13	27	27	NUM
dpc-3121	218	14	,	,	PUNCT
dpc-3121	218	15	2022	2022	NUM
dpc-3121	218	16	.	.	PUNCT
dpc-3121	219	1	27	27	NUM
dpc-3121	219	2	.	.	PUNCT
dpc-3121	220	1	smith	smith	PROPN
dpc-3121	220	2	sh	sh	PROPN
dpc-3121	220	3	,	,	PUNCT
dpc-3121	220	4	jayawickreme	jayawickreme	PROPN
dpc-3121	220	5	c	c	PROPN
dpc-3121	220	6	,	,	PUNCT
dpc-3121	220	7	rickard	rickard	PROPN
dpc-3121	220	8	dj	dj	PROPN
dpc-3121	220	9	,	,	PUNCT
dpc-3121	220	10	et	et	PROPN
dpc-3121	220	11	al	al	PROPN
dpc-3121	220	12	.	.	PROPN
dpc-3121	220	13	tapinarof	tapinarof	PROPN
dpc-3121	220	14	is	be	AUX
dpc-3121	220	15	a	a	DET
dpc-3121	220	16	natural	natural	ADJ
dpc-3121	220	17	ahr	ahr	NOUN
dpc-3121	220	18	agonist	agonist	NOUN
dpc-3121	220	19	that	that	SCONJ
dpc-3121	220	20	  	  	SPACE
dpc-3121	220	21	resolves	resolve	VERB
dpc-3121	220	22	skin	skin	NOUN
dpc-3121	220	23	inflammation	inflammation	NOUN
dpc-3121	220	24	in	in	ADP
dpc-3121	220	25	mice	mouse	NOUN
dpc-3121	220	26	 	 	SPACE
dpc-3121	220	27	and	and	CCONJ
dpc-3121	220	28	 	 	SPACE
dpc-3121	220	29	humans	human	NOUN
dpc-3121	220	30	.	.	PUNCT
dpc-3121	221	1	j	j	PROPN
dpc-3121	221	2	invest	invest	VERB
dpc-3121	221	3	dermatol	dermatol	NOUN
dpc-3121	221	4	.	.	PUNCT
dpc-3121	222	1	2017;137(10):2110	2017;137(10):2110	PROPN
dpc-3121	222	2	-	-	SYM
dpc-3121	222	3	2119	2119	NUM
dpc-3121	222	4	.	.	PUNCT
dpc-3121	223	1	doi:10.1016	doi:10.1016	PROPN
dpc-3121	223	2	/	/	SYM
dpc-3121	223	3	j.jid.2017.05.004	j.jid.2017.05.004	PROPN
dpc-3121	223	4	.	.	PUNCT
dpc-3121	224	1	pmid	pmid	NOUN
dpc-3121	224	2	:	:	PUNCT
dpc-3121	224	3	28595996	28595996	NUM
dpc-3121	224	4	.	.	PUNCT
dpc-3121	225	1	28	28	NUM
dpc-3121	225	2	.	.	PUNCT
dpc-3121	225	3	paller	paller	NOUN
dpc-3121	225	4	as	as	ADP
dpc-3121	225	5	,	,	PUNCT
dpc-3121	225	6	stein	stein	PROPN
dpc-3121	225	7	gold	gold	PROPN
dpc-3121	225	8	l	l	PROPN
dpc-3121	225	9	,	,	PUNCT
dpc-3121	225	10	soung	soung	PROPN
dpc-3121	225	11	j	j	PROPN
dpc-3121	225	12	,	,	PUNCT
dpc-3121	225	13	tallman	tallman	PROPN
dpc-3121	225	14	am	am	PROPN
dpc-3121	225	15	,	,	PUNCT
dpc-3121	225	16	rubenstein	rubenstein	PROPN
dpc-3121	225	17	ds	ds	PROPN
dpc-3121	225	18	,	,	PUNCT
dpc-3121	225	19	gooderham	gooderham	PROPN
dpc-3121	225	20	m.	m.	NOUN
dpc-3121	225	21	efficacy	efficacy	NOUN
dpc-3121	225	22	and	and	CCONJ
dpc-3121	225	23	patient	patient	NOUN
dpc-3121	225	24	-	-	PUNCT
dpc-3121	225	25	reported	report	VERB
dpc-3121	225	26	outcomes	outcome	NOUN
dpc-3121	225	27	from	from	ADP
dpc-3121	225	28	a	a	DET
dpc-3121	225	29	phase	phase	NOUN
dpc-3121	225	30	2b	2b	NOUN
dpc-3121	225	31	,	,	PUNCT
dpc-3121	225	32	randomized	randomize	VERB
dpc-3121	225	33	clinical	clinical	ADJ
dpc-3121	225	34	trial	trial	NOUN
dpc-3121	225	35	of	of	ADP
dpc-3121	225	36	tapinarof	tapinarof	NOUN
dpc-3121	225	37	cream	cream	NOUN
dpc-3121	225	38	for	for	ADP
dpc-3121	225	39	the	the	DET
dpc-3121	225	40	treatment	treatment	NOUN
dpc-3121	225	41	of	of	ADP
dpc-3121	225	42	adolescents	adolescent	NOUN
dpc-3121	225	43	and	and	CCONJ
dpc-3121	225	44	adults	adult	NOUN
dpc-3121	225	45	with	with	ADP
dpc-3121	225	46	atopic	atopic	NOUN
dpc-3121	225	47	dermatitis	dermatitis	NOUN
dpc-3121	225	48	.	.	PUNCT
dpc-3121	226	1	j	j	PROPN
dpc-3121	226	2	am	be	AUX
dpc-3121	226	3	acad	acad	ADJ
dpc-3121	226	4	dermatol	dermatol	NOUN
dpc-3121	226	5	.	.	PUNCT
dpc-3121	227	1	2021;84(3):632	2021;84(3):632	NUM
dpc-3121	227	2	-	-	PUNCT
dpc-3121	227	3	638	638	NUM
dpc-3121	227	4	.	.	PUNCT
dpc-3121	228	1	doi:10.1016	doi:10.1016	PROPN
dpc-3121	228	2	/	/	SYM
dpc-3121	228	3	j	j	PROPN
dpc-3121	228	4	.jaad.2020.05.135	.jaad.2020.05.135	PUNCT
dpc-3121	228	5	.	.	PUNCT
dpc-3121	229	1	pmid	pmid	NOUN
dpc-3121	229	2	:	:	PUNCT
dpc-3121	229	3	32502588	32502588	NUM
dpc-3121	229	4	.	.	PUNCT
dpc-3121	230	1	29	29	NUM
dpc-3121	230	2	.	.	PUNCT
dpc-3121	231	1	peppers	peppers	PROPN
dpc-3121	231	2	j	j	PROPN
dpc-3121	231	3	,	,	PUNCT
dpc-3121	231	4	paller	paller	NOUN
dpc-3121	231	5	as	as	ADP
dpc-3121	231	6	,	,	PUNCT
dpc-3121	231	7	maeda	maeda	PROPN
dpc-3121	231	8	-	-	PROPN
dpc-3121	231	9	chubachi	chubachi	PROPN
dpc-3121	231	10	t	t	PROPN
dpc-3121	231	11	,	,	PUNCT
dpc-3121	231	12	et	et	PROPN
dpc-3121	231	13	al	al	PROPN
dpc-3121	231	14	.	.	PUNCT
dpc-3121	232	1	a	a	DET
dpc-3121	232	2	phase	phase	NOUN
dpc-3121	232	3	2	2	NUM
dpc-3121	232	4	,	,	PUNCT
dpc-3121	232	5	randomized	randomize	VERB
dpc-3121	232	6	dose	dose	NOUN
dpc-3121	232	7	-	-	PUNCT
dpc-3121	232	8	finding	find	VERB
dpc-3121	232	9	study	study	NOUN
dpc-3121	232	10	of	of	ADP
dpc-3121	232	11	tapinarof	tapinarof	NOUN
dpc-3121	232	12	(	(	PUNCT
dpc-3121	232	13	gsk2894512	gsk2894512	NOUN
dpc-3121	232	14	cream	cream	NOUN
dpc-3121	232	15	)	)	PUNCT
dpc-3121	232	16	for	for	ADP
dpc-3121	232	17	the	the	DET
dpc-3121	232	18	treatment	treatment	NOUN
dpc-3121	232	19	of	of	ADP
dpc-3121	232	20	atopic	atopic	NOUN
dpc-3121	232	21	dermatitis	dermatitis	NOUN
dpc-3121	232	22	.	.	PUNCT
dpc-3121	233	1	j	j	PROPN
dpc-3121	233	2	am	be	AUX
dpc-3121	233	3	acad	acad	ADJ
dpc-3121	233	4	dermatol	dermatol	NOUN
dpc-3121	233	5	.	.	PUNCT
dpc-3121	234	1	2019;80(1):89	2019;80(1):89	NOUN
dpc-3121	234	2	-	-	SYM
dpc-3121	234	3	98.e3	98.e3	NUM
dpc-3121	234	4	.	.	PUNCT
dpc-3121	235	1	doi:10.1016	doi:10.1016	PROPN
dpc-3121	235	2	/	/	SYM
dpc-3121	235	3	j.jaad.2018.06.047	j.jaad.2018.06.047	PROPN
dpc-3121	235	4	.	.	PUNCT
dpc-3121	236	1	pmid	pmid	NOUN
dpc-3121	236	2	:	:	PUNCT
dpc-3121	236	3	30554600	30554600	NUM
dpc-3121	236	4	.	.	PUNCT
dpc-3121	237	1	30	30	NUM
dpc-3121	237	2	.	.	PUNCT
dpc-3121	238	1	wollenberg	wollenberg	PROPN
dpc-3121	238	2	a	a	PRON
dpc-3121	238	3	,	,	PUNCT
dpc-3121	238	4	barbarot	barbarot	NOUN
dpc-3121	238	5	s	s	PROPN
dpc-3121	238	6	,	,	PUNCT
dpc-3121	238	7	bieber	bieber	PROPN
dpc-3121	238	8	t	t	PROPN
dpc-3121	238	9	,	,	PUNCT
dpc-3121	238	10	et	et	PROPN
dpc-3121	238	11	al	al	PROPN
dpc-3121	238	12	.	.	PUNCT
dpc-3121	238	13	consensus	consensus	NOUN
dpc-3121	238	14	-	-	PUNCT
dpc-3121	238	15	based	base	VERB
dpc-3121	238	16	european	european	ADJ
dpc-3121	238	17	guidelines	guideline	NOUN
dpc-3121	238	18	for	for	ADP
dpc-3121	238	19	treatment	treatment	NOUN
dpc-3121	238	20	of	of	ADP
dpc-3121	238	21	atopic	atopic	NOUN
dpc-3121	238	22	eczema	eczema	NOUN
dpc-3121	238	23	(	(	PUNCT
dpc-3121	238	24	atopic	atopic	NOUN
dpc-3121	238	25	dermatitis	dermatitis	NOUN
dpc-3121	238	26	)	)	PUNCT
dpc-3121	238	27	in	in	ADP
dpc-3121	238	28	adults	adult	NOUN
dpc-3121	238	29	and	and	CCONJ
dpc-3121	238	30	children	child	NOUN
dpc-3121	238	31	:	:	PUNCT
dpc-3121	238	32	part	part	NOUN
dpc-3121	238	33	i.	i.	PROPN
dpc-3121	238	34	j	j	PROPN
dpc-3121	238	35	eur	eur	PROPN
dpc-3121	238	36	acad	acad	PROPN
dpc-3121	238	37	dermatol	dermatol	NOUN
dpc-3121	238	38	venereol	venereol	NOUN
dpc-3121	238	39	.	.	PUNCT
dpc-3121	239	1	2018;32(5):657	2018;32(5):657	PROPN
dpc-3121	239	2	-	-	PUNCT
dpc-3121	239	3	682	682	NUM
dpc-3121	239	4	.	.	PUNCT
dpc-3121	240	1	doi:10.1111	doi:10.1111	ADJ
dpc-3121	240	2	/	/	SYM
dpc-3121	240	3	jdv.14891	jdv.14891	NOUN
dpc-3121	240	4	.	.	PUNCT
dpc-3121	241	1	pmid	pmid	NOUN
dpc-3121	241	2	:	:	PUNCT
dpc-3121	241	3	29676534	29676534	NUM
dpc-3121	241	4	.	.	PUNCT
dpc-3121	242	1	31	31	NUM
dpc-3121	242	2	.	.	PUNCT
dpc-3121	243	1	stein	stein	PROPN
dpc-3121	243	2	gold	gold	PROPN
dpc-3121	243	3	lf	lf	PROPN
dpc-3121	243	4	,	,	PUNCT
dpc-3121	243	5	spelman	spelman	PROPN
dpc-3121	243	6	l	l	PROPN
dpc-3121	243	7	,	,	PUNCT
dpc-3121	243	8	spellman	spellman	PROPN
dpc-3121	243	9	mc	mc	PROPN
dpc-3121	243	10	,	,	PUNCT
dpc-3121	243	11	hughes	hughes	PROPN
dpc-3121	243	12	mh	mh	PROPN
dpc-3121	243	13	,	,	PUNCT
dpc-3121	243	14	zane	zane	PROPN
dpc-3121	243	15	lt	lt	PROPN
dpc-3121	243	16	.	.	PROPN
dpc-3121	243	17	a	a	DET
dpc-3121	243	18	phase	phase	NOUN
dpc-3121	243	19	2	2	NUM
dpc-3121	243	20	,	,	PUNCT
dpc-3121	243	21	randomized	randomize	VERB
dpc-3121	243	22	,	,	PUNCT
dpc-3121	243	23	controlled	control	VERB
dpc-3121	243	24	,	,	PUNCT
dpc-3121	243	25	dose	dose	NOUN
dpc-3121	243	26	-	-	PUNCT
dpc-3121	243	27	ranging	range	VERB
dpc-3121	243	28	study	study	NOUN
dpc-3121	243	29	evaluating	evaluate	VERB
dpc-3121	243	30	crisaborole	crisaborole	ADJ
dpc-3121	243	31	topical	topical	ADJ
dpc-3121	243	32	ointment	ointment	NOUN
dpc-3121	243	33	,	,	PUNCT
dpc-3121	243	34	0.5	0.5	NUM
dpc-3121	243	35	%	%	NOUN
dpc-3121	243	36	and	and	CCONJ
dpc-3121	243	37	2	2	NUM
dpc-3121	243	38	%	%	NOUN
dpc-3121	243	39	in	in	ADP
dpc-3121	243	40	adolescents	adolescent	NOUN
dpc-3121	243	41	with	with	ADP
dpc-3121	243	42	mild	mild	ADJ
dpc-3121	243	43	to	to	ADP
dpc-3121	243	44	moderate	moderate	ADJ
dpc-3121	243	45	atopic	atopic	NOUN
dpc-3121	243	46	dermatitis	dermatitis	NOUN
dpc-3121	243	47	.	.	PUNCT
dpc-3121	244	1	j	j	PROPN
dpc-3121	244	2	drugs	drug	NOUN
dpc-3121	244	3	dermatol	dermatol	NOUN
dpc-3121	244	4	.	.	PUNCT
dpc-3121	245	1	2015;14(12):1394	2015;14(12):1394	NUM
dpc-3121	245	2	-	-	SYM
dpc-3121	245	3	1399	1399	NUM
dpc-3121	245	4	.	.	PUNCT
dpc-3121	246	1	pmid	pmid	NOUN
dpc-3121	246	2	:	:	PUNCT
dpc-3121	246	3	26659931	26659931	NUM
dpc-3121	246	4	.	.	PUNCT
dpc-3121	247	1	32	32	NUM
dpc-3121	247	2	.	.	PUNCT
dpc-3121	248	1	mcdowell	mcdowell	PROPN
dpc-3121	248	2	l	l	PROPN
dpc-3121	248	3	,	,	PUNCT
dpc-3121	248	4	olin	olin	PROPN
dpc-3121	248	5	b.	b.	PROPN
dpc-3121	248	6	crisaborole	crisaborole	PROPN
dpc-3121	248	7	:	:	PUNCT
dpc-3121	248	8	a	a	DET
dpc-3121	248	9	novel	novel	ADJ
dpc-3121	248	10	nonsteroidal	nonsteroidal	NOUN
dpc-3121	248	11	topical	topical	ADJ
dpc-3121	248	12	treatment	treatment	NOUN
dpc-3121	248	13	for	for	ADP
dpc-3121	248	14	atopic	atopic	NOUN
dpc-3121	248	15	dermatitis	dermatitis	NOUN
dpc-3121	248	16	.	.	PUNCT
dpc-3121	249	1	j	j	PROPN
dpc-3121	249	2	pharm	pharm	PROPN
dpc-3121	249	3	technol	technol	NOUN
dpc-3121	249	4	.	.	PUNCT
dpc-3121	250	1	2019;35(4):172	2019;35(4):172	NUM
dpc-3121	250	2	-	-	PUNCT
dpc-3121	250	3	178	178	NUM
dpc-3121	250	4	.	.	PUNCT
dpc-3121	251	1	doi:10.1177/8755122519844507	doi:10.1177/8755122519844507	NOUN
dpc-3121	251	2	.	.	PUNCT
dpc-3121	252	1	pmid	pmid	NOUN
dpc-3121	252	2	:	:	PUNCT
dpc-3121	252	3	34861031	34861031	NUM
dpc-3121	252	4	.	.	PUNCT
dpc-3121	253	1	pmcid	pmcid	ADJ
dpc-3121	253	2	:	:	PUNCT
dpc-3121	253	3	pmc6600556	pmc6600556	NOUN
dpc-3121	253	4	.	.	PUNCT
dpc-3121	254	1	33	33	NUM
dpc-3121	254	2	.	.	PUNCT
dpc-3121	255	1	thom	thom	PROPN
dpc-3121	255	2	h	h	PROPN
dpc-3121	255	3	,	,	PUNCT
dpc-3121	255	4	cheng	cheng	PROPN
dpc-3121	255	5	v	v	PROPN
dpc-3121	255	6	,	,	PUNCT
dpc-3121	255	7	keeney	keeney	PROPN
dpc-3121	255	8	e	e	PROPN
dpc-3121	255	9	,	,	PUNCT
dpc-3121	255	10	et	et	PROPN
dpc-3121	255	11	al	al	PROPN
dpc-3121	255	12	.	.	PUNCT
dpc-3121	256	1	matching	matching	NOUN
dpc-3121	256	2	-	-	PUNCT
dpc-3121	256	3	adjusted	adjust	VERB
dpc-3121	256	4	indirect	indirect	ADJ
dpc-3121	256	5	comparison	comparison	NOUN
dpc-3121	256	6	of	of	ADP
dpc-3121	256	7	crisaborole	crisaborole	PROPN
dpc-3121	256	8	ointment	ointment	NOUN
dpc-3121	256	9	2	2	NUM
dpc-3121	256	10	%	%	NOUN
dpc-3121	256	11	vs.	vs.	ADP
dpc-3121	256	12	topical	topical	ADJ
dpc-3121	256	13	calcineurin	calcineurin	NOUN
dpc-3121	256	14	inhibitors	inhibitor	NOUN
dpc-3121	256	15	in	in	ADP
dpc-3121	256	16	the	the	DET
dpc-3121	256	17	treatment	treatment	NOUN
dpc-3121	256	18	of	of	ADP
dpc-3121	256	19	patients	patient	NOUN
dpc-3121	256	20	with	with	ADP
dpc-3121	256	21	mild	mild	ADJ
dpc-3121	256	22	-	-	PUNCT
dpc-3121	256	23	to	to	ADP
dpc-3121	256	24	-	-	PUNCT
dpc-3121	256	25	moderate	moderate	ADJ
dpc-3121	256	26	atopic	atopic	NOUN
dpc-3121	256	27	dermatitis	dermatitis	NOUN
dpc-3121	256	28	.	.	PUNCT
dpc-3121	257	1	dermatol	dermatol	NOUN
dpc-3121	257	2	ther	ther	ADV
dpc-3121	257	3	(	(	PUNCT
dpc-3121	257	4	heidelb	heidelb	NOUN
dpc-3121	257	5	)	)	PUNCT
dpc-3121	257	6	.	.	PUNCT
dpc-3121	258	1	2022;12(1):185	2022;12(1):185	NUM
dpc-3121	258	2	-	-	SYM
dpc-3121	258	3	194	194	NUM
dpc-3121	258	4	.	.	PUNCT
dpc-3121	259	1	doi:10.1007	doi:10.1007	PROPN
dpc-3121	259	2	/	/	SYM
dpc-3121	259	3	s13555	s13555	PROPN
dpc-3121	259	4	-	-	PUNCT
dpc-3121	259	5	021	021	NUM
dpc-3121	259	6	-	-	PUNCT
dpc-3121	259	7	00646	00646	NUM
dpc-3121	259	8	-	-	SYM
dpc-3121	259	9	1	1	NUM
dpc-3121	259	10	.	.	PUNCT
dpc-3121	260	1	pmid	pmid	NOUN
dpc-3121	260	2	:	:	PUNCT
dpc-3121	260	3	34877623	34877623	NUM
dpc-3121	260	4	.	.	PUNCT
dpc-3121	261	1	pmcid	pmcid	NOUN
dpc-3121	261	2	:	:	PUNCT
dpc-3121	261	3	pmc8776944	pmc8776944	ADJ
dpc-3121	261	4	.	.	PUNCT
dpc-3121	262	1	34	34	NUM
dpc-3121	262	2	.	.	PUNCT
dpc-3121	263	1	clinicaltrials.gov	clinicaltrials.gov	X
dpc-3121	263	2	.	.	PUNCT
dpc-3121	264	1	a	a	DET
dpc-3121	264	2	study	study	NOUN
dpc-3121	264	3	of	of	ADP
dpc-3121	264	4	crisaborole	crisaborole	PROPN
dpc-3121	264	5	ointment	ointment	NOUN
dpc-3121	264	6	2	2	NUM
dpc-3121	264	7	%	%	NOUN
dpc-3121	264	8	;	;	PUNCT
dpc-3121	264	9	crisaborole	crisaborole	NOUN
dpc-3121	264	10	vehicle	vehicle	NOUN
dpc-3121	264	11	;	;	PUNCT
dpc-3121	264	12	tcs	tcs	NOUN
dpc-3121	264	13	and	and	CCONJ
dpc-3121	264	14	tci	tci	NOUN
dpc-3121	264	15	in	in	ADP
dpc-3121	264	16	subjects	subject	NOUN
dpc-3121	264	17	aged	age	VERB
dpc-3121	264	18	≥	≥	NOUN
dpc-3121	264	19	2	2	NUM
dpc-3121	264	20	years	year	NOUN
dpc-3121	264	21	,	,	PUNCT
dpc-3121	264	22	with	with	ADP
dpc-3121	264	23	mild	mild	ADJ
dpc-3121	264	24	-	-	PUNCT
dpc-3121	264	25	moderate	moderate	ADJ
dpc-3121	264	26	ad	ad	NOUN
dpc-3121	264	27	.	.	PUNCT
dpc-3121	264	28	,	,	PUNCT
dpc-3121	264	29	available	available	ADJ
dpc-3121	264	30	from	from	ADP
dpc-3121	264	31	:	:	PUNCT
dpc-3121	264	32	https://clinicaltrials	https://clinicaltrial	NOUN
dpc-3121	264	33	.	.	PUNCT
dpc-3121	265	1	g	g	NOUN
dpc-3121	265	2	o	o	NOUN
dpc-3121	265	3	v	v	NOUN
dpc-3121	265	4	/	/	SYM
dpc-3121	265	5	c	c	NOUN
dpc-3121	265	6	t	t	PROPN
dpc-3121	265	7	2	2	NUM
dpc-3121	265	8	/	/	SYM
dpc-3121	265	9	s	s	NOUN
dpc-3121	265	10	h	h	NOUN
dpc-3121	266	1	o	o	NOUN
dpc-3121	266	2	w	w	NOUN
dpc-3121	266	3	/	/	SYM
dpc-3121	266	4	r	r	NOUN
dpc-3121	266	5	e	e	NOUN
dpc-3121	266	6	s	s	NOUN
dpc-3121	266	7	u	u	X
dpc-3121	266	8	l	l	NOUN
dpc-3121	266	9	t	t	NOUN
dpc-3121	266	10	s	s	PART
dpc-3121	266	11	/	/	SYM
dpc-3121	266	12	n	n	PROPN
dpc-3121	266	13	c	c	NOUN
dpc-3121	266	14	t	t	NOUN
dpc-3121	266	15	0	0	NUM
dpc-3121	266	16	3	3	NUM
dpc-3121	266	17	5	5	NUM
dpc-3121	266	18	3	3	NUM
dpc-3121	266	19	9	9	NUM
dpc-3121	266	20	6	6	NUM
dpc-3121	266	21	0	0	NUM
dpc-3121	266	22	1	1	NUM
dpc-3121	266	23	?	?	PUNCT
dpc-3121	267	1	t	t	NOUN
dpc-3121	267	2	e	e	X
dpc-3121	267	3	r	r	NOUN
dpc-3121	267	4	m	m	PROPN
dpc-3121	267	5	=	=	NOUN
dpc-3121	267	6	c3291037&draw=2&rank=1	c3291037&draw=2&rank=1	NOUN
dpc-3121	267	7	,	,	PUNCT
dpc-3121	267	8	accessed	access	VERB
dpc-3121	267	9	01.11.2022	01.11.2022	NOUN
dpc-3121	267	10	9	9	NUM
dpc-3121	267	11	.	.	PUNCT
dpc-3121	268	1	buys	buy	VERB
dpc-3121	268	2	lm	lm	PROPN
dpc-3121	268	3	.	.	PUNCT
dpc-3121	269	1	treatment	treatment	NOUN
dpc-3121	269	2	options	option	NOUN
dpc-3121	269	3	for	for	ADP
dpc-3121	269	4	atopic	atopic	NOUN
dpc-3121	269	5	dermatitis	dermatitis	NOUN
dpc-3121	269	6	.	.	PUNCT
dpc-3121	270	1	am	be	AUX
dpc-3121	270	2	fam	fam	NOUN
dpc-3121	270	3	physician	physician	NOUN
dpc-3121	270	4	.	.	PUNCT
dpc-3121	271	1	2007;75(4):523	2007;75(4):523	NOUN
dpc-3121	271	2	-	-	SYM
dpc-3121	271	3	8	8	NUM
dpc-3121	271	4	.	.	PUNCT
dpc-3121	272	1	pmid	pmid	NOUN
dpc-3121	272	2	:	:	PUNCT
dpc-3121	272	3	17323714	17323714	NUM
dpc-3121	272	4	.	.	PUNCT
dpc-3121	273	1	10	10	NUM
dpc-3121	273	2	.	.	X
dpc-3121	274	1	axon	axon	PROPN
dpc-3121	274	2	e	e	NOUN
dpc-3121	274	3	,	,	PUNCT
dpc-3121	274	4	chalmers	chalmer	VERB
dpc-3121	274	5	jr	jr	PROPN
dpc-3121	274	6	,	,	PUNCT
dpc-3121	274	7	santer	santer	PROPN
dpc-3121	274	8	m	m	PROPN
dpc-3121	274	9	,	,	PUNCT
dpc-3121	274	10	et	et	PROPN
dpc-3121	274	11	al	al	PROPN
dpc-3121	274	12	.	.	PUNCT
dpc-3121	274	13	safety	safety	NOUN
dpc-3121	274	14	of	of	ADP
dpc-3121	274	15	topical	topical	ADJ
dpc-3121	274	16	corticosteroids	corticosteroid	NOUN
dpc-3121	274	17	in	in	ADP
dpc-3121	274	18	atopic	atopic	ADJ
dpc-3121	274	19	eczema	eczema	NOUN
dpc-3121	274	20	:	:	PUNCT
dpc-3121	274	21	an	an	DET
dpc-3121	274	22	umbrella	umbrella	NOUN
dpc-3121	274	23	review	review	NOUN
dpc-3121	274	24	.	.	PUNCT
dpc-3121	275	1	bmj	bmj	PROPN
dpc-3121	275	2	open	open	ADJ
dpc-3121	275	3	.	.	PUNCT
dpc-3121	276	1	2021;11(7):e046476	2021;11(7):e046476	X
dpc-3121	276	2	.	.	PUNCT
dpc-3121	276	3	doi:10.1136	doi:10.1136	NOUN
dpc-3121	276	4	/	/	SYM
dpc-3121	276	5	bmjopen-2020	bmjopen-2020	NOUN
dpc-3121	276	6	-	-	PUNCT
dpc-3121	276	7	046476	046476	NUM
dpc-3121	276	8	.	.	PUNCT
dpc-3121	277	1	pmid	pmid	NOUN
dpc-3121	277	2	:	:	PUNCT
dpc-3121	277	3	34233978	34233978	NUM
dpc-3121	277	4	;	;	PUNCT
dpc-3121	277	5	pmcid	pmcid	NOUN
dpc-3121	277	6	:	:	PUNCT
dpc-3121	277	7	pmc8264889	pmc8264889	ADJ
dpc-3121	277	8	.	.	PUNCT
dpc-3121	278	1	11	11	NUM
dpc-3121	278	2	.	.	PUNCT
dpc-3121	279	1	li	li	PROPN
dpc-3121	279	2	aw	aw	INTJ
dpc-3121	279	3	,	,	PUNCT
dpc-3121	279	4	yin	yin	PROPN
dpc-3121	279	5	es	es	PROPN
dpc-3121	279	6	,	,	PUNCT
dpc-3121	279	7	antaya	antaya	PROPN
dpc-3121	279	8	rj	rj	PROPN
dpc-3121	279	9	.	.	PUNCT
dpc-3121	279	10	topical	topical	ADJ
dpc-3121	279	11	corticosteroid	corticosteroid	ADJ
dpc-3121	279	12	phobia	phobia	NOUN
dpc-3121	279	13	in	in	ADP
dpc-3121	279	14	atopic	atopic	NOUN
dpc-3121	279	15	dermatitis	dermatitis	NOUN
dpc-3121	279	16	:	:	PUNCT
dpc-3121	279	17	a	a	DET
dpc-3121	279	18	systematic	systematic	ADJ
dpc-3121	279	19	review	review	NOUN
dpc-3121	279	20	.	.	PUNCT
dpc-3121	280	1	jama	jama	PROPN
dpc-3121	280	2	dermatol	dermatol	NOUN
dpc-3121	280	3	.	.	PUNCT
dpc-3121	281	1	2017;153(10):1036	2017;153(10):1036	NUM
dpc-3121	281	2	-	-	SYM
dpc-3121	281	3	1042	1042	NUM
dpc-3121	281	4	.	.	PUNCT
dpc-3121	282	1	doi	doi	NOUN
dpc-3121	282	2	:	:	PUNCT
dpc-3121	282	3	10.1001	10.1001	NUM
dpc-3121	282	4	/	/	SYM
dpc-3121	282	5	jamadermatol	jamadermatol	NOUN
dpc-3121	282	6	.2017.2437	.2017.2437	NOUN
dpc-3121	282	7	.	.	PUNCT
dpc-3121	283	1	pmid	pmid	NOUN
dpc-3121	283	2	:	:	PUNCT
dpc-3121	283	3	28724128	28724128	NUM
dpc-3121	283	4	.	.	PUNCT
dpc-3121	284	1	12	12	NUM
dpc-3121	284	2	.	.	PUNCT
dpc-3121	285	1	arkwright	arkwright	PROPN
dpc-3121	285	2	pd	pd	PROPN
dpc-3121	285	3	,	,	PUNCT
dpc-3121	285	4	motala	motala	PROPN
dpc-3121	285	5	c	c	X
dpc-3121	285	6	,	,	PUNCT
dpc-3121	285	7	subramanian	subramanian	ADJ
dpc-3121	285	8	h	h	NOUN
dpc-3121	285	9	,	,	PUNCT
dpc-3121	285	10	spergel	spergel	PROPN
dpc-3121	285	11	j	j	PROPN
dpc-3121	285	12	,	,	PUNCT
dpc-3121	285	13	schneider	schneider	PROPN
dpc-3121	285	14	lc	lc	PROPN
dpc-3121	285	15	,	,	PUNCT
dpc-3121	285	16	wollenberg	wollenberg	PROPN
dpc-3121	285	17	a.	a.	NOUN
dpc-3121	285	18	management	management	NOUN
dpc-3121	285	19	of	of	ADP
dpc-3121	285	20	difficult	difficult	ADJ
dpc-3121	285	21	-	-	PUNCT
dpc-3121	285	22	to	to	ADP
dpc-3121	285	23	-	-	PUNCT
dpc-3121	285	24	treat	treat	VERB
dpc-3121	285	25	atopic	atopic	NOUN
dpc-3121	285	26	dermatitis	dermatitis	NOUN
dpc-3121	285	27	.	.	PUNCT
dpc-3121	286	1	j	j	PROPN
dpc-3121	286	2	allergy	allergy	PROPN
dpc-3121	286	3	clin	clin	PROPN
dpc-3121	286	4	immunol	immunol	PROPN
dpc-3121	286	5	pract	pract	PROPN
dpc-3121	286	6	.	.	PUNCT
dpc-3121	287	1	2013;1(2):142	2013;1(2):142	NUM
dpc-3121	287	2	-	-	SYM
dpc-3121	287	3	151	151	NUM
dpc-3121	287	4	.	.	PUNCT
dpc-3121	287	5	doi:10.1016	doi:10.1016	PROPN
dpc-3121	287	6	/	/	SYM
dpc-3121	287	7	j.jaip.2012.09.002	j.jaip.2012.09.002	PROPN
dpc-3121	287	8	.	.	PUNCT
dpc-3121	288	1	pmid	pmid	NOUN
dpc-3121	288	2	:	:	PUNCT
dpc-3121	288	3	24565453	24565453	NUM
dpc-3121	288	4	.	.	PUNCT
dpc-3121	289	1	13	13	NUM
dpc-3121	289	2	.	.	X
dpc-3121	289	3	drucker	drucker	PROPN
dpc-3121	289	4	am	be	AUX
dpc-3121	289	5	,	,	PUNCT
dpc-3121	289	6	eyerich	eyerich	PROPN
dpc-3121	289	7	k	k	X
dpc-3121	289	8	,	,	PUNCT
dpc-3121	289	9	de	de	PROPN
dpc-3121	289	10	bruin	bruin	NOUN
dpc-3121	289	11	-	-	PUNCT
dpc-3121	289	12	weller	weller	PROPN
dpc-3121	289	13	ms	ms	PROPN
dpc-3121	289	14	,	,	PUNCT
dpc-3121	289	15	et	et	PROPN
dpc-3121	289	16	al	al	PROPN
dpc-3121	289	17	.	.	PUNCT
dpc-3121	289	18	use	use	NOUN
dpc-3121	289	19	of	of	ADP
dpc-3121	289	20	systemic	systemic	ADJ
dpc-3121	289	21	corticosteroids	corticosteroid	NOUN
dpc-3121	289	22	for	for	ADP
dpc-3121	289	23	atopic	atopic	NOUN
dpc-3121	289	24	dermatitis	dermatitis	NOUN
dpc-3121	289	25	:	:	PUNCT
dpc-3121	289	26	international	international	PROPN
dpc-3121	289	27	eczema	eczema	PROPN
dpc-3121	289	28	council	council	PROPN
dpc-3121	289	29	consensus	consensus	NOUN
dpc-3121	289	30	statement	statement	NOUN
dpc-3121	289	31	.	.	PUNCT
dpc-3121	289	32	.	.	PUNCT
dpc-3121	290	1	br	br	PROPN
dpc-3121	290	2	j	j	PROPN
dpc-3121	290	3	dermatol	dermatol	NOUN
dpc-3121	290	4	.	.	PUNCT
dpc-3121	291	1	2018	2018	NUM
dpc-3121	291	2	;	;	PUNCT
dpc-3121	291	3	178(3):768	178(3):768	NUM
dpc-3121	291	4	-	-	SYM
dpc-3121	291	5	775	775	NUM
dpc-3121	291	6	.	.	PUNCT
dpc-3121	292	1	doi	doi	NOUN
dpc-3121	292	2	:	:	PUNCT
dpc-3121	292	3	10.1111	10.1111	NUM
dpc-3121	292	4	/	/	SYM
dpc-3121	292	5	bjd.15928	bjd.15928	NUM
dpc-3121	292	6	.	.	PUNCT
dpc-3121	293	1	pmid	pmid	NOUN
dpc-3121	293	2	:	:	PUNCT
dpc-3121	293	3	28865094	28865094	NUM
dpc-3121	293	4	.	.	PUNCT
dpc-3121	294	1	pmcid	pmcid	ADJ
dpc-3121	294	2	:	:	PUNCT
dpc-3121	294	3	pmc5901393	pmc5901393	ADJ
dpc-3121	294	4	.	.	PUNCT
dpc-3121	295	1	14	14	NUM
dpc-3121	295	2	.	.	PUNCT
dpc-3121	296	1	quintás	quintás	NOUN
dpc-3121	296	2	-	-	PUNCT
dpc-3121	296	3	cardama	cardama	NOUN
dpc-3121	296	4	a	a	DET
dpc-3121	296	5	,	,	PUNCT
dpc-3121	296	6	vaddi	vaddi	ADJ
dpc-3121	296	7	k	k	PROPN
dpc-3121	296	8	,	,	PUNCT
dpc-3121	296	9	liu	liu	PROPN
dpc-3121	296	10	p	p	PROPN
dpc-3121	296	11	,	,	PUNCT
dpc-3121	296	12	et	et	PROPN
dpc-3121	296	13	al	al	PROPN
dpc-3121	296	14	.	.	PUNCT
dpc-3121	297	1	preclinical	preclinical	ADJ
dpc-3121	297	2	characterization	characterization	NOUN
dpc-3121	297	3	of	of	ADP
dpc-3121	297	4	the	the	DET
dpc-3121	297	5	selective	selective	ADJ
dpc-3121	297	6	jak1/2	jak1/2	PROPN
dpc-3121	297	7	inhibitor	inhibitor	NOUN
dpc-3121	297	8	incb018424	incb018424	PROPN
dpc-3121	297	9	:	:	PUNCT
dpc-3121	297	10	therapeutic	therapeutic	ADJ
dpc-3121	297	11	implications	implication	NOUN
dpc-3121	297	12	for	for	ADP
dpc-3121	297	13	the	the	DET
dpc-3121	297	14	treatment	treatment	NOUN
dpc-3121	297	15	of	of	ADP
dpc-3121	297	16	myeloproliferative	myeloproliferative	ADJ
dpc-3121	297	17	  	  	SPACE
dpc-3121	297	18	neoplasms	neoplasm	NOUN
dpc-3121	297	19	.	.	PUNCT
dpc-3121	298	1	blood	blood	NOUN
dpc-3121	298	2	.	.	PUNCT
dpc-3121	299	1	2010;115(15):3109	2010;115(15):3109	NUM
dpc-3121	299	2	-	-	SYM
dpc-3121	299	3	3117	3117	NUM
dpc-3121	299	4	.	.	PUNCT
dpc-3121	300	1	doi:10	doi:10	PROPN
dpc-3121	300	2	.1182	.1182	PROPN
dpc-3121	300	3	/	/	SYM
dpc-3121	300	4	blood-2009	blood-2009	NOUN
dpc-3121	300	5	-	-	PUNCT
dpc-3121	300	6	04	04	NUM
dpc-3121	300	7	-	-	PUNCT
dpc-3121	300	8	214957	214957	NUM
dpc-3121	300	9	pmid	pmid	NOUN
dpc-3121	300	10	:	:	PUNCT
dpc-3121	300	11	20130243	20130243	NUM
dpc-3121	300	12	.	.	PUNCT
dpc-3121	301	1	pmcid	pmcid	NOUN
dpc-3121	301	2	:	:	PUNCT
dpc-3121	301	3	pmc3953826	pmc3953826	ADJ
dpc-3121	301	4	.	.	PUNCT
dpc-3121	302	1	15	15	X
dpc-3121	302	2	.	.	PUNCT
dpc-3121	303	1	he	he	PRON
dpc-3121	303	2	h	h	NOUN
dpc-3121	303	3	,	,	PUNCT
dpc-3121	303	4	guttman	guttman	ADJ
dpc-3121	303	5	-	-	PUNCT
dpc-3121	303	6	yassky	yassky	NOUN
dpc-3121	303	7	e.	e.	PROPN
dpc-3121	303	8	jak	jak	PROPN
dpc-3121	303	9	inhibitors	inhibitor	NOUN
dpc-3121	303	10	for	for	ADP
dpc-3121	303	11	atopic	atopic	NOUN
dpc-3121	303	12	dermatitis	dermatitis	NOUN
dpc-3121	303	13	:	:	PUNCT
dpc-3121	303	14	an	an	DET
dpc-3121	303	15	update	update	NOUN
dpc-3121	303	16	.	.	PUNCT
dpc-3121	304	1	am	be	AUX
dpc-3121	304	2	j	j	PROPN
dpc-3121	304	3	clin	clin	PROPN
dpc-3121	304	4	dermatol	dermatol	NOUN
dpc-3121	304	5	.	.	PUNCT
dpc-3121	305	1	2019;20(2):181	2019;20(2):181	NUM
dpc-3121	305	2	-	-	PUNCT
dpc-3121	305	3	192	192	NUM
dpc-3121	305	4	.	.	PUNCT
dpc-3121	306	1	doi:10.1007	doi:10.1007	VERB
dpc-3121	306	2	/	/	SYM
dpc-3121	306	3	s40257	s40257	NOUN
dpc-3121	306	4	-	-	PUNCT
dpc-3121	306	5	018	018	NUM
dpc-3121	306	6	-	-	PUNCT
dpc-3121	306	7	0413	0413	NUM
dpc-3121	306	8	-	-	PUNCT
dpc-3121	306	9	2	2	NUM
dpc-3121	306	10	.	.	PUNCT
dpc-3121	306	11	pmid	pmid	NOUN
dpc-3121	306	12	:	:	PUNCT
dpc-3121	306	13	30536048	30536048	NUM
dpc-3121	306	14	.	.	PUNCT
dpc-3121	307	1	16	16	NUM
dpc-3121	307	2	.	.	PUNCT
dpc-3121	308	1	kim	kim	PROPN
dpc-3121	308	2	bs	bs	PROPN
dpc-3121	308	3	,	,	PUNCT
dpc-3121	308	4	sun	sun	PROPN
dpc-3121	308	5	k	k	PROPN
dpc-3121	308	6	,	,	PUNCT
dpc-3121	308	7	papp	papp	PROPN
dpc-3121	308	8	k	k	PROPN
dpc-3121	308	9	,	,	PUNCT
dpc-3121	308	10	venturanza	venturanza	ADP
dpc-3121	308	11	m	m	PROPN
dpc-3121	308	12	,	,	PUNCT
dpc-3121	308	13	nasir	nasir	PROPN
dpc-3121	308	14	a	a	PROPN
dpc-3121	308	15	,	,	PUNCT
dpc-3121	308	16	kuligowski	kuligowski	ADJ
dpc-3121	308	17	me	i	PRON
dpc-3121	308	18	.	.	PUNCT
dpc-3121	309	1	effects	effect	NOUN
dpc-3121	309	2	of	of	ADP
dpc-3121	309	3	ruxolitinib	ruxolitinib	NOUN
dpc-3121	309	4	cream	cream	NOUN
dpc-3121	309	5	on	on	ADP
dpc-3121	309	6	pruritus	pruritus	PROPN
dpc-3121	309	7	and	and	CCONJ
dpc-3121	309	8	quality	quality	NOUN
dpc-3121	309	9	of	of	ADP
dpc-3121	309	10	life	life	NOUN
dpc-3121	309	11	in	in	ADP
dpc-3121	309	12	atopic	atopic	NOUN
dpc-3121	309	13	dermatitis	dermatitis	NOUN
dpc-3121	309	14	:	:	PUNCT
dpc-3121	309	15	results	result	VERB
dpc-3121	309	16	from	from	ADP
dpc-3121	309	17	a	a	DET
dpc-3121	309	18	phase	phase	NOUN
dpc-3121	309	19	2	2	NUM
dpc-3121	309	20	,	,	PUNCT
dpc-3121	309	21	randomized	randomize	VERB
dpc-3121	309	22	,	,	PUNCT
dpc-3121	309	23	dose	dose	NOUN
dpc-3121	309	24	-	-	PUNCT
dpc-3121	309	25	ranging	ranging	NOUN
dpc-3121	309	26	,	,	PUNCT
dpc-3121	309	27	vehicleand	vehicleand	VERB
dpc-3121	309	28	active	active	ADV
dpc-3121	309	29	-	-	PUNCT
dpc-3121	309	30	controlled	control	VERB
dpc-3121	309	31	study	study	NOUN
dpc-3121	309	32	.	.	PUNCT
dpc-3121	310	1	j	j	PROPN
dpc-3121	310	2	am	be	AUX
dpc-3121	310	3	acad	acad	ADJ
dpc-3121	310	4	dermatol	dermatol	NOUN
dpc-3121	310	5	.	.	PUNCT
dpc-3121	311	1	2020;82(6):1305	2020;82(6):1305	NUM
dpc-3121	311	2	-	-	SYM
dpc-3121	311	3	1313	1313	NUM
dpc-3121	311	4	.	.	PUNCT
dpc-3121	312	1	doi:10.1016	doi:10.1016	PROPN
dpc-3121	312	2	/	/	SYM
dpc-3121	312	3	j	j	PROPN
dpc-3121	312	4	.jaad.2020.02.009	.jaad.2020.02.009	PUNCT
dpc-3121	312	5	.	.	PUNCT
dpc-3121	313	1	pmid	pmid	NOUN
dpc-3121	313	2	:	:	PUNCT
dpc-3121	313	3	32057960	32057960	NUM
dpc-3121	313	4	.	.	PUNCT
dpc-3121	314	1	17	17	NUM
dpc-3121	314	2	.	.	PUNCT
dpc-3121	315	1	kim	kim	PROPN
dpc-3121	315	2	bs	bs	PROPN
dpc-3121	315	3	,	,	PUNCT
dpc-3121	315	4	howell	howell	PROPN
dpc-3121	315	5	md	md	PROPN
dpc-3121	315	6	,	,	PUNCT
dpc-3121	315	7	sun	sun	PROPN
dpc-3121	315	8	k	k	PROPN
dpc-3121	315	9	,	,	PUNCT
dpc-3121	315	10	papp	papp	PROPN
dpc-3121	315	11	k	k	PROPN
dpc-3121	315	12	,	,	PUNCT
dpc-3121	315	13	nasir	nasir	PROPN
dpc-3121	315	14	a	a	PROPN
dpc-3121	315	15	,	,	PUNCT
dpc-3121	315	16	kuligowski	kuligowski	ADJ
dpc-3121	315	17	me	i	PRON
dpc-3121	315	18	.	.	PUNCT
dpc-3121	316	1	treatment	treatment	NOUN
dpc-3121	316	2	of	of	ADP
dpc-3121	316	3	atopic	atopic	NOUN
dpc-3121	316	4	dermatitis	dermatitis	NOUN
dpc-3121	316	5	with	with	ADP
dpc-3121	316	6	ruxolitinib	ruxolitinib	NOUN
dpc-3121	316	7	cream	cream	NOUN
dpc-3121	316	8	(	(	PUNCT
dpc-3121	316	9	jak1/	jak1/	PROPN
dpc-3121	316	10	jak2	jak2	PROPN
dpc-3121	316	11	inhibitor	inhibitor	NOUN
dpc-3121	316	12	)	)	PUNCT
dpc-3121	316	13	or	or	CCONJ
dpc-3121	316	14	triamcinolone	triamcinolone	NOUN
dpc-3121	316	15	cream	cream	NOUN
dpc-3121	316	16	.	.	PUNCT
dpc-3121	317	1	j	j	PROPN
dpc-3121	317	2	allergy	allergy	PROPN
dpc-3121	317	3	clin	clin	PROPN
dpc-3121	317	4	immunol	immunol	PROPN
dpc-3121	317	5	.	.	PUNCT
dpc-3121	318	1	2020;145(2):572	2020;145(2):572	X
dpc-3121	318	2	-	-	SYM
dpc-3121	318	3	582	582	NUM
dpc-3121	318	4	.	.	PUNCT
dpc-3121	319	1	doi:10.1016	doi:10.1016	PROPN
dpc-3121	319	2	/	/	SYM
dpc-3121	319	3	j.jaci.2019.08.042	j.jaci.2019.08.042	PROPN
dpc-3121	319	4	.	.	PUNCT
dpc-3121	320	1	pmid	pmid	NOUN
dpc-3121	320	2	:	:	PUNCT
dpc-3121	320	3	31629805	31629805	NUM
dpc-3121	320	4	.	.	PUNCT
dpc-3121	321	1	18	18	NUM
dpc-3121	321	2	.	.	PUNCT
dpc-3121	321	3	papp	papp	PROPN
dpc-3121	321	4	k	k	PROPN
dpc-3121	321	5	,	,	PUNCT
dpc-3121	321	6	szepietowski	szepietowski	PROPN
dpc-3121	321	7	jc	jc	PROPN
dpc-3121	321	8	,	,	PUNCT
dpc-3121	321	9	kircik	kircik	PROPN
dpc-3121	321	10	l	l	PROPN
dpc-3121	321	11	,	,	PUNCT
dpc-3121	321	12	et	et	PROPN
dpc-3121	321	13	al	al	PROPN
dpc-3121	321	14	.	.	PROPN
dpc-3121	321	15	efficacy	efficacy	NOUN
dpc-3121	321	16	and	and	CCONJ
dpc-3121	321	17	safety	safety	NOUN
dpc-3121	321	18	of	of	ADP
dpc-3121	321	19	ruxolitinib	ruxolitinib	NOUN
dpc-3121	321	20	cream	cream	NOUN
dpc-3121	321	21	for	for	ADP
dpc-3121	321	22	the	the	DET
dpc-3121	321	23	treatment	treatment	NOUN
dpc-3121	321	24	of	of	ADP
dpc-3121	321	25	atopic	atopic	NOUN
dpc-3121	321	26	dermatitis	dermatitis	NOUN
dpc-3121	321	27	:	:	PUNCT
dpc-3121	321	28	results	result	NOUN
dpc-3121	321	29	from	from	ADP
dpc-3121	321	30	2	2	NUM
dpc-3121	321	31	phase	phase	NOUN
dpc-3121	321	32	3	3	NUM
dpc-3121	321	33	,	,	PUNCT
dpc-3121	321	34	randomized	randomize	VERB
dpc-3121	321	35	,	,	PUNCT
dpc-3121	321	36	double	double	ADJ
dpc-3121	321	37	-	-	PUNCT
dpc-3121	321	38	blind	blind	ADJ
dpc-3121	321	39	studies	study	NOUN
dpc-3121	321	40	.	.	PUNCT
dpc-3121	322	1	j	j	PROPN
dpc-3121	322	2	am	be	AUX
dpc-3121	322	3	acad	acad	ADJ
dpc-3121	322	4	dermatol	dermatol	NOUN
dpc-3121	322	5	.	.	PUNCT
dpc-3121	323	1	2021;85(4):863	2021;85(4):863	NUM
dpc-3121	323	2	-	-	PUNCT
dpc-3121	323	3	872	872	NUM
dpc-3121	323	4	.	.	PUNCT
dpc-3121	323	5	doi:10.1016	doi:10.1016	PROPN
dpc-3121	323	6	/	/	SYM
dpc-3121	323	7	j.jaad	j.jaad	PROPN
dpc-3121	323	8	.2021.04.085	.2021.04.085	PUNCT
dpc-3121	323	9	.	.	PUNCT
dpc-3121	324	1	pmid	pmid	NOUN
dpc-3121	324	2	:	:	PUNCT
dpc-3121	324	3	33957195	33957195	NUM
dpc-3121	324	4	.	.	PUNCT
dpc-3121	325	1	19	19	NUM
dpc-3121	325	2	.	.	X
dpc-3121	325	3	bissonnette	bissonnette	NOUN
dpc-3121	325	4	r	r	NOUN
dpc-3121	325	5	,	,	PUNCT
dpc-3121	325	6	call	call	NOUN
dpc-3121	325	7	rs	rs	NOUN
dpc-3121	325	8	,	,	PUNCT
dpc-3121	325	9	raoof	raoof	NOUN
dpc-3121	325	10	t	t	PROPN
dpc-3121	325	11	,	,	PUNCT
dpc-3121	325	12	et	et	PROPN
dpc-3121	325	13	al	al	PROPN
dpc-3121	325	14	.	.	PUNCT
dpc-3121	326	1	a	a	DET
dpc-3121	326	2	maximum	maximum	ADJ
dpc-3121	326	3	-	-	PUNCT
dpc-3121	326	4	use	use	NOUN
dpc-3121	326	5	trial	trial	NOUN
dpc-3121	326	6	of	of	ADP
dpc-3121	326	7	ruxolitinib	ruxolitinib	NOUN
dpc-3121	326	8	cream	cream	NOUN
dpc-3121	326	9	in	in	ADP
dpc-3121	326	10	adolescents	adolescent	NOUN
dpc-3121	326	11	and	and	CCONJ
dpc-3121	326	12	adults	adult	NOUN
dpc-3121	326	13	with	with	ADP
dpc-3121	326	14	atopic	atopic	NOUN
dpc-3121	326	15	dermatitis	dermatitis	NOUN
dpc-3121	326	16	.	.	PUNCT
dpc-3121	326	17	am	be	AUX
dpc-3121	326	18	j	j	PROPN
dpc-3121	326	19	clin	clin	PROPN
dpc-3121	326	20	dermatol	dermatol	NOUN
dpc-3121	326	21	.	.	PUNCT
dpc-3121	327	1	2022;23(3):355	2022;23(3):355	NUM
dpc-3121	327	2	-	-	PUNCT
dpc-3121	327	3	364	364	NUM
dpc-3121	327	4	.	.	PUNCT
dpc-3121	328	1	doi:10.1007	doi:10.1007	PROPN
dpc-3121	328	2	/s40257	/s40257	PROPN
dpc-3121	328	3	-	-	PUNCT
dpc-3121	328	4	022	022	NUM
dpc-3121	328	5	-	-	PUNCT
dpc-3121	328	6	00690	00690	NUM
dpc-3121	328	7	-	-	PUNCT
dpc-3121	328	8	3	3	NUM
dpc-3121	328	9	.	.	PUNCT
dpc-3121	329	1	pmid	pmid	NOUN
dpc-3121	329	2	:	:	PUNCT
dpc-3121	329	3	35368221	35368221	NUM
dpc-3121	329	4	.	.	PUNCT
dpc-3121	330	1	pmcid	pmcid	NOUN
dpc-3121	330	2	:	:	PUNCT
dpc-3121	330	3	pmc9142470	pmc9142470	NOUN
dpc-3121	330	4	.	.	PUNCT
dpc-3121	331	1	20	20	NUM
dpc-3121	331	2	.	.	PUNCT
dpc-3121	332	1	murrell	murrell	PROPN
dpc-3121	332	2	df	df	PROPN
dpc-3121	332	3	,	,	PUNCT
dpc-3121	332	4	gebauer	gebauer	PROPN
dpc-3121	332	5	k	k	PROPN
dpc-3121	332	6	,	,	PUNCT
dpc-3121	332	7	spelman	spelman	PROPN
dpc-3121	332	8	l	l	PROPN
dpc-3121	332	9	,	,	PUNCT
dpc-3121	332	10	zane	zane	PROPN
dpc-3121	332	11	lt	lt	PROPN
dpc-3121	332	12	.	.	PROPN
dpc-3121	332	13	crisaborole	crisaborole	ADJ
dpc-3121	332	14	topical	topical	ADJ
dpc-3121	332	15	ointment	ointment	NOUN
dpc-3121	332	16	,	,	PUNCT
dpc-3121	332	17	2	2	NUM
dpc-3121	332	18	%	%	NOUN
dpc-3121	332	19	in	in	ADP
dpc-3121	332	20	adults	adult	NOUN
dpc-3121	332	21	with	with	ADP
dpc-3121	332	22	atopic	atopic	NOUN
dpc-3121	332	23	dermatitis	dermatitis	NOUN
dpc-3121	332	24	:	:	PUNCT
dpc-3121	332	25	a	a	DET
dpc-3121	332	26	phase	phase	NOUN
dpc-3121	332	27	2a	2a	NUM
dpc-3121	332	28	,	,	PUNCT
dpc-3121	332	29	vehicle	vehicle	NOUN
dpc-3121	332	30	-	-	PUNCT
dpc-3121	332	31	controlled	control	VERB
dpc-3121	332	32	,	,	PUNCT
dpc-3121	332	33	proof	proof	NOUN
dpc-3121	332	34	-	-	PUNCT
dpc-3121	332	35	of	of	ADP
dpc-3121	332	36	-	-	PUNCT
dpc-3121	332	37	concept	concept	NOUN
dpc-3121	332	38	study	study	NOUN
dpc-3121	332	39	.	.	PUNCT
dpc-3121	333	1	j	j	PROPN
dpc-3121	333	2	drugs	drug	NOUN
dpc-3121	333	3	dermatol	dermatol	NOUN
dpc-3121	333	4	.	.	PUNCT
dpc-3121	334	1	2015;14(10):1108	2015;14(10):1108	X
dpc-3121	334	2	-	-	SYM
dpc-3121	334	3	1112	1112	NUM
dpc-3121	334	4	.	.	PUNCT
dpc-3121	335	1	pmid	pmid	NOUN
dpc-3121	335	2	:	:	PUNCT
dpc-3121	335	3	26461821	26461821	NUM
dpc-3121	335	4	.	.	PUNCT
dpc-3121	336	1	21	21	NUM
dpc-3121	336	2	.	.	PUNCT
dpc-3121	337	1	maurice	maurice	PROPN
dpc-3121	337	2	dh	dh	PROPN
dpc-3121	337	3	,	,	PUNCT
dpc-3121	337	4	ke	ke	PROPN
dpc-3121	337	5	h	h	PROPN
dpc-3121	337	6	,	,	PUNCT
dpc-3121	337	7	ahmad	ahmad	PROPN
dpc-3121	337	8	f	f	PROPN
dpc-3121	337	9	,	,	PUNCT
dpc-3121	337	10	wang	wang	PROPN
dpc-3121	337	11	y	y	PROPN
dpc-3121	337	12	,	,	PUNCT
dpc-3121	337	13	chung	chung	PROPN
dpc-3121	337	14	j	j	PROPN
dpc-3121	337	15	,	,	PUNCT
dpc-3121	337	16	manganiello	manganiello	PROPN
dpc-3121	337	17	vc	vc	PROPN
dpc-3121	337	18	.	.	PROPN
dpc-3121	337	19	advances	advance	NOUN
dpc-3121	337	20	in	in	ADP
dpc-3121	337	21	targeting	target	VERB
dpc-3121	337	22	cyclic	cyclic	ADJ
dpc-3121	337	23	nucleotide	nucleotide	NOUN
dpc-3121	337	24	phosphodiesterases	phosphodiesterase	NOUN
dpc-3121	337	25	.	.	PUNCT
dpc-3121	338	1	nat	nat	PROPN
dpc-3121	338	2	rev	rev	VERB
dpc-3121	338	3	drug	drug	NOUN
dpc-3121	338	4	discov	discov	NOUN
dpc-3121	338	5	.	.	PUNCT
dpc-3121	339	1	2014;13(4):290	2014;13(4):290	NUM
dpc-3121	339	2	-	-	SYM
dpc-3121	339	3	314	314	NUM
dpc-3121	339	4	.	.	PUNCT
dpc-3121	339	5	doi:10.1038	doi:10.1038	NOUN
dpc-3121	339	6	/nrd4228	/nrd4228	PUNCT
dpc-3121	339	7	.	.	PUNCT
dpc-3121	340	1	pmid	pmid	NOUN
dpc-3121	340	2	:	:	PUNCT
dpc-3121	340	3	24687066	24687066	NUM
dpc-3121	340	4	.	.	PUNCT
dpc-3121	341	1	pmcid	pmcid	NOUN
dpc-3121	341	2	:	:	PUNCT
dpc-3121	341	3	pmc4155750	pmc4155750	ADJ
dpc-3121	341	4	.	.	PUNCT
dpc-3121	342	1	22	22	NUM
dpc-3121	342	2	.	.	PUNCT
dpc-3121	342	3	paller	paller	NOUN
dpc-3121	342	4	as	as	ADP
dpc-3121	342	5	,	,	PUNCT
dpc-3121	342	6	tom	tom	PROPN
dpc-3121	342	7	wl	wl	PROPN
dpc-3121	342	8	,	,	PUNCT
dpc-3121	342	9	lebwohl	lebwohl	VERB
dpc-3121	342	10	mg	mg	PROPN
dpc-3121	342	11	,	,	PUNCT
dpc-3121	342	12	et	et	PROPN
dpc-3121	342	13	al	al	PROPN
dpc-3121	342	14	.	.	PROPN
dpc-3121	342	15	efficacy	efficacy	NOUN
dpc-3121	342	16	and	and	CCONJ
dpc-3121	342	17	safety	safety	NOUN
dpc-3121	342	18	of	of	ADP
dpc-3121	342	19	crisaborole	crisaborole	PROPN
dpc-3121	342	20	ointment	ointment	NOUN
dpc-3121	342	21	,	,	PUNCT
dpc-3121	342	22	a	a	DET
dpc-3121	342	23	novel	novel	NOUN
dpc-3121	342	24	,	,	PUNCT
dpc-3121	342	25	nonsteroidal	nonsteroidal	NOUN
dpc-3121	342	26	phosphodiesterase	phosphodiesterase	NOUN
dpc-3121	342	27	4	4	NUM
dpc-3121	342	28	(	(	PUNCT
dpc-3121	342	29	pde4	pde4	NOUN
dpc-3121	342	30	)	)	PUNCT
dpc-3121	342	31	inhibitor	inhibitor	NOUN
dpc-3121	342	32	for	for	ADP
dpc-3121	342	33	the	the	DET
dpc-3121	342	34	topical	topical	ADJ
dpc-3121	342	35	treatment	treatment	NOUN
dpc-3121	342	36	of	of	ADP
dpc-3121	342	37	atopic	atopic	NOUN
dpc-3121	342	38	dermatitis	dermatitis	NOUN
dpc-3121	342	39	(	(	PUNCT
dpc-3121	342	40	ad	ad	NOUN
dpc-3121	342	41	)	)	PUNCT
dpc-3121	342	42	in	in	ADP
dpc-3121	342	43	children	child	NOUN
dpc-3121	342	44	and	and	CCONJ
dpc-3121	342	45	adults	adult	NOUN
dpc-3121	342	46	.	.	PUNCT
dpc-3121	343	1	j	j	PROPN
dpc-3121	343	2	am	be	AUX
dpc-3121	343	3	review	review	NOUN
dpc-3121	343	4	|	|	ADV
dpc-3121	343	5	dermatol	dermatol	ADJ
dpc-3121	343	6	pract	pract	NOUN
dpc-3121	343	7	concept	concept	NOUN
dpc-3121	343	8	.	.	PUNCT
dpc-3121	344	1	2023;13(4):e2023216	2023;13(4):e2023216	NUM
dpc-3121	344	2	7	7	NUM
dpc-3121	344	3	48	48	NUM
dpc-3121	344	4	.	.	PUNCT
dpc-3121	345	1	md	md	PROPN
dpc-3121	345	2	s	s	PROPN
dpc-3121	345	3	,	,	PUNCT
dpc-3121	345	4	kuldeep	kuldeep	PROPN
dpc-3121	345	5	singh	singh	PROPN
dpc-3121	345	6	jka	jka	PROPN
dpc-3121	345	7	,	,	PUNCT
dpc-3121	345	8	waqas	waqas	PROPN
dpc-3121	345	9	m	m	PROPN
dpc-3121	345	10	,	,	PUNCT
dpc-3121	345	11	et	et	PROPN
dpc-3121	345	12	al	al	PROPN
dpc-3121	345	13	.	.	PUNCT
dpc-3121	345	14	nanoencapsulation	nanoencapsulation	NOUN
dpc-3121	345	15	of	of	ADP
dpc-3121	345	16	betamethasone	betamethasone	PROPN
dpc-3121	345	17	valerate	valerate	NOUN
dpc-3121	345	18	using	use	VERB
dpc-3121	345	19	high	high	ADJ
dpc-3121	345	20	pressure	pressure	NOUN
dpc-3121	345	21	homogenization	homogenization	NOUN
dpc-3121	345	22	solvent	solvent	NOUN
dpc-3121	345	23	evaporation	evaporation	NOUN
dpc-3121	345	24	technique	technique	NOUN
dpc-3121	345	25	:	:	PUNCT
dpc-3121	345	26	optimization	optimization	NOUN
dpc-3121	345	27	of	of	ADP
dpc-3121	345	28	formulation	formulation	NOUN
dpc-3121	345	29	and	and	CCONJ
dpc-3121	345	30	process	process	NOUN
dpc-3121	345	31	parameters	parameter	NOUN
dpc-3121	345	32	for	for	ADP
dpc-3121	345	33	efficient	efficient	ADJ
dpc-3121	345	34	dermal	dermal	ADJ
dpc-3121	345	35	targeting	targeting	NOUN
dpc-3121	345	36	.	.	PUNCT
dpc-3121	346	1	drug	drug	PROPN
dpc-3121	346	2	dev	dev	PROPN
dpc-3121	346	3	ind	ind	PROPN
dpc-3121	346	4	pharm	pharm	PROPN
dpc-3121	346	5	.	.	PUNCT
dpc-3121	347	1	2019;45(2):323	2019;45(2):323	NUM
dpc-3121	347	2	-	-	PUNCT
dpc-3121	347	3	332	332	NUM
dpc-3121	347	4	.	.	PUNCT
dpc-3121	347	5	doi:10.1080/03639045.2018.154	doi:10.1080/03639045.2018.154	NOUN
dpc-3121	347	6	2704	2704	NUM
dpc-3121	347	7	.	.	PUNCT
dpc-3121	348	1	pmid	pmid	NOUN
dpc-3121	348	2	:	:	PUNCT
dpc-3121	348	3	30404554	30404554	NUM
dpc-3121	348	4	.	.	PUNCT
dpc-3121	349	1	49	49	NUM
dpc-3121	349	2	.	.	PUNCT
dpc-3121	350	1	siddique	siddique	PROPN
dpc-3121	350	2	mi	mi	PROPN
dpc-3121	350	3	,	,	PUNCT
dpc-3121	350	4	katas	katas	PROPN
dpc-3121	350	5	h	h	PROPN
dpc-3121	350	6	,	,	PUNCT
dpc-3121	350	7	jamil	jamil	PROPN
dpc-3121	350	8	a	a	PROPN
dpc-3121	350	9	,	,	PUNCT
dpc-3121	350	10	et	et	PROPN
dpc-3121	350	11	al	al	PROPN
dpc-3121	350	12	.	.	PROPN
dpc-3121	350	13	potential	potential	ADJ
dpc-3121	350	14	treatment	treatment	NOUN
dpc-3121	350	15	of	of	ADP
dpc-3121	350	16	atopic	atopic	NOUN
dpc-3121	350	17	dermatitis	dermatitis	NOUN
dpc-3121	350	18	:	:	PUNCT
dpc-3121	350	19	tolerability	tolerability	NOUN
dpc-3121	350	20	and	and	CCONJ
dpc-3121	350	21	safety	safety	NOUN
dpc-3121	350	22	of	of	ADP
dpc-3121	350	23	cream	cream	NOUN
dpc-3121	350	24	containing	contain	VERB
dpc-3121	350	25	nanoparticles	nanoparticle	NOUN
dpc-3121	350	26	loaded	load	VERB
dpc-3121	350	27	with	with	ADP
dpc-3121	350	28	hydrocortisone	hydrocortisone	NOUN
dpc-3121	350	29	and	and	CCONJ
dpc-3121	350	30	hydroxytyrosol	hydroxytyrosol	VERB
dpc-3121	350	31	in	in	ADP
dpc-3121	350	32	human	human	ADJ
dpc-3121	350	33	subjects	subject	NOUN
dpc-3121	350	34	.	.	PUNCT
dpc-3121	351	1	drug	drug	NOUN
dpc-3121	351	2	deliv	deliv	VERB
dpc-3121	351	3	transl	transl	PROPN
dpc-3121	351	4	res	re	NOUN
dpc-3121	351	5	.	.	PUNCT
dpc-3121	352	1	2019;9(2):469	2019;9(2):469	X
dpc-3121	352	2	-	-	SYM
dpc-3121	352	3	481	481	NUM
dpc-3121	352	4	.	.	PUNCT
dpc-3121	352	5	doi:10.1007	doi:10.1007	VERB
dpc-3121	352	6	/	/	SYM
dpc-3121	352	7	s13346	s13346	VERB
dpc-3121	352	8	-	-	PUNCT
dpc-3121	352	9	017	017	NUM
dpc-3121	352	10	-	-	PUNCT
dpc-3121	352	11	0439	0439	NUM
dpc-3121	352	12	-	-	PUNCT
dpc-3121	352	13	7	7	NUM
dpc-3121	352	14	.	.	PUNCT
dpc-3121	353	1	pmid	pmid	NOUN
dpc-3121	353	2	:	:	PUNCT
dpc-3121	353	3	29159691	29159691	NUM
dpc-3121	353	4	.	.	PUNCT
dpc-3121	354	1	50	50	NUM
dpc-3121	354	2	.	.	X
dpc-3121	354	3	siddique	siddique	PROPN
dpc-3121	354	4	mi	mi	PROPN
dpc-3121	354	5	,	,	PUNCT
dpc-3121	354	6	tufail	tufail	NOUN
dpc-3121	354	7	s	s	PROPN
dpc-3121	354	8	,	,	PUNCT
dpc-3121	354	9	ker	ker	PROPN
dpc-3121	354	10	zh	zh	PROPN
dpc-3121	354	11	,	,	PUNCT
dpc-3121	354	12	et	et	PROPN
dpc-3121	354	13	al	al	PROPN
dpc-3121	354	14	.	.	PROPN
dpc-3121	355	1	towards	towards	ADP
dpc-3121	355	2	fast	fast	ADJ
dpc-3121	355	3	and	and	CCONJ
dpc-3121	355	4	cost	cost	NOUN
dpc-3121	355	5	-	-	PUNCT
dpc-3121	355	6	effective	effective	ADJ
dpc-3121	355	7	up	up	NOUN
dpc-3121	355	8	-	-	PUNCT
dpc-3121	355	9	scaling	scaling	NOUN
dpc-3121	355	10	of	of	ADP
dpc-3121	355	11	nano	nano	NOUN
dpc-3121	355	12	-	-	PUNCT
dpc-3121	355	13	encapsulations	encapsulation	NOUN
dpc-3121	355	14	by	by	ADP
dpc-3121	355	15	ionicgelation	ionicgelation	NOUN
dpc-3121	355	16	method	method	NOUN
dpc-3121	355	17	using	use	VERB
dpc-3121	355	18	model	model	NOUN
dpc-3121	355	19	drug	drug	NOUN
dpc-3121	355	20	for	for	ADP
dpc-3121	355	21	the	the	DET
dpc-3121	355	22	treatment	treatment	NOUN
dpc-3121	355	23	of	of	ADP
dpc-3121	355	24	atopic	atopic	NOUN
dpc-3121	355	25	dermatitis	dermatitis	NOUN
dpc-3121	355	26	.	.	PUNCT
dpc-3121	356	1	pak	pak	PROPN
dpc-3121	356	2	j	j	PROPN
dpc-3121	356	3	pharm	pharm	PROPN
dpc-3121	356	4	sci	sci	PROPN
dpc-3121	356	5	.	.	PUNCT
dpc-3121	357	1	2019;32(5(supplementary)):2299	2019;32(5(supplementary)):2299	NUM
dpc-3121	357	2	-	-	SYM
dpc-3121	357	3	2304	2304	NUM
dpc-3121	357	4	.	.	PUNCT
dpc-3121	358	1	pmid	pmid	NOUN
dpc-3121	358	2	:	:	PUNCT
dpc-3121	358	3	31894058	31894058	NUM
dpc-3121	358	4	.	.	PUNCT
dpc-3121	359	1	51	51	NUM
dpc-3121	359	2	.	.	PUNCT
dpc-3121	359	3	sahle	sahle	PROPN
dpc-3121	359	4	ff	ff	NOUN
dpc-3121	359	5	,	,	PUNCT
dpc-3121	359	6	gerecke	gerecke	PROPN
dpc-3121	359	7	c	c	PROPN
dpc-3121	359	8	,	,	PUNCT
dpc-3121	359	9	kleuser	kleuser	PROPN
dpc-3121	359	10	b	b	PROPN
dpc-3121	359	11	,	,	PUNCT
dpc-3121	359	12	bodmeier	bodmeier	PROPN
dpc-3121	359	13	r.	r.	PROPN
dpc-3121	359	14	formulation	formulation	NOUN
dpc-3121	359	15	and	and	CCONJ
dpc-3121	359	16	comparative	comparative	ADJ
dpc-3121	359	17	in	in	ADP
dpc-3121	359	18	vitro	vitro	X
dpc-3121	359	19	evaluation	evaluation	NOUN
dpc-3121	359	20	of	of	ADP
dpc-3121	359	21	various	various	ADJ
dpc-3121	359	22	dexamethasone	dexamethasone	NOUN
dpc-3121	359	23	-	-	PUNCT
dpc-3121	359	24	loaded	load	VERB
dpc-3121	359	25	ph	ph	ADJ
dpc-3121	359	26	-	-	ADJ
dpc-3121	359	27	sensitive	sensitive	ADJ
dpc-3121	359	28	polymeric	polymeric	ADJ
dpc-3121	359	29	nanoparticles	nanoparticle	NOUN
dpc-3121	359	30	intended	intend	VERB
dpc-3121	359	31	for	for	ADP
dpc-3121	359	32	dermal	dermal	ADJ
dpc-3121	359	33	applications	application	NOUN
dpc-3121	359	34	.	.	PUNCT
dpc-3121	360	1	int	int	NOUN
dpc-3121	360	2	j	j	PROPN
dpc-3121	360	3	pharm	pharm	PROPN
dpc-3121	360	4	.	.	PUNCT
dpc-3121	361	1	2017;516(1	2017;516(1	X
dpc-3121	361	2	-	-	PUNCT
dpc-3121	361	3	2):21	2):21	NUM
dpc-3121	361	4	-	-	SYM
dpc-3121	361	5	31	31	NUM
dpc-3121	361	6	.	.	PUNCT
dpc-3121	362	1	doi:10.1016	doi:10.1016	PROPN
dpc-3121	362	2	/	/	SYM
dpc-3121	362	3	j	j	PROPN
dpc-3121	362	4	.ijpharm.2016.11.029	.ijpharm.2016.11.029	PROPN
dpc-3121	362	5	.	.	PUNCT
dpc-3121	363	1	pmid	pmid	NOUN
dpc-3121	363	2	:	:	PUNCT
dpc-3121	363	3	27845215	27845215	NUM
dpc-3121	363	4	.	.	PUNCT
dpc-3121	364	1	52	52	NUM
dpc-3121	364	2	.	.	PUNCT
dpc-3121	365	1	zhuo	zhuo	PROPN
dpc-3121	365	2	f	f	PROPN
dpc-3121	365	3	,	,	PUNCT
dpc-3121	365	4	abourehab	abourehab	PROPN
dpc-3121	365	5	mas	mas	PROPN
dpc-3121	365	6	,	,	PUNCT
dpc-3121	365	7	hussain	hussain	PROPN
dpc-3121	365	8	z.	z.	PROPN
dpc-3121	365	9	hyaluronic	hyaluronic	PROPN
dpc-3121	365	10	acid	acid	NOUN
dpc-3121	365	11	decorated	decorate	VERB
dpc-3121	365	12	tacrolimus	tacrolimus	NOUN
dpc-3121	365	13	-	-	PUNCT
dpc-3121	365	14	loaded	load	VERB
dpc-3121	365	15	nanoparticles	nanoparticle	NOUN
dpc-3121	365	16	:	:	PUNCT
dpc-3121	365	17	efficient	efficient	ADJ
dpc-3121	365	18	approach	approach	NOUN
dpc-3121	365	19	to	to	PART
dpc-3121	365	20	maximize	maximize	VERB
dpc-3121	365	21	  	  	SPACE
dpc-3121	365	22	dermal	dermal	VERB
dpc-3121	365	23	targeting	targeting	NOUN
dpc-3121	365	24	and	and	CCONJ
dpc-3121	365	25	anti	anti	ADJ
dpc-3121	365	26	-	-	ADJ
dpc-3121	365	27	dermatitis	dermatitis	ADJ
dpc-3121	365	28	efficacy	efficacy	NOUN
dpc-3121	365	29	.	.	PUNCT
dpc-3121	366	1	carbohydr	carbohydr	NOUN
dpc-3121	366	2	polym	polym	PROPN
dpc-3121	366	3	.	.	PUNCT
dpc-3121	367	1	2018;197:478	2018;197:478	NUM
dpc-3121	367	2	-	-	SYM
dpc-3121	367	3	489	489	NUM
dpc-3121	367	4	.	.	PUNCT
dpc-3121	368	1	doi:10.1016	doi:10.1016	PROPN
dpc-3121	368	2	/	/	SYM
dpc-3121	368	3	j.carbpol	j.carbpol	NOUN
dpc-3121	368	4	.2018.06.023	.2018.06.023	PROPN
dpc-3121	368	5	.	.	PUNCT
dpc-3121	369	1	pmid	pmid	NOUN
dpc-3121	369	2	:	:	PUNCT
dpc-3121	369	3	30007638	30007638	NUM
dpc-3121	369	4	.	.	PUNCT
dpc-3121	370	1	53	53	NUM
dpc-3121	370	2	.	.	PUNCT
dpc-3121	370	3	yu	yu	PROPN
dpc-3121	371	1	k	k	PROPN
dpc-3121	371	2	,	,	PUNCT
dpc-3121	371	3	wang	wang	PROPN
dpc-3121	371	4	y	y	PROPN
dpc-3121	371	5	,	,	PUNCT
dpc-3121	371	6	wan	wan	PROPN
dpc-3121	371	7	t	t	PROPN
dpc-3121	371	8	,	,	PUNCT
dpc-3121	371	9	et	et	PROPN
dpc-3121	371	10	al	al	PROPN
dpc-3121	371	11	.	.	PUNCT
dpc-3121	372	1	tacrolimus	tacrolimus	PROPN
dpc-3121	372	2	nanoparticles	nanoparticle	NOUN
dpc-3121	372	3	based	base	VERB
dpc-3121	372	4	on	on	ADP
dpc-3121	372	5	chitosan	chitosan	NOUN
dpc-3121	372	6	combined	combine	VERB
dpc-3121	372	7	with	with	ADP
dpc-3121	372	8	nicotinamide	nicotinamide	NOUN
dpc-3121	372	9	:	:	PUNCT
dpc-3121	372	10	enhancing	enhance	VERB
dpc-3121	372	11	percutaneous	percutaneous	ADJ
dpc-3121	372	12	delivery	delivery	NOUN
dpc-3121	372	13	and	and	CCONJ
dpc-3121	372	14	treatment	treatment	NOUN
dpc-3121	372	15	efficacy	efficacy	NOUN
dpc-3121	372	16	for	for	ADP
dpc-3121	372	17	atopic	atopic	NOUN
dpc-3121	372	18	dermatitis	dermatitis	NOUN
dpc-3121	372	19	and	and	CCONJ
dpc-3121	372	20	reducing	reduce	VERB
dpc-3121	372	21	dose	dose	NOUN
dpc-3121	372	22	.	.	PUNCT
dpc-3121	373	1	int	int	PROPN
dpc-3121	373	2	j	j	PROPN
dpc-3121	373	3	nanomedicine	nanomedicine	PROPN
dpc-3121	373	4	.	.	PUNCT
dpc-3121	374	1	2018;13:129	2018;13:129	NUM
dpc-3121	374	2	-	-	SYM
dpc-3121	374	3	142	142	NUM
dpc-3121	374	4	.	.	PUNCT
dpc-3121	375	1	doi:10.2147/	doi:10.2147/	NUM
dpc-3121	375	2	ijn.s150319	ijn.s150319	PROPN
dpc-3121	375	3	.	.	PUNCT
dpc-3121	376	1	pmid	pmid	NOUN
dpc-3121	376	2	:	:	PUNCT
dpc-3121	376	3	29317821	29317821	NUM
dpc-3121	376	4	.	.	PUNCT
dpc-3121	377	1	pmcid	pmcid	ADJ
dpc-3121	377	2	:	:	PUNCT
dpc-3121	377	3	pmc5743175	pmc5743175	NOUN
dpc-3121	377	4	.	.	PUNCT
dpc-3121	378	1	54	54	NUM
dpc-3121	378	2	.	.	PUNCT
dpc-3121	378	3	choi	choi	PROPN
dpc-3121	378	4	jk	jk	PROPN
dpc-3121	378	5	,	,	PUNCT
dpc-3121	378	6	park	park	PROPN
dpc-3121	378	7	jy	jy	PROPN
dpc-3121	378	8	,	,	PUNCT
dpc-3121	378	9	lee	lee	PROPN
dpc-3121	378	10	s	s	PROPN
dpc-3121	378	11	,	,	PUNCT
dpc-3121	378	12	et	et	PROPN
dpc-3121	378	13	al	al	PROPN
dpc-3121	378	14	.	.	PUNCT
dpc-3121	379	1	greater	great	ADJ
dpc-3121	379	2	plasma	plasma	NOUN
dpc-3121	379	3	protein	protein	NOUN
dpc-3121	379	4	adsorption	adsorption	NOUN
dpc-3121	379	5	on	on	ADP
dpc-3121	379	6	mesoporous	mesoporous	ADJ
dpc-3121	379	7	silica	silica	NOUN
dpc-3121	379	8	nanoparticles	nanoparticle	NOUN
dpc-3121	379	9	aggravates	aggravate	VERB
dpc-3121	379	10	atopic	atopic	NOUN
dpc-3121	379	11	dermatitis	dermatitis	NOUN
dpc-3121	379	12	.	.	PUNCT
dpc-3121	380	1	int	int	PROPN
dpc-3121	380	2	j	j	PROPN
dpc-3121	380	3	nanomedicine	nanomedicine	NOUN
dpc-3121	380	4	.	.	PUNCT
dpc-3121	381	1	2022;17:4599	2022;17:4599	NUM
dpc-3121	381	2	-	-	SYM
dpc-3121	381	3	4617	4617	NUM
dpc-3121	381	4	.	.	PUNCT
dpc-3121	382	1	doi:10.2147	doi:10.2147	NOUN
dpc-3121	382	2	/	/	SYM
dpc-3121	382	3	ijn	ijn	PROPN
dpc-3121	382	4	.s383324	.s383324	PUNCT
dpc-3121	382	5	.	.	PUNCT
dpc-3121	383	1	pmid	pmid	NOUN
dpc-3121	383	2	:	:	PUNCT
dpc-3121	383	3	36199478	36199478	NUM
dpc-3121	383	4	.	.	PUNCT
dpc-3121	384	1	pmcid	pmcid	ADJ
dpc-3121	384	2	:	:	PUNCT
dpc-3121	384	3	pmc9528962	pmc9528962	NOUN
dpc-3121	384	4	.	.	PUNCT
dpc-3121	385	1	55	55	NUM
dpc-3121	385	2	.	.	PUNCT
dpc-3121	385	3	kalia	kalia	PROPN
dpc-3121	385	4	yn	yn	PROPN
dpc-3121	385	5	,	,	PUNCT
dpc-3121	385	6	naik	naik	PROPN
dpc-3121	385	7	a	a	PROPN
dpc-3121	385	8	,	,	PUNCT
dpc-3121	385	9	garrison	garrison	PROPN
dpc-3121	385	10	j	j	PROPN
dpc-3121	385	11	,	,	PUNCT
dpc-3121	385	12	guy	guy	PROPN
dpc-3121	385	13	rh	rh	PROPN
dpc-3121	385	14	.	.	PROPN
dpc-3121	385	15	iontophoretic	iontophoretic	PROPN
dpc-3121	385	16	drug	drug	NOUN
dpc-3121	385	17	delivery	delivery	NOUN
dpc-3121	385	18	.	.	PUNCT
dpc-3121	386	1	adv	adv	PROPN
dpc-3121	386	2	drug	drug	PROPN
dpc-3121	386	3	deliv	deliv	PROPN
dpc-3121	386	4	rev	rev	VERB
dpc-3121	386	5	.	.	PROPN
dpc-3121	386	6	2004;56(5):619	2004;56(5):619	NUM
dpc-3121	386	7	-	-	SYM
dpc-3121	386	8	658	658	NUM
dpc-3121	386	9	.	.	PUNCT
dpc-3121	387	1	doi:10.1016	doi:10.1016	PROPN
dpc-3121	387	2	/	/	SYM
dpc-3121	387	3	j	j	PROPN
dpc-3121	387	4	.addr.2003.10.026	.addr.2003.10.026	PUNCT
dpc-3121	387	5	.	.	PUNCT
dpc-3121	388	1	pmid	pmid	NOUN
dpc-3121	388	2	:	:	PUNCT
dpc-3121	388	3	15019750	15019750	NUM
dpc-3121	388	4	.	.	PUNCT
dpc-3121	389	1	56	56	NUM
dpc-3121	389	2	.	.	X
dpc-3121	389	3	le	le	X
dpc-3121	390	1	qv	qv	PROPN
dpc-3121	390	2	,	,	PUNCT
dpc-3121	390	3	howard	howard	PROPN
dpc-3121	390	4	a.	a.	NOUN
dpc-3121	390	5	dexamethasone	dexamethasone	NOUN
dpc-3121	390	6	iontophoresis	iontophoresis	NOUN
dpc-3121	390	7	for	for	ADP
dpc-3121	390	8	the	the	DET
dpc-3121	390	9	treatment	treatment	NOUN
dpc-3121	390	10	of	of	ADP
dpc-3121	390	11	nail	nail	NOUN
dpc-3121	390	12	psoriasis	psoriasis	NOUN
dpc-3121	390	13	.	.	PUNCT
dpc-3121	391	1	australas	australas	PROPN
dpc-3121	391	2	j	j	PROPN
dpc-3121	391	3	dermatol	dermatol	NOUN
dpc-3121	391	4	.	.	PUNCT
dpc-3121	392	1	2013;54(2):115	2013;54(2):115	NUM
dpc-3121	392	2	-	-	SYM
dpc-3121	392	3	119	119	NUM
dpc-3121	392	4	.	.	PUNCT
dpc-3121	393	1	doi:10.1111	doi:10.1111	PROPN
dpc-3121	393	2	/	/	SYM
dpc-3121	393	3	ajd.12029	ajd.12029	PROPN
dpc-3121	393	4	.	.	PUNCT
dpc-3121	394	1	pmid	pmid	NOUN
dpc-3121	394	2	:	:	PUNCT
dpc-3121	394	3	23425157	23425157	NUM
dpc-3121	394	4	.	.	PUNCT
dpc-3121	395	1	57	57	NUM
dpc-3121	395	2	.	.	X
dpc-3121	395	3	dasht	dasht	PROPN
dpc-3121	395	4	bozorg	bozorg	PROPN
dpc-3121	395	5	b	b	PROPN
dpc-3121	395	6	,	,	PUNCT
dpc-3121	395	7	bhattaccharjee	bhattaccharjee	PROPN
dpc-3121	395	8	sa	sa	PROPN
dpc-3121	395	9	,	,	PUNCT
dpc-3121	395	10	somayaji	somayaji	PROPN
dpc-3121	395	11	mr	mr	PROPN
dpc-3121	395	12	,	,	PUNCT
dpc-3121	395	13	banga	banga	PROPN
dpc-3121	395	14	ak	ak	PROPN
dpc-3121	395	15	.	.	PROPN
dpc-3121	395	16	topical	topical	ADJ
dpc-3121	395	17	and	and	CCONJ
dpc-3121	395	18	transdermal	transdermal	ADJ
dpc-3121	395	19	delivery	delivery	NOUN
dpc-3121	395	20	with	with	ADP
dpc-3121	395	21	diseased	diseased	ADJ
dpc-3121	395	22	human	human	ADJ
dpc-3121	395	23	skin	skin	NOUN
dpc-3121	395	24	:	:	PUNCT
dpc-3121	395	25	passive	passive	ADJ
dpc-3121	395	26	and	and	CCONJ
dpc-3121	395	27	iontophoretic	iontophoretic	ADJ
dpc-3121	395	28	delivery	delivery	NOUN
dpc-3121	395	29	of	of	ADP
dpc-3121	395	30	hydrocortisone	hydrocortisone	NOUN
dpc-3121	395	31	into	into	ADP
dpc-3121	395	32	psoriatic	psoriatic	ADJ
dpc-3121	395	33	and	and	CCONJ
dpc-3121	395	34	eczematous	eczematous	ADJ
dpc-3121	395	35	skin	skin	NOUN
dpc-3121	395	36	.	.	PUNCT
dpc-3121	396	1	drug	drug	NOUN
dpc-3121	396	2	deliv	deliv	VERB
dpc-3121	396	3	transl	transl	PROPN
dpc-3121	396	4	res	re	NOUN
dpc-3121	396	5	.	.	PUNCT
dpc-3121	397	1	2022;12(1):197	2022;12(1):197	NUM
dpc-3121	397	2	-	-	PUNCT
dpc-3121	397	3	212	212	NUM
dpc-3121	397	4	.	.	PUNCT
dpc-3121	398	1	doi:10.1007	doi:10.1007	VERB
dpc-3121	398	2	/	/	SYM
dpc-3121	398	3	s13346	s13346	VERB
dpc-3121	398	4	-	-	PUNCT
dpc-3121	398	5	021	021	NUM
dpc-3121	398	6	-	-	PUNCT
dpc-3121	398	7	00897	00897	NUM
dpc-3121	398	8	-	-	SYM
dpc-3121	398	9	7	7	NUM
dpc-3121	398	10	.	.	PUNCT
dpc-3121	398	11	pmid	pmid	NOUN
dpc-3121	398	12	:	:	PUNCT
dpc-3121	398	13	33432519	33432519	NUM
dpc-3121	398	14	.	.	PUNCT
dpc-3121	399	1	pmcid	pmcid	NOUN
dpc-3121	399	2	:	:	PUNCT
dpc-3121	399	3	pmc9351627	pmc9351627	NOUN
dpc-3121	399	4	.	.	PUNCT
dpc-3121	400	1	58	58	NUM
dpc-3121	400	2	.	.	PUNCT
dpc-3121	401	1	bissonnette	bissonnette	NOUN
dpc-3121	401	2	r	r	PROPN
dpc-3121	401	3	,	,	PUNCT
dpc-3121	401	4	pavel	pavel	PROPN
dpc-3121	401	5	ab	ab	PROPN
dpc-3121	401	6	,	,	PUNCT
dpc-3121	401	7	diaz	diaz	PROPN
dpc-3121	401	8	a	a	PROPN
dpc-3121	401	9	,	,	PUNCT
dpc-3121	401	10	et	et	PROPN
dpc-3121	401	11	al	al	PROPN
dpc-3121	401	12	.	.	PROPN
dpc-3121	401	13	crisaborole	crisaborole	PROPN
dpc-3121	401	14	and	and	CCONJ
dpc-3121	401	15	atopic	atopic	NOUN
dpc-3121	401	16	dermatitis	dermatitis	NOUN
dpc-3121	401	17	skin	skin	NOUN
dpc-3121	401	18	biomarkers	biomarker	NOUN
dpc-3121	401	19	:	:	PUNCT
dpc-3121	401	20	an	an	DET
dpc-3121	401	21	intrapatient	intrapatient	NOUN
dpc-3121	401	22	randomized	randomize	VERB
dpc-3121	401	23	trial	trial	NOUN
dpc-3121	401	24	.	.	PUNCT
dpc-3121	402	1	j	j	PROPN
dpc-3121	402	2	allergy	allergy	PROPN
dpc-3121	402	3	clin	clin	PROPN
dpc-3121	402	4	immunol	immunol	PROPN
dpc-3121	402	5	.	.	PUNCT
dpc-3121	403	1	2019;144(5):1274	2019;144(5):1274	NUM
dpc-3121	403	2	-	-	SYM
dpc-3121	403	3	1289	1289	NUM
dpc-3121	403	4	.	.	PUNCT
dpc-3121	404	1	doi:10.1016	doi:10.1016	PROPN
dpc-3121	404	2	/	/	SYM
dpc-3121	404	3	j	j	PROPN
dpc-3121	404	4	.jaci.2019.06.047	.jaci.2019.06.047	PUNCT
dpc-3121	404	5	.	.	PUNCT
dpc-3121	405	1	pmid	pmid	NOUN
dpc-3121	405	2	:	:	PUNCT
dpc-3121	405	3	31419544	31419544	NUM
dpc-3121	405	4	.	.	PUNCT
dpc-3121	406	1	59	59	NUM
dpc-3121	406	2	.	.	PUNCT
dpc-3121	407	1	callender	callender	NOUN
dpc-3121	407	2	vd	vd	PROPN
dpc-3121	407	3	,	,	PUNCT
dpc-3121	407	4	alexis	alexis	PROPN
dpc-3121	407	5	af	af	PROPN
dpc-3121	407	6	,	,	PUNCT
dpc-3121	407	7	stein	stein	PROPN
dpc-3121	407	8	gold	gold	PROPN
dpc-3121	407	9	lf	lf	PROPN
dpc-3121	407	10	,	,	PUNCT
dpc-3121	407	11	et	et	PROPN
dpc-3121	407	12	al	al	PROPN
dpc-3121	407	13	.	.	PROPN
dpc-3121	407	14	efficacy	efficacy	NOUN
dpc-3121	407	15	and	and	CCONJ
dpc-3121	407	16	safety	safety	NOUN
dpc-3121	407	17	of	of	ADP
dpc-3121	407	18	crisaborole	crisaborole	ADJ
dpc-3121	407	19	ointment	ointment	NOUN
dpc-3121	407	20	,	,	PUNCT
dpc-3121	407	21	2	2	NUM
dpc-3121	407	22	%	%	NOUN
dpc-3121	407	23	,	,	PUNCT
dpc-3121	407	24	for	for	ADP
dpc-3121	407	25	the	the	DET
dpc-3121	407	26	treatment	treatment	NOUN
dpc-3121	407	27	of	of	ADP
dpc-3121	407	28	mild	mild	ADJ
dpc-3121	407	29	-	-	PUNCT
dpc-3121	407	30	to	to	ADP
dpc-3121	407	31	-	-	PUNCT
dpc-3121	407	32	moderate	moderate	ADJ
dpc-3121	407	33	atopic	atopic	NOUN
dpc-3121	407	34	dermatitis	dermatitis	NOUN
dpc-3121	407	35	across	across	ADP
dpc-3121	407	36	racial	racial	ADJ
dpc-3121	407	37	and	and	CCONJ
dpc-3121	407	38	ethnic	ethnic	ADJ
dpc-3121	407	39	groups	group	NOUN
dpc-3121	407	40	.	.	PUNCT
dpc-3121	407	41	am	be	AUX
dpc-3121	407	42	j	j	PROPN
dpc-3121	407	43	clin	clin	PROPN
dpc-3121	407	44	dermatol	dermatol	NOUN
dpc-3121	407	45	.	.	PUNCT
dpc-3121	408	1	2019;20(5):711	2019;20(5):711	NOUN
dpc-3121	408	2	-	-	SYM
dpc-3121	408	3	723	723	NUM
dpc-3121	408	4	.	.	PUNCT
dpc-3121	409	1	doi:10.1007	doi:10.1007	PROPN
dpc-3121	409	2	/s40257	/s40257	PROPN
dpc-3121	409	3	-	-	PUNCT
dpc-3121	409	4	019	019	NUM
dpc-3121	409	5	-	-	PUNCT
dpc-3121	409	6	00450	00450	NUM
dpc-3121	409	7	-	-	PUNCT
dpc-3121	409	8	w.	w.	NOUN
dpc-3121	409	9	pmid	pmid	PROPN
dpc-3121	409	10	:	:	PUNCT
dpc-3121	409	11	31419544	31419544	NUM
dpc-3121	409	12	.	.	PUNCT
dpc-3121	410	1	60	60	NUM
dpc-3121	410	2	.	.	PUNCT
dpc-3121	411	1	cheape	cheape	NOUN
dpc-3121	411	2	ac	ac	PROPN
dpc-3121	411	3	,	,	PUNCT
dpc-3121	411	4	murrell	murrell	PROPN
dpc-3121	411	5	df	df	PROPN
dpc-3121	411	6	.	.	PROPN
dpc-3121	411	7	2	2	NUM
dpc-3121	411	8	%	%	NOUN
dpc-3121	411	9	crisaborole	crisaborole	ADJ
dpc-3121	411	10	topical	topical	ADJ
dpc-3121	411	11	ointment	ointment	NOUN
dpc-3121	411	12	for	for	ADP
dpc-3121	411	13	the	the	DET
dpc-3121	411	14	treatment	treatment	NOUN
dpc-3121	411	15	of	of	ADP
dpc-3121	411	16	mild	mild	ADJ
dpc-3121	411	17	-	-	PUNCT
dpc-3121	411	18	to	to	ADP
dpc-3121	411	19	-	-	PUNCT
dpc-3121	411	20	moderate	moderate	ADJ
dpc-3121	411	21	atopic	atopic	NOUN
dpc-3121	411	22	dermatitis	dermatitis	NOUN
dpc-3121	411	23	.	.	PUNCT
dpc-3121	412	1	expert	expert	PROPN
dpc-3121	412	2	rev	rev	VERB
dpc-3121	412	3	clin	clin	PROPN
dpc-3121	412	4	immunol	immunol	NOUN
dpc-3121	412	5	.	.	PUNCT
dpc-3121	413	1	2017;13(5):415	2017;13(5):415	NUM
dpc-3121	413	2	-	-	PUNCT
dpc-3121	413	3	423	423	NUM
dpc-3121	413	4	.	.	PUNCT
dpc-3121	413	5	doi:10.1080/17446	doi:10.1080/17446	NOUN
dpc-3121	413	6	66x.2017.1304820	66x.2017.1304820	NOUN
dpc-3121	413	7	.	.	PUNCT
dpc-3121	414	1	pmid	pmid	NOUN
dpc-3121	414	2	:	:	PUNCT
dpc-3121	414	3	28290219	28290219	NUM
dpc-3121	414	4	.	.	PUNCT
dpc-3121	415	1	35	35	NUM
dpc-3121	415	2	.	.	PUNCT
dpc-3121	416	1	krysiak	krysiak	PROPN
dpc-3121	416	2	zj	zj	PROPN
dpc-3121	416	3	,	,	PUNCT
dpc-3121	416	4	stachewicz	stachewicz	ADJ
dpc-3121	416	5	u.	u.	PROPN
dpc-3121	416	6	urea	urea	PROPN
dpc-3121	416	7	-	-	PUNCT
dpc-3121	416	8	based	base	VERB
dpc-3121	416	9	patches	patch	NOUN
dpc-3121	416	10	with	with	ADP
dpc-3121	416	11	controlled	control	VERB
dpc-3121	416	12	release	release	NOUN
dpc-3121	416	13	for	for	ADP
dpc-3121	416	14	potential	potential	ADJ
dpc-3121	416	15	atopic	atopic	NOUN
dpc-3121	416	16	dermatitis	dermatitis	NOUN
dpc-3121	416	17	treatment	treatment	NOUN
dpc-3121	416	18	.	.	PUNCT
dpc-3121	417	1	pharmaceutics	pharmaceutic	NOUN
dpc-3121	417	2	.	.	PUNCT
dpc-3121	418	1	2022;14(7):1494	2022;14(7):1494	NUM
dpc-3121	418	2	.	.	PUNCT
dpc-3121	418	3	doi	doi	NOUN
dpc-3121	418	4	:	:	PUNCT
dpc-3121	418	5	10.3390	10.3390	NUM
dpc-3121	418	6	/	/	SYM
dpc-3121	418	7	pharmaceutics14071494	pharmaceutics14071494	PROPN
dpc-3121	418	8	.	.	PUNCT
dpc-3121	419	1	pmid	pmid	NOUN
dpc-3121	419	2	:	:	PUNCT
dpc-3121	419	3	35890388	35890388	NUM
dpc-3121	419	4	.	.	PUNCT
dpc-3121	420	1	pmcid	pmcid	NOUN
dpc-3121	420	2	:	:	PUNCT
dpc-3121	420	3	pmc9320356	pmc9320356	NOUN
dpc-3121	420	4	.	.	PUNCT
dpc-3121	421	1	36	36	NUM
dpc-3121	421	2	.	.	PUNCT
dpc-3121	422	1	obaidat	obaidat	PROPN
dpc-3121	422	2	r	r	PROPN
dpc-3121	422	3	,	,	PUNCT
dpc-3121	422	4	shameh	shameh	PROPN
dpc-3121	422	5	aa	aa	PROPN
dpc-3121	422	6	,	,	PUNCT
dpc-3121	422	7	aljarrah	aljarrah	PROPN
dpc-3121	422	8	m	m	PROPN
dpc-3121	422	9	,	,	PUNCT
dpc-3121	422	10	hamed	hamed	PROPN
dpc-3121	422	11	r.	r.	PROPN
dpc-3121	422	12	preparation	preparation	NOUN
dpc-3121	422	13	and	and	CCONJ
dpc-3121	422	14	evaluation	evaluation	NOUN
dpc-3121	422	15	of	of	ADP
dpc-3121	422	16	polyvinylpyrrolidone	polyvinylpyrrolidone	PROPN
dpc-3121	422	17	electrospun	electrospun	PROPN
dpc-3121	422	18	nanofiber	nanofiber	PROPN
dpc-3121	422	19	patches	patch	NOUN
dpc-3121	422	20	of	of	ADP
dpc-3121	422	21	pioglitazone	pioglitazone	NOUN
dpc-3121	422	22	for	for	ADP
dpc-3121	422	23	the	the	DET
dpc-3121	422	24	treatment	treatment	NOUN
dpc-3121	422	25	of	of	ADP
dpc-3121	422	26	atopic	atopic	NOUN
dpc-3121	422	27	dermatitis	dermatitis	NOUN
dpc-3121	422	28	.	.	PUNCT
dpc-3121	423	1	aaps	aap	NOUN
dpc-3121	423	2	pharmscitech	pharmscitech	VERB
dpc-3121	423	3	.	.	PUNCT
dpc-3121	424	1	2022;23(1):51	2022;23(1):51	NUM
dpc-3121	424	2	.	.	NOUN
dpc-3121	424	3	doi:10.1208	doi:10.1208	PROPN
dpc-3121	424	4	/	/	SYM
dpc-3121	424	5	s12249	s12249	PROPN
dpc-3121	424	6	-	-	PUNCT
dpc-3121	424	7	021	021	NUM
dpc-3121	424	8	-02204	-02204	PROPN
dpc-3121	424	9	-	-	PUNCT
dpc-3121	424	10	6	6	NUM
dpc-3121	424	11	.	.	PUNCT
dpc-3121	425	1	pmid	pmid	NOUN
dpc-3121	425	2	:	:	PUNCT
dpc-3121	425	3	35013801	35013801	NUM
dpc-3121	425	4	.	.	PUNCT
dpc-3121	426	1	37	37	NUM
dpc-3121	426	2	.	.	PUNCT
dpc-3121	427	1	yang	yang	PROPN
dpc-3121	427	2	y	y	PROPN
dpc-3121	427	3	,	,	PUNCT
dpc-3121	427	4	chen	chen	PROPN
dpc-3121	427	5	bz	bz	PROPN
dpc-3121	427	6	,	,	PUNCT
dpc-3121	427	7	zhang	zhang	PROPN
dpc-3121	427	8	xp	xp	PROPN
dpc-3121	427	9	,	,	PUNCT
dpc-3121	427	10	et	et	PROPN
dpc-3121	427	11	al	al	PROPN
dpc-3121	427	12	.	.	PROPN
dpc-3121	427	13	conductive	conductive	PROPN
dpc-3121	427	14	microneedle	microneedle	PROPN
dpc-3121	427	15	patch	patch	NOUN
dpc-3121	427	16	with	with	ADP
dpc-3121	427	17	electricity	electricity	NOUN
dpc-3121	427	18	-	-	PUNCT
dpc-3121	427	19	triggered	trigger	VERB
dpc-3121	427	20	drug	drug	NOUN
dpc-3121	427	21	release	release	NOUN
dpc-3121	427	22	performance	performance	NOUN
dpc-3121	427	23	for	for	ADP
dpc-3121	427	24	atopic	atopic	NOUN
dpc-3121	427	25	dermatitis	dermatitis	NOUN
dpc-3121	427	26	treatment	treatment	NOUN
dpc-3121	427	27	.	.	PUNCT
dpc-3121	428	1	acs	acs	PROPN
dpc-3121	428	2	appl	appl	PROPN
dpc-3121	428	3	mater	mater	NOUN
dpc-3121	428	4	interfaces	interface	NOUN
dpc-3121	428	5	.	.	PUNCT
dpc-3121	428	6	  	  	SPACE
dpc-3121	429	1	2022;14(28):31645	2022;14(28):31645	PROPN
dpc-3121	429	2	-	-	PROPN
dpc-3121	429	3	31654	31654	NUM
dpc-3121	429	4	.	.	PUNCT
dpc-3121	430	1	doi:10.1021	doi:10.1021	ADJ
dpc-3121	430	2	/	/	SYM
dpc-3121	430	3	acsami	acsami	PROPN
dpc-3121	430	4	.2c05952	.2c05952	NOUN
dpc-3121	430	5	.	.	PUNCT
dpc-3121	431	1	pmid	pmid	NOUN
dpc-3121	431	2	:	:	PUNCT
dpc-3121	431	3	35790212	35790212	NUM
dpc-3121	431	4	.	.	PUNCT
dpc-3121	432	1	38	38	NUM
dpc-3121	432	2	.	.	PUNCT
dpc-3121	433	1	draelos	draelos	PROPN
dpc-3121	433	2	zd	zd	PROPN
dpc-3121	433	3	,	,	PUNCT
dpc-3121	433	4	traub	traub	PROPN
dpc-3121	433	5	m	m	PROPN
dpc-3121	433	6	,	,	PUNCT
dpc-3121	433	7	gold	gold	PROPN
dpc-3121	433	8	mh	mh	PROPN
dpc-3121	433	9	,	,	PUNCT
dpc-3121	433	10	et	et	PROPN
dpc-3121	433	11	al	al	PROPN
dpc-3121	433	12	.	.	PROPN
dpc-3121	433	13	efficacy	efficacy	NOUN
dpc-3121	433	14	of	of	ADP
dpc-3121	433	15	topical	topical	ADJ
dpc-3121	433	16	botanical	botanical	ADJ
dpc-3121	433	17	treatment	treatment	NOUN
dpc-3121	433	18	of	of	ADP
dpc-3121	433	19	children	child	NOUN
dpc-3121	433	20	with	with	ADP
dpc-3121	433	21	mild	mild	ADJ
dpc-3121	433	22	to	to	ADP
dpc-3121	433	23	moderate	moderate	ADJ
dpc-3121	433	24	atopic	atopic	NOUN
dpc-3121	433	25	dermatitis	dermatitis	NOUN
dpc-3121	433	26	.	.	PUNCT
dpc-3121	434	1	j	j	PROPN
dpc-3121	434	2	drugs	drug	NOUN
dpc-3121	434	3	dermatol	dermatol	NOUN
dpc-3121	434	4	.	.	PUNCT
dpc-3121	435	1	2019;18(10):1038	2019;18(10):1038	NUM
dpc-3121	435	2	-	-	SYM
dpc-3121	435	3	1045	1045	NUM
dpc-3121	435	4	.	.	PUNCT
dpc-3121	436	1	pmid	pmid	NOUN
dpc-3121	436	2	:	:	PUNCT
dpc-3121	436	3	31584783	31584783	NUM
dpc-3121	436	4	.	.	PUNCT
dpc-3121	437	1	39	39	NUM
dpc-3121	437	2	.	.	PUNCT
dpc-3121	438	1	draelos	draelos	PROPN
dpc-3121	438	2	zd	zd	PROPN
dpc-3121	438	3	,	,	PUNCT
dpc-3121	438	4	traub	traub	PROPN
dpc-3121	438	5	m	m	PROPN
dpc-3121	438	6	,	,	PUNCT
dpc-3121	438	7	gold	gold	PROPN
dpc-3121	438	8	mh	mh	PROPN
dpc-3121	438	9	,	,	PUNCT
dpc-3121	438	10	et	et	PROPN
dpc-3121	438	11	al	al	PROPN
dpc-3121	438	12	.	.	PUNCT
dpc-3121	439	1	validation	validation	NOUN
dpc-3121	439	2	of	of	ADP
dpc-3121	439	3	botanical	botanical	ADJ
dpc-3121	439	4	treatment	treatment	NOUN
dpc-3121	439	5	efficiency	efficiency	NOUN
dpc-3121	439	6	for	for	ADP
dpc-3121	439	7	adults	adult	NOUN
dpc-3121	439	8	and	and	CCONJ
dpc-3121	439	9	children	child	NOUN
dpc-3121	439	10	suffering	suffer	VERB
dpc-3121	439	11	from	from	ADP
dpc-3121	439	12	mild	mild	ADJ
dpc-3121	439	13	to	to	ADP
dpc-3121	439	14	moderate	moderate	ADJ
dpc-3121	439	15	atopic	atopic	NOUN
dpc-3121	439	16	dermatitis	dermatitis	NOUN
dpc-3121	439	17	.	.	PUNCT
dpc-3121	440	1	j	j	PROPN
dpc-3121	440	2	drugs	drug	NOUN
dpc-3121	440	3	dermatol	dermatol	NOUN
dpc-3121	440	4	.	.	PUNCT
dpc-3121	441	1	2019;18(6):557	2019;18(6):557	NUM
dpc-3121	441	2	.	.	PUNCT
dpc-3121	442	1	pmid	pmid	NOUN
dpc-3121	442	2	:	:	PUNCT
dpc-3121	442	3	31251548	31251548	NUM
dpc-3121	442	4	.	.	PUNCT
dpc-3121	443	1	40	40	NUM
dpc-3121	443	2	.	.	PUNCT
dpc-3121	444	1	hogue	hogue	PROPN
dpc-3121	444	2	l	l	PROPN
dpc-3121	444	3	,	,	PUNCT
dpc-3121	444	4	cardwell	cardwell	PROPN
dpc-3121	444	5	la	la	PROPN
dpc-3121	444	6	,	,	PUNCT
dpc-3121	444	7	roach	roach	NOUN
dpc-3121	444	8	c	c	NOUN
dpc-3121	444	9	,	,	PUNCT
dpc-3121	444	10	et	et	PROPN
dpc-3121	444	11	al	al	PROPN
dpc-3121	444	12	.	.	PUNCT
dpc-3121	444	13	psoriasis	psoriasis	NOUN
dpc-3121	444	14	and	and	CCONJ
dpc-3121	444	15	atopic	atopic	NOUN
dpc-3121	444	16	dermatitis	dermatitis	NOUN
dpc-3121	444	17	“	"	PUNCT
dpc-3121	444	18	resistant	resistant	ADJ
dpc-3121	444	19	”	"	PUNCT
dpc-3121	444	20	to	to	ADP
dpc-3121	444	21	topical	topical	ADJ
dpc-3121	444	22	treatment	treatment	NOUN
dpc-3121	444	23	responds	respond	VERB
dpc-3121	444	24	rapidly	rapidly	ADV
dpc-3121	444	25	to	to	ADP
dpc-3121	444	26	topical	topical	ADJ
dpc-3121	444	27	desoximetasone	desoximetasone	NOUN
dpc-3121	444	28	spray	spray	NOUN
dpc-3121	444	29	.	.	PUNCT
dpc-3121	445	1	j	j	PROPN
dpc-3121	445	2	cutan	cutan	PROPN
dpc-3121	445	3	med	med	ADJ
dpc-3121	445	4	surg	surg	NOUN
dpc-3121	445	5	.	.	PUNCT
dpc-3121	446	1	2019;23(2):157	2019;23(2):157	NUM
dpc-3121	446	2	-	-	PUNCT
dpc-3121	446	3	163	163	NUM
dpc-3121	446	4	.	.	PUNCT
dpc-3121	447	1	doi:10.1177/1203475418818082	doi:10.1177/1203475418818082	NOUN
dpc-3121	447	2	.	.	PUNCT
dpc-3121	448	1	pmid	pmid	NOUN
dpc-3121	448	2	:	:	PUNCT
dpc-3121	448	3	30556414	30556414	NUM
dpc-3121	448	4	.	.	PUNCT
dpc-3121	449	1	41	41	NUM
dpc-3121	449	2	.	.	PUNCT
dpc-3121	450	1	zivkovich	zivkovich	PROPN
dpc-3121	450	2	ah	ah	INTJ
dpc-3121	450	3	,	,	PUNCT
dpc-3121	450	4	feldman	feldman	PROPN
dpc-3121	450	5	sr	sr	PROPN
dpc-3121	450	6	.	.	PROPN
dpc-3121	451	1	are	be	AUX
dpc-3121	451	2	ointments	ointment	NOUN
dpc-3121	451	3	better	well	ADJ
dpc-3121	451	4	than	than	ADP
dpc-3121	451	5	other	other	ADJ
dpc-3121	451	6	vehicles	vehicle	NOUN
dpc-3121	451	7	for	for	ADP
dpc-3121	451	8	corticosteroid	corticosteroid	ADJ
dpc-3121	451	9	treatment	treatment	NOUN
dpc-3121	451	10	of	of	ADP
dpc-3121	451	11	psoriasis	psoriasis	NOUN
dpc-3121	451	12	?	?	PUNCT
dpc-3121	452	1	j	j	NOUN
dpc-3121	452	2	drugs	drug	NOUN
dpc-3121	452	3	dermatol	dermatol	NOUN
dpc-3121	452	4	.	.	PUNCT
dpc-3121	453	1	2009;8(6):570	2009;8(6):570	X
dpc-3121	453	2	-	-	PUNCT
dpc-3121	453	3	572	572	NUM
dpc-3121	453	4	.	.	PUNCT
dpc-3121	454	1	pmid	pmid	NOUN
dpc-3121	454	2	:	:	PUNCT
dpc-3121	454	3	19537382	19537382	NUM
dpc-3121	454	4	.	.	PUNCT
dpc-3121	455	1	42	42	NUM
dpc-3121	455	2	.	.	PUNCT
dpc-3121	456	1	naeimifar	naeimifar	ADV
dpc-3121	456	2	a	a	X
dpc-3121	456	3	,	,	PUNCT
dpc-3121	456	4	ahmad	ahmad	PROPN
dpc-3121	456	5	nasrollahi	nasrollahi	PROPN
dpc-3121	456	6	s	s	PROPN
dpc-3121	456	7	,	,	PUNCT
dpc-3121	456	8	samadi	samadi	VERB
dpc-3121	456	9	a	a	PRON
dpc-3121	456	10	,	,	PUNCT
dpc-3121	456	11	et	et	PROPN
dpc-3121	456	12	al	al	PROPN
dpc-3121	456	13	.	.	PUNCT
dpc-3121	456	14	evaluation	evaluation	NOUN
dpc-3121	456	15	of	of	ADP
dpc-3121	456	16	tolerability	tolerability	NOUN
dpc-3121	456	17	and	and	CCONJ
dpc-3121	456	18	efficacy	efficacy	NOUN
dpc-3121	456	19	of	of	ADP
dpc-3121	456	20	a	a	DET
dpc-3121	456	21	topical	topical	ADJ
dpc-3121	456	22	emulgel	emulgel	NOUN
dpc-3121	456	23	containing	contain	VERB
dpc-3121	456	24	nanoliposomal	nanoliposomal	ADJ
dpc-3121	456	25	ruxolitinib	ruxolitinib	NOUN
dpc-3121	456	26	phosphate	phosphate	VERB
dpc-3121	456	27	in	in	ADP
dpc-3121	456	28	the	the	DET
dpc-3121	456	29	treatment	treatment	NOUN
dpc-3121	456	30	of	of	ADP
dpc-3121	456	31	mild	mild	ADJ
dpc-3121	456	32	atopic	atopic	NOUN
dpc-3121	456	33	dermatitis	dermatitis	NOUN
dpc-3121	456	34	:	:	PUNCT
dpc-3121	456	35	a	a	DET
dpc-3121	456	36	before	before	ADP
dpc-3121	456	37	-	-	PUNCT
dpc-3121	456	38	after	after	ADJ
dpc-3121	456	39	single	single	ADJ
dpc-3121	456	40	group	group	NOUN
dpc-3121	456	41	pilot	pilot	NOUN
dpc-3121	456	42	study	study	NOUN
dpc-3121	456	43	.	.	PUNCT
dpc-3121	457	1	j	j	PROPN
dpc-3121	457	2	dermatolog	dermatolog	PROPN
dpc-3121	457	3	treat	treat	NOUN
dpc-3121	457	4	.	.	PUNCT
dpc-3121	458	1	2022:1	2022:1	NUM
dpc-3121	458	2	-	-	SYM
dpc-3121	458	3	7	7	NUM
dpc-3121	458	4	.	.	PUNCT
dpc-3121	459	1	doi:10.1080/09546634.2022.2112138	doi:10.1080/09546634.2022.2112138	PROPN
dpc-3121	459	2	.	.	PUNCT
dpc-3121	459	3	pmid	pmid	PROPN
dpc-3121	459	4	:	:	PUNCT
dpc-3121	459	5	35943737	35943737	NUM
dpc-3121	459	6	.	.	PUNCT
dpc-3121	460	1	43	43	NUM
dpc-3121	460	2	.	.	PUNCT
dpc-3121	461	1	purohit	purohit	PROPN
dpc-3121	461	2	vs	vs	ADP
dpc-3121	461	3	,	,	PUNCT
dpc-3121	461	4	ports	port	NOUN
dpc-3121	461	5	wc	wc	PROPN
dpc-3121	461	6	,	,	PUNCT
dpc-3121	461	7	wang	wang	PROPN
dpc-3121	461	8	c	c	PROPN
dpc-3121	461	9	,	,	PUNCT
dpc-3121	461	10	riley	riley	PROPN
dpc-3121	461	11	s.	s.	PROPN
dpc-3121	461	12	systemic	systemic	PROPN
dpc-3121	461	13	tofacitinib	tofacitinib	PROPN
dpc-3121	461	14	concentrations	concentration	NOUN
dpc-3121	461	15	in	in	ADP
dpc-3121	461	16	adult	adult	NOUN
dpc-3121	461	17	patients	patient	NOUN
dpc-3121	461	18	with	with	ADP
dpc-3121	461	19	atopic	atopic	NOUN
dpc-3121	461	20	dermatitis	dermatitis	NOUN
dpc-3121	461	21	treated	treat	VERB
dpc-3121	461	22	with	with	ADP
dpc-3121	461	23	2	2	NUM
dpc-3121	461	24	%	%	NOUN
dpc-3121	461	25	tofacitinib	tofacitinib	NOUN
dpc-3121	461	26	ointment	ointment	NOUN
dpc-3121	461	27	and	and	CCONJ
dpc-3121	461	28	application	application	NOUN
dpc-3121	461	29	to	to	ADP
dpc-3121	461	30	pediatric	pediatric	ADJ
dpc-3121	461	31	study	study	NOUN
dpc-3121	461	32	planning	planning	NOUN
dpc-3121	461	33	.	.	PUNCT
dpc-3121	462	1	j	j	PROPN
dpc-3121	462	2	clin	clin	PROPN
dpc-3121	462	3	pharmacol	pharmacol	PROPN
dpc-3121	462	4	.	.	PUNCT
dpc-3121	463	1	2019;59(6):811	2019;59(6):811	NUM
dpc-3121	463	2	-	-	PUNCT
dpc-3121	463	3	820	820	NUM
dpc-3121	463	4	.	.	PUNCT
dpc-3121	464	1	doi:10.1002	doi:10.1002	NOUN
dpc-3121	464	2	/jcph.1360	/jcph.1360	PUNCT
dpc-3121	464	3	.	.	PUNCT
dpc-3121	465	1	pmid	pmid	NOUN
dpc-3121	465	2	:	:	PUNCT
dpc-3121	465	3	30556911	30556911	NUM
dpc-3121	465	4	.	.	PUNCT
dpc-3121	466	1	pmcid	pmcid	NOUN
dpc-3121	466	2	:	:	PUNCT
dpc-3121	466	3	pmc6590358	pmc6590358	NOUN
dpc-3121	466	4	.	.	PUNCT
dpc-3121	467	1	44	44	NUM
dpc-3121	467	2	.	.	PUNCT
dpc-3121	468	1	purohit	purohit	PROPN
dpc-3121	468	2	v	v	PROPN
dpc-3121	468	3	,	,	PUNCT
dpc-3121	468	4	riley	riley	PROPN
dpc-3121	468	5	s	s	PROPN
dpc-3121	468	6	,	,	PUNCT
dpc-3121	468	7	tan	tan	PROPN
dpc-3121	468	8	h	h	NOUN
dpc-3121	468	9	,	,	PUNCT
dpc-3121	468	10	ports	port	NOUN
dpc-3121	468	11	wc	wc	PROPN
dpc-3121	468	12	.	.	PROPN
dpc-3121	468	13	predictors	predictor	NOUN
dpc-3121	468	14	of	of	ADP
dpc-3121	468	15	systemic	systemic	ADJ
dpc-3121	468	16	exposure	exposure	NOUN
dpc-3121	468	17	to	to	ADP
dpc-3121	468	18	topical	topical	ADJ
dpc-3121	468	19	crisaborole	crisaborole	NOUN
dpc-3121	468	20	:	:	PUNCT
dpc-3121	468	21	a	a	DET
dpc-3121	468	22	nonlinear	nonlinear	ADJ
dpc-3121	468	23	regression	regression	NOUN
dpc-3121	468	24	analysis	analysis	NOUN
dpc-3121	468	25	.	.	PUNCT
dpc-3121	469	1	j	j	PROPN
dpc-3121	469	2	clin	clin	PROPN
dpc-3121	469	3	pharmacol	pharmacol	PROPN
dpc-3121	469	4	.	.	PUNCT
dpc-3121	470	1	2020;60(10):1344	2020;60(10):1344	NUM
dpc-3121	470	2	-	-	SYM
dpc-3121	470	3	1354	1354	NUM
dpc-3121	470	4	.	.	PUNCT
dpc-3121	471	1	doi:10.1002	doi:10.1002	NOUN
dpc-3121	471	2	/jcph.1624	/jcph.1624	PUNCT
dpc-3121	471	3	.	.	PUNCT
dpc-3121	472	1	pmid	pmid	NOUN
dpc-3121	472	2	:	:	PUNCT
dpc-3121	472	3	32433779	32433779	NUM
dpc-3121	472	4	.	.	PUNCT
dpc-3121	473	1	pmcid	pmcid	ADJ
dpc-3121	473	2	:	:	PUNCT
dpc-3121	473	3	pmc7540423	pmc7540423	NOUN
dpc-3121	473	4	.	.	PUNCT
dpc-3121	474	1	45	45	NUM
dpc-3121	474	2	.	.	PUNCT
dpc-3121	474	3	damiani	damiani	PROPN
dpc-3121	474	4	g	g	PROPN
dpc-3121	474	5	,	,	PUNCT
dpc-3121	474	6	eggenhöffner	eggenhöffner	NOUN
dpc-3121	474	7	r	r	NOUN
dpc-3121	474	8	,	,	PUNCT
dpc-3121	474	9	pigatto	pigatto	ADJ
dpc-3121	474	10	pdm	pdm	NOUN
dpc-3121	474	11	,	,	PUNCT
dpc-3121	474	12	bragazzi	bragazzi	PROPN
dpc-3121	474	13	nl	nl	PROPN
dpc-3121	474	14	.	.	PUNCT
dpc-3121	475	1	nanotechnology	nanotechnology	PROPN
dpc-3121	475	2	meets	meet	VERB
dpc-3121	475	3	atopic	atopic	NOUN
dpc-3121	475	4	dermatitis	dermatitis	NOUN
dpc-3121	475	5	:	:	PUNCT
dpc-3121	475	6	current	current	ADJ
dpc-3121	475	7	solutions	solution	NOUN
dpc-3121	475	8	,	,	PUNCT
dpc-3121	475	9	challenges	challenge	NOUN
dpc-3121	475	10	and	and	CCONJ
dpc-3121	475	11	future	future	ADJ
dpc-3121	475	12	prospects	prospect	NOUN
dpc-3121	475	13	.	.	PUNCT
dpc-3121	476	1	insights	insight	NOUN
dpc-3121	476	2	and	and	CCONJ
dpc-3121	476	3	implications	implication	NOUN
dpc-3121	476	4	from	from	ADP
dpc-3121	476	5	a	a	DET
dpc-3121	476	6	systematic	systematic	ADJ
dpc-3121	476	7	review	review	NOUN
dpc-3121	476	8	of	of	ADP
dpc-3121	476	9	the	the	DET
dpc-3121	476	10	literature	literature	NOUN
dpc-3121	476	11	.	.	PUNCT
dpc-3121	477	1	bioact	bioact	PROPN
dpc-3121	477	2	mater	mater	NOUN
dpc-3121	477	3	.	.	PUNCT
dpc-3121	478	1	2019;4:380	2019;4:380	NUM
dpc-3121	478	2	-	-	PUNCT
dpc-3121	478	3	386	386	NUM
dpc-3121	478	4	.	.	PUNCT
dpc-3121	478	5	doi	doi	NOUN
dpc-3121	478	6	:	:	PUNCT
dpc-3121	478	7	10.1016	10.1016	NUM
dpc-3121	478	8	/	/	SYM
dpc-3121	478	9	j.bioactmat.2019.11.003	j.bioactmat.2019.11.003	PROPN
dpc-3121	478	10	.	.	PUNCT
dpc-3121	479	1	pmid	pmid	NOUN
dpc-3121	479	2	:	:	PUNCT
dpc-3121	479	3	31872162	31872162	NUM
dpc-3121	479	4	.	.	PUNCT
dpc-3121	480	1	pmcid	pmcid	NOUN
dpc-3121	480	2	:	:	PUNCT
dpc-3121	480	3	pmc6909150	pmc6909150	ADJ
dpc-3121	480	4	.	.	PUNCT
dpc-3121	481	1	46	46	NUM
dpc-3121	481	2	.	.	PUNCT
dpc-3121	482	1	parekh	parekh	PROPN
dpc-3121	482	2	k	k	PROPN
dpc-3121	482	3	,	,	PUNCT
dpc-3121	482	4	mehta	mehta	PROPN
dpc-3121	482	5	ta	ta	PROPN
dpc-3121	482	6	,	,	PUNCT
dpc-3121	482	7	dhas	dhas	PROPN
dpc-3121	482	8	n	n	CCONJ
dpc-3121	482	9	,	,	PUNCT
dpc-3121	482	10	kumar	kumar	PROPN
dpc-3121	482	11	p	p	PROPN
dpc-3121	482	12	,	,	PUNCT
dpc-3121	482	13	popat	popat	PROPN
dpc-3121	482	14	a.	a.	NOUN
dpc-3121	482	15	emerging	emerge	VERB
dpc-3121	482	16	nanomedicines	nanomedicine	NOUN
dpc-3121	482	17	for	for	ADP
dpc-3121	482	18	the	the	DET
dpc-3121	482	19	treatment	treatment	NOUN
dpc-3121	482	20	of	of	ADP
dpc-3121	482	21	atopic	atopic	NOUN
dpc-3121	482	22	dermatitis	dermatitis	NOUN
dpc-3121	482	23	.	.	PUNCT
dpc-3121	483	1	aaps	aap	NOUN
dpc-3121	483	2	 	 	SPACE
dpc-3121	483	3	pharmscitech	pharmscitech	NOUN
dpc-3121	483	4	.	.	PUNCT
dpc-3121	484	1	2021;22(2):55	2021;22(2):55	NUM
dpc-3121	484	2	.	.	PUNCT
dpc-3121	484	3	doi:10.1208	doi:10.1208	PROPN
dpc-3121	484	4	/	/	SYM
dpc-3121	484	5	s12249	s12249	PROPN
dpc-3121	484	6	-	-	PUNCT
dpc-3121	484	7	021	021	NUM
dpc-3121	484	8	-01920	-01920	NUM
dpc-3121	484	9	-	-	PUNCT
dpc-3121	484	10	3	3	NUM
dpc-3121	484	11	.	.	PUNCT
dpc-3121	485	1	pmid	pmid	NOUN
dpc-3121	485	2	:	:	PUNCT
dpc-3121	485	3	33486609	33486609	NUM
dpc-3121	485	4	.	.	PUNCT
dpc-3121	486	1	pmcid	pmcid	NOUN
dpc-3121	486	2	:	:	PUNCT
dpc-3121	486	3	pmc7828097	pmc7828097	PROPN
dpc-3121	486	4	.	.	PUNCT
dpc-3121	487	1	47	47	NUM
dpc-3121	487	2	.	.	PUNCT
dpc-3121	488	1	pandey	pandey	PROPN
dpc-3121	488	2	m	m	PROPN
dpc-3121	488	3	,	,	PUNCT
dpc-3121	488	4	choudhury	choudhury	PROPN
dpc-3121	488	5	h	h	PROPN
dpc-3121	488	6	,	,	PUNCT
dpc-3121	488	7	gunasegaran	gunasegaran	NOUN
dpc-3121	488	8	tap	tap	NOUN
dpc-3121	488	9	,	,	PUNCT
dpc-3121	488	10	et	et	PROPN
dpc-3121	488	11	al	al	PROPN
dpc-3121	488	12	.	.	PROPN
dpc-3121	488	13	hyaluronic	hyaluronic	ADJ
dpc-3121	488	14	acid	acid	NOUN
dpc-3121	488	15	-	-	PUNCT
dpc-3121	488	16	modified	modify	VERB
dpc-3121	488	17	betamethasone	betamethasone	NOUN
dpc-3121	488	18	encapsulated	encapsulate	VERB
dpc-3121	488	19	polymeric	polymeric	ADJ
dpc-3121	488	20	nanoparticles	nanoparticle	NOUN
dpc-3121	488	21	:	:	PUNCT
dpc-3121	488	22	fabrication	fabrication	NOUN
dpc-3121	488	23	,	,	PUNCT
dpc-3121	488	24	characterisation	characterisation	NOUN
dpc-3121	488	25	,	,	PUNCT
dpc-3121	488	26	in	in	ADP
dpc-3121	488	27	vitro	vitro	X
dpc-3121	488	28	release	release	NOUN
dpc-3121	488	29	kinetics	kinetic	NOUN
dpc-3121	488	30	,	,	PUNCT
dpc-3121	488	31	and	and	CCONJ
dpc-3121	488	32	dermal	dermal	VERB
dpc-3121	488	33	targeting	targeting	NOUN
dpc-3121	488	34	.	.	PUNCT
dpc-3121	489	1	drug	drug	PROPN
dpc-3121	489	2	deliv	deliv	VERB
dpc-3121	489	3	transl	transl	PROPN
dpc-3121	489	4	res	re	NOUN
dpc-3121	489	5	.	.	PUNCT
dpc-3121	490	1	2019;9(2):520	2019;9(2):520	NUM
dpc-3121	490	2	-	-	SYM
dpc-3121	490	3	533	533	NUM
dpc-3121	490	4	.	.	PUNCT
dpc-3121	490	5	doi:10.1007	doi:10.1007	VERB
dpc-3121	490	6	/	/	SYM
dpc-3121	490	7	s13346	s13346	VERB
dpc-3121	490	8	-	-	PUNCT
dpc-3121	490	9	018	018	NUM
dpc-3121	490	10	-	-	PUNCT
dpc-3121	490	11	0480	0480	NUM
dpc-3121	490	12	-	-	PUNCT
dpc-3121	490	13	1	1	NUM
dpc-3121	490	14	.	.	PUNCT
dpc-3121	491	1	pmid	pmid	NOUN
dpc-3121	491	2	:	:	PUNCT
dpc-3121	491	3	29488170	29488170	NUM
dpc-3121	491	4	.	.	PUNCT
dpc-3121	492	1	8	8	NUM
dpc-3121	492	2	review	review	NOUN
dpc-3121	492	3	|	|	ADV
dpc-3121	492	4	dermatol	dermatol	ADJ
dpc-3121	492	5	pract	pract	NOUN
dpc-3121	492	6	concept	concept	NOUN
dpc-3121	492	7	.	.	PUNCT
dpc-3121	493	1	2023;13(4):e2023216	2023;13(4):e2023216	NUM
dpc-3121	493	2	3	3	NUM
dpc-3121	493	3	  	  	SPACE
dpc-3121	493	4	to	to	ADP
dpc-3121	493	5	<	<	X
dpc-3121	493	6	24	24	NUM
dpc-3121	493	7	  	  	SPACE
dpc-3121	493	8	months	month	NOUN
dpc-3121	493	9	with	with	ADP
dpc-3121	493	10	mild	mild	ADJ
dpc-3121	493	11	-	-	PUNCT
dpc-3121	493	12	to	to	ADP
dpc-3121	493	13	-	-	PUNCT
dpc-3121	493	14	moderate	moderate	ADJ
dpc-3121	493	15	atopic	atopic	NOUN
dpc-3121	493	16	dermatitis	dermatitis	NOUN
dpc-3121	493	17	:	:	PUNCT
dpc-3121	493	18	a	a	DET
dpc-3121	493	19	phase	phase	NOUN
dpc-3121	493	20	iv	iv	NUM
dpc-3121	493	21	open	open	ADJ
dpc-3121	493	22	-	-	PUNCT
dpc-3121	493	23	label	label	NOUN
dpc-3121	493	24	study	study	NOUN
dpc-3121	493	25	(	(	PUNCT
dpc-3121	493	26	crisade	crisade	PROPN
dpc-3121	493	27	care	care	VERB
dpc-3121	493	28	1	1	NUM
dpc-3121	493	29	)	)	PUNCT
dpc-3121	493	30	.	.	PUNCT
dpc-3121	494	1	am	be	AUX
dpc-3121	494	2	j	j	PROPN
dpc-3121	494	3	clin	clin	PROPN
dpc-3121	494	4	dermatol	dermatol	NOUN
dpc-3121	494	5	.	.	PUNCT
dpc-3121	495	1	2020;21(2):275	2020;21(2):275	NUM
dpc-3121	495	2	-	-	PUNCT
dpc-3121	495	3	284	284	NUM
dpc-3121	495	4	.	.	PUNCT
dpc-3121	496	1	doi:10.1007	doi:10.1007	VERB
dpc-3121	496	2	/	/	SYM
dpc-3121	496	3	s40257	s40257	NOUN
dpc-3121	496	4	-	-	PUNCT
dpc-3121	496	5	020	020	NUM
dpc-3121	496	6	-00510	-00510	NOUN
dpc-3121	496	7	-	-	PUNCT
dpc-3121	496	8	6	6	NUM
dpc-3121	496	9	.	.	PUNCT
dpc-3121	497	1	pmid	pmid	NOUN
dpc-3121	497	2	:	:	PUNCT
dpc-3121	497	3	32212104	32212104	NUM
dpc-3121	497	4	.	.	PUNCT
dpc-3121	498	1	pmcid	pmcid	NOUN
dpc-3121	498	2	:	:	PUNCT
dpc-3121	498	3	pmc7125059	pmc7125059	NOUN
dpc-3121	498	4	.	.	PUNCT
dpc-3121	499	1	66	66	NUM
dpc-3121	499	2	.	.	PUNCT
dpc-3121	500	1	silverberg	silverberg	PROPN
dpc-3121	500	2	ji	ji	PROPN
dpc-3121	500	3	,	,	PUNCT
dpc-3121	500	4	tallman	tallman	PROPN
dpc-3121	500	5	am	am	PROPN
dpc-3121	500	6	,	,	PUNCT
dpc-3121	500	7	ports	port	NOUN
dpc-3121	500	8	wc	wc	PROPN
dpc-3121	500	9	,	,	PUNCT
dpc-3121	500	10	gerber	gerber	PROPN
dpc-3121	500	11	ra	ra	PROPN
dpc-3121	500	12	,	,	PUNCT
dpc-3121	500	13	tan	tan	PROPN
dpc-3121	500	14	h	h	NOUN
dpc-3121	500	15	,	,	PUNCT
dpc-3121	500	16	zielinski	zielinski	PROPN
dpc-3121	500	17	ma	ma	PROPN
dpc-3121	500	18	.	.	PROPN
dpc-3121	500	19	evaluating	evaluate	VERB
dpc-3121	500	20	the	the	DET
dpc-3121	500	21	efficacy	efficacy	NOUN
dpc-3121	500	22	of	of	ADP
dpc-3121	500	23	crisaborole	crisaborole	NOUN
dpc-3121	500	24	using	use	VERB
dpc-3121	500	25	the	the	DET
dpc-3121	500	26	atopic	atopic	NOUN
dpc-3121	500	27	dermatitis	dermatitis	NOUN
dpc-3121	500	28	severity	severity	NOUN
dpc-3121	500	29	index	index	NOUN
dpc-3121	500	30	and	and	CCONJ
dpc-3121	500	31	percentage	percentage	NOUN
dpc-3121	500	32	of	of	ADP
dpc-3121	500	33	affected	affected	ADJ
dpc-3121	500	34	body	body	NOUN
dpc-3121	500	35	surface	surface	NOUN
dpc-3121	500	36	area	area	NOUN
dpc-3121	500	37	.	.	PUNCT
dpc-3121	501	1	acta	acta	PROPN
dpc-3121	501	2	derm	derm	PROPN
dpc-3121	501	3	venereol	venereol	NOUN
dpc-3121	501	4	.	.	PUNCT
dpc-3121	502	1	2020;100(13):adv00170	2020;100(13):adv00170	X
dpc-3121	502	2	.	.	PUNCT
dpc-3121	503	1	doi:10.2340/00015555	doi:10.2340/00015555	NOUN
dpc-3121	503	2	-	-	PUNCT
dpc-3121	503	3	3489	3489	NUM
dpc-3121	503	4	.	.	PUNCT
dpc-3121	504	1	pmid	pmid	NOUN
dpc-3121	504	2	:	:	PUNCT
dpc-3121	504	3	32318744	32318744	NUM
dpc-3121	504	4	.	.	PUNCT
dpc-3121	505	1	pmcid	pmcid	NOUN
dpc-3121	505	2	:	:	PUNCT
dpc-3121	505	3	pmc9175045	pmc9175045	ADV
dpc-3121	505	4	.	.	PUNCT
dpc-3121	506	1	67	67	NUM
dpc-3121	506	2	.	.	PUNCT
dpc-3121	507	1	spergel	spergel	PROPN
dpc-3121	507	2	jm	jm	PROPN
dpc-3121	507	3	,	,	PUNCT
dpc-3121	507	4	blaiss	blaiss	PROPN
dpc-3121	507	5	ms	ms	PROPN
dpc-3121	507	6	,	,	PUNCT
dpc-3121	507	7	lio	lio	PROPN
dpc-3121	507	8	p	p	X
dpc-3121	507	9	,	,	PUNCT
dpc-3121	507	10	et	et	PROPN
dpc-3121	507	11	al	al	PROPN
dpc-3121	507	12	.	.	PROPN
dpc-3121	507	13	efficacy	efficacy	NOUN
dpc-3121	507	14	and	and	CCONJ
dpc-3121	507	15	safety	safety	NOUN
dpc-3121	507	16	of	of	ADP
dpc-3121	507	17	crisaborole	crisaborole	NOUN
dpc-3121	507	18	in	in	ADP
dpc-3121	507	19	patients	patient	NOUN
dpc-3121	507	20	with	with	ADP
dpc-3121	507	21	mild	mild	ADJ
dpc-3121	507	22	-	-	PUNCT
dpc-3121	507	23	to	to	ADP
dpc-3121	507	24	-	-	PUNCT
dpc-3121	507	25	moderate	moderate	ADJ
dpc-3121	507	26	atopic	atopic	NOUN
dpc-3121	507	27	dermatitis	dermatitis	NOUN
dpc-3121	507	28	and	and	CCONJ
dpc-3121	507	29	other	other	ADJ
dpc-3121	507	30	atopic	atopic	NOUN
dpc-3121	507	31	comorbidities	comorbiditie	NOUN
dpc-3121	507	32	.	.	PUNCT
dpc-3121	508	1	allergy	allergy	NOUN
dpc-3121	508	2	asthma	asthma	PROPN
dpc-3121	508	3	proc	proc	PROPN
dpc-3121	508	4	.	.	PUNCT
dpc-3121	509	1	2021;42(5):425	2021;42(5):425	NUM
dpc-3121	509	2	-	-	PUNCT
dpc-3121	509	3	431	431	NUM
dpc-3121	509	4	.	.	PUNCT
dpc-3121	510	1	doi:10.2500	doi:10.2500	NOUN
dpc-3121	510	2	/	/	SYM
dpc-3121	510	3	aap.2021.42.210064	aap.2021.42.210064	NOUN
dpc-3121	510	4	.	.	PUNCT
dpc-3121	511	1	pmid	pmid	PROPN
dpc-3121	511	2	:	:	PUNCT
dpc-3121	511	3	34474712	34474712	NUM
dpc-3121	511	4	.	.	PUNCT
dpc-3121	512	1	68	68	NUM
dpc-3121	512	2	.	.	PUNCT
dpc-3121	513	1	bissonnette	bissonnette	NOUN
dpc-3121	513	2	r	r	NOUN
dpc-3121	513	3	,	,	PUNCT
dpc-3121	513	4	vasist	vasist	NOUN
dpc-3121	513	5	ls	ls	PROPN
dpc-3121	513	6	,	,	PUNCT
dpc-3121	513	7	bullman	bullman	NOUN
dpc-3121	513	8	jn	jn	PROPN
dpc-3121	513	9	,	,	PUNCT
dpc-3121	513	10	collingwood	collingwood	PROPN
dpc-3121	513	11	t	t	PROPN
dpc-3121	513	12	,	,	PUNCT
dpc-3121	513	13	chen	chen	PROPN
dpc-3121	513	14	g	g	PROPN
dpc-3121	513	15	,	,	PUNCT
dpc-3121	513	16	maeda	maeda	NOUN
dpc-3121	513	17	-	-	NOUN
dpc-3121	513	18	chubachi	chubachi	NOUN
dpc-3121	513	19	t.	t.	NOUN
dpc-3121	513	20	systemic	systemic	ADJ
dpc-3121	513	21	pharmacokinetics	pharmacokinetic	NOUN
dpc-3121	513	22	,	,	PUNCT
dpc-3121	513	23	safety	safety	NOUN
dpc-3121	513	24	,	,	PUNCT
dpc-3121	513	25	and	and	CCONJ
dpc-3121	513	26	preliminary	preliminary	ADJ
dpc-3121	513	27	efficacy	efficacy	NOUN
dpc-3121	513	28	of	of	ADP
dpc-3121	513	29	topical	topical	ADJ
dpc-3121	513	30	ahr	ahr	PROPN
dpc-3121	513	31	agonist	agonist	PROPN
dpc-3121	513	32	tapinarof	tapinarof	NOUN
dpc-3121	513	33	:	:	PUNCT
dpc-3121	513	34	results	result	NOUN
dpc-3121	513	35	of	of	ADP
dpc-3121	513	36	a	a	DET
dpc-3121	513	37	phase	phase	NOUN
dpc-3121	513	38	1	1	NUM
dpc-3121	513	39	study	study	NOUN
dpc-3121	513	40	.	.	PUNCT
dpc-3121	514	1	clin	clin	PROPN
dpc-3121	514	2	pharmacol	pharmacol	PROPN
dpc-3121	514	3	drug	drug	PROPN
dpc-3121	514	4	dev	dev	PROPN
dpc-3121	514	5	.	.	PUNCT
dpc-3121	514	6	2018;7(5):524	2018;7(5):524	NUM
dpc-3121	514	7	-	-	PUNCT
dpc-3121	514	8	531	531	NUM
dpc-3121	514	9	.	.	PUNCT
dpc-3121	514	10	doi:10.1002	doi:10.1002	NOUN
dpc-3121	514	11	/	/	SYM
dpc-3121	514	12	cpdd.439	cpdd.439	NOUN
dpc-3121	514	13	.	.	PUNCT
dpc-3121	515	1	pmid	pmid	NOUN
dpc-3121	515	2	:	:	PUNCT
dpc-3121	515	3	29389078	29389078	NUM
dpc-3121	515	4	.	.	PUNCT
dpc-3121	516	1	69	69	NUM
dpc-3121	516	2	.	.	PUNCT
dpc-3121	517	1	keam	keam	PROPN
dpc-3121	517	2	sj	sj	PROPN
dpc-3121	517	3	.	.	PUNCT
dpc-3121	517	4	tapinarof	tapinarof	PROPN
dpc-3121	517	5	cream	cream	PROPN
dpc-3121	517	6	1	1	NUM
dpc-3121	517	7	%	%	NOUN
dpc-3121	517	8	:	:	PUNCT
dpc-3121	517	9	first	first	ADJ
dpc-3121	517	10	approval	approval	NOUN
dpc-3121	517	11	.	.	PUNCT
dpc-3121	518	1	drugs	drug	NOUN
dpc-3121	518	2	.	.	PUNCT
dpc-3121	519	1	2022;82(11):1221	2022;82(11):1221	NUM
dpc-3121	519	2	-	-	SYM
dpc-3121	519	3	1228	1228	NUM
dpc-3121	519	4	.	.	PUNCT
dpc-3121	520	1	doi:10.1007	doi:10.1007	VERB
dpc-3121	520	2	/	/	SYM
dpc-3121	520	3	s40265	s40265	NOUN
dpc-3121	520	4	-	-	PUNCT
dpc-3121	520	5	022	022	NUM
dpc-3121	520	6	-	-	PUNCT
dpc-3121	520	7	01748	01748	NUM
dpc-3121	520	8	-	-	SYM
dpc-3121	520	9	6	6	NUM
dpc-3121	520	10	.	.	PUNCT
dpc-3121	521	1	pmid	pmid	NOUN
dpc-3121	521	2	:	:	PUNCT
dpc-3121	521	3	35939180	35939180	NUM
dpc-3121	521	4	.	.	PUNCT
dpc-3121	522	1	pmcid	pmcid	NOUN
dpc-3121	522	2	:	:	PUNCT
dpc-3121	522	3	pmc9427914	pmc9427914	NOUN
dpc-3121	522	4	.	.	PUNCT
dpc-3121	523	1	61	61	NUM
dpc-3121	523	2	.	.	PUNCT
dpc-3121	524	1	draelos	draelos	PROPN
dpc-3121	524	2	zd	zd	PROPN
dpc-3121	524	3	,	,	PUNCT
dpc-3121	524	4	stein	stein	PROPN
dpc-3121	524	5	gold	gold	PROPN
dpc-3121	524	6	lf	lf	PROPN
dpc-3121	524	7	,	,	PUNCT
dpc-3121	524	8	murrell	murrell	PROPN
dpc-3121	524	9	df	df	PROPN
dpc-3121	524	10	,	,	PUNCT
dpc-3121	524	11	hughes	hughes	PROPN
dpc-3121	524	12	mh	mh	PROPN
dpc-3121	524	13	,	,	PUNCT
dpc-3121	524	14	zane	zane	PROPN
dpc-3121	524	15	lt	lt	PROPN
dpc-3121	524	16	.	.	PROPN
dpc-3121	524	17	post	post	X
dpc-3121	524	18	hoc	hoc	X
dpc-3121	524	19	analyses	analysis	NOUN
dpc-3121	524	20	of	of	ADP
dpc-3121	524	21	the	the	DET
dpc-3121	524	22	effect	effect	NOUN
dpc-3121	524	23	of	of	ADP
dpc-3121	524	24	crisaborole	crisaborole	ADJ
dpc-3121	524	25	topical	topical	ADJ
dpc-3121	524	26	ointment	ointment	NOUN
dpc-3121	524	27	,	,	PUNCT
dpc-3121	524	28	2	2	NUM
dpc-3121	524	29	%	%	NOUN
dpc-3121	524	30	on	on	ADP
dpc-3121	524	31	atopic	atopic	NOUN
dpc-3121	524	32	dermatitis	dermatitis	NOUN
dpc-3121	524	33	:	:	PUNCT
dpc-3121	524	34	associated	associated	ADJ
dpc-3121	524	35	pruritus	pruritus	NOUN
dpc-3121	524	36	from	from	ADP
dpc-3121	524	37	phase	phase	NOUN
dpc-3121	524	38	1	1	NUM
dpc-3121	524	39	and	and	CCONJ
dpc-3121	524	40	2	2	NUM
dpc-3121	524	41	clinical	clinical	ADJ
dpc-3121	524	42	studies	study	NOUN
dpc-3121	524	43	.	.	PUNCT
dpc-3121	525	1	j	j	PROPN
dpc-3121	525	2	drugs	drug	NOUN
dpc-3121	525	3	dermatol	dermatol	NOUN
dpc-3121	525	4	.	.	PUNCT
dpc-3121	526	1	2016;15(2):172	2016;15(2):172	NUM
dpc-3121	526	2	-	-	SYM
dpc-3121	526	3	176	176	NUM
dpc-3121	526	4	.	.	PUNCT
dpc-3121	527	1	pmid	pmid	NOUN
dpc-3121	527	2	:	:	PUNCT
dpc-3121	527	3	26885784	26885784	NUM
dpc-3121	527	4	.	.	PUNCT
dpc-3121	528	1	62	62	NUM
dpc-3121	528	2	.	.	PUNCT
dpc-3121	529	1	eichenfield	eichenfield	PROPN
dpc-3121	529	2	lf	lf	PROPN
dpc-3121	529	3	,	,	PUNCT
dpc-3121	529	4	call	call	NOUN
dpc-3121	529	5	rs	r	NOUN
dpc-3121	529	6	,	,	PUNCT
dpc-3121	529	7	forsha	forsha	PROPN
dpc-3121	529	8	dw	dw	PROPN
dpc-3121	529	9	,	,	PUNCT
dpc-3121	529	10	et	et	PROPN
dpc-3121	529	11	al	al	PROPN
dpc-3121	529	12	.	.	PUNCT
dpc-3121	530	1	long	long	ADJ
dpc-3121	530	2	-	-	PUNCT
dpc-3121	530	3	term	term	NOUN
dpc-3121	530	4	safety	safety	NOUN
dpc-3121	530	5	of	of	ADP
dpc-3121	530	6	crisaborole	crisaborole	ADJ
dpc-3121	530	7	ointment	ointment	NOUN
dpc-3121	530	8	2	2	NUM
dpc-3121	530	9	%	%	NOUN
dpc-3121	530	10	in	in	ADP
dpc-3121	530	11	children	child	NOUN
dpc-3121	530	12	and	and	CCONJ
dpc-3121	530	13	adults	adult	NOUN
dpc-3121	530	14	with	with	ADP
dpc-3121	530	15	mild	mild	ADJ
dpc-3121	530	16	to	to	ADP
dpc-3121	530	17	moderate	moderate	ADJ
dpc-3121	530	18	atopic	atopic	NOUN
dpc-3121	530	19	dermatitis	dermatitis	NOUN
dpc-3121	530	20	.	.	PUNCT
dpc-3121	531	1	j	j	PROPN
dpc-3121	531	2	am	be	AUX
dpc-3121	531	3	acad	acad	ADJ
dpc-3121	531	4	dermatol	dermatol	NOUN
dpc-3121	531	5	.	.	PUNCT
dpc-3121	532	1	2017;77(4):641	2017;77(4):641	NUM
dpc-3121	532	2	-	-	SYM
dpc-3121	532	3	649	649	NUM
dpc-3121	532	4	.	.	PUNCT
dpc-3121	533	1	e5	e5	PROPN
dpc-3121	533	2	.	.	PUNCT
dpc-3121	534	1	doi:10.1016	doi:10.1016	PROPN
dpc-3121	534	2	/	/	SYM
dpc-3121	534	3	j.jaad.2017.06.010	j.jaad.2017.06.010	PROPN
dpc-3121	534	4	.	.	PUNCT
dpc-3121	535	1	pmid	pmid	NOUN
dpc-3121	535	2	:	:	PUNCT
dpc-3121	535	3	28823881	28823881	NUM
dpc-3121	535	4	.	.	PUNCT
dpc-3121	536	1	63	63	NUM
dpc-3121	536	2	.	.	PUNCT
dpc-3121	537	1	eichenfield	eichenfield	PROPN
dpc-3121	537	2	lf	lf	PROPN
dpc-3121	537	3	,	,	PUNCT
dpc-3121	537	4	yosipovitch	yosipovitch	VERB
dpc-3121	537	5	g	g	PROPN
dpc-3121	537	6	,	,	PUNCT
dpc-3121	537	7	stein	stein	PROPN
dpc-3121	537	8	gold	gold	PROPN
dpc-3121	537	9	lf	lf	PROPN
dpc-3121	537	10	,	,	PUNCT
dpc-3121	537	11	et	et	PROPN
dpc-3121	537	12	al	al	PROPN
dpc-3121	537	13	.	.	PUNCT
dpc-3121	537	14	improvement	improvement	NOUN
dpc-3121	537	15	in	in	ADP
dpc-3121	537	16	disease	disease	NOUN
dpc-3121	537	17	severity	severity	NOUN
dpc-3121	537	18	and	and	CCONJ
dpc-3121	537	19	pruritus	pruritus	ADJ
dpc-3121	537	20	outcomes	outcome	NOUN
dpc-3121	537	21	with	with	ADP
dpc-3121	537	22	crisaborole	crisaborole	PROPN
dpc-3121	537	23	ointment	ointment	NOUN
dpc-3121	537	24	,	,	PUNCT
dpc-3121	537	25	2	2	NUM
dpc-3121	537	26	%	%	NOUN
dpc-3121	537	27	,	,	PUNCT
dpc-3121	537	28	by	by	ADP
dpc-3121	537	29	baseline	baseline	ADJ
dpc-3121	537	30	atopic	atopic	NOUN
dpc-3121	537	31	dermatitis	dermatitis	NOUN
dpc-3121	537	32	severity	severity	NOUN
dpc-3121	537	33	in	in	ADP
dpc-3121	537	34	children	child	NOUN
dpc-3121	537	35	and	and	CCONJ
dpc-3121	537	36	adolescents	adolescent	NOUN
dpc-3121	537	37	with	with	ADP
dpc-3121	537	38	mild	mild	ADJ
dpc-3121	537	39	-	-	PUNCT
dpc-3121	537	40	to	to	ADP
dpc-3121	537	41	-	-	PUNCT
dpc-3121	537	42	moderate	moderate	ADJ
dpc-3121	537	43	atopic	atopic	NOUN
dpc-3121	537	44	dermatitis	dermatitis	NOUN
dpc-3121	537	45	.	.	PUNCT
dpc-3121	538	1	pediatr	pediatr	ADJ
dpc-3121	538	2	dermatol	dermatol	NOUN
dpc-3121	538	3	.	.	PUNCT
dpc-3121	539	1	2020;37(6):1030	2020;37(6):1030	NUM
dpc-3121	539	2	-	-	SYM
dpc-3121	539	3	1037	1037	NUM
dpc-3121	539	4	.	.	PUNCT
dpc-3121	540	1	doi:10.1111	doi:10.1111	NOUN
dpc-3121	540	2	/	/	SYM
dpc-3121	540	3	pde.14328	pde.14328	NOUN
dpc-3121	540	4	.	.	PUNCT
dpc-3121	541	1	pmid	pmid	NOUN
dpc-3121	541	2	:	:	PUNCT
dpc-3121	541	3	28823881	28823881	NUM
dpc-3121	541	4	.	.	PUNCT
dpc-3121	542	1	64	64	NUM
dpc-3121	542	2	.	.	PUNCT
dpc-3121	543	1	fujita	fujita	PROPN
dpc-3121	543	2	k	k	PROPN
dpc-3121	543	3	,	,	PUNCT
dpc-3121	543	4	yagi	yagi	PROPN
dpc-3121	543	5	m	m	PROPN
dpc-3121	543	6	,	,	PUNCT
dpc-3121	543	7	moriwaki	moriwaki	PROPN
dpc-3121	543	8	s	s	PROPN
dpc-3121	543	9	,	,	PUNCT
dpc-3121	543	10	yoshida	yoshida	PROPN
dpc-3121	543	11	m	m	PROPN
dpc-3121	543	12	,	,	PUNCT
dpc-3121	543	13	graham	graham	PROPN
dpc-3121	543	14	d.	d.	PROPN
dpc-3121	543	15	a	a	DET
dpc-3121	543	16	phase	phase	NOUN
dpc-3121	543	17	2b	2b	NOUN
dpc-3121	543	18	,	,	PUNCT
dpc-3121	543	19	randomized	randomize	VERB
dpc-3121	543	20	,	,	PUNCT
dpc-3121	543	21	double	double	ADJ
dpc-3121	543	22	-	-	PUNCT
dpc-3121	543	23	blind	blind	ADJ
dpc-3121	543	24	,	,	PUNCT
dpc-3121	543	25	multicenter	multicenter	NOUN
dpc-3121	543	26	,	,	PUNCT
dpc-3121	543	27	vehicle	vehicle	NOUN
dpc-3121	543	28	-	-	PUNCT
dpc-3121	543	29	controlled	control	VERB
dpc-3121	543	30	study	study	NOUN
dpc-3121	543	31	to	to	PART
dpc-3121	543	32	assess	assess	VERB
dpc-3121	543	33	the	the	DET
dpc-3121	543	34	efficacy	efficacy	NOUN
dpc-3121	543	35	and	and	CCONJ
dpc-3121	543	36	safety	safety	NOUN
dpc-3121	543	37	of	of	ADP
dpc-3121	543	38	two	two	NUM
dpc-3121	543	39	crisaborole	crisaborole	NOUN
dpc-3121	543	40	regimens	regimen	NOUN
dpc-3121	543	41	in	in	ADP
dpc-3121	543	42	japanese	japanese	ADJ
dpc-3121	543	43	patients	patient	NOUN
dpc-3121	543	44	aged	age	VERB
dpc-3121	543	45	2	2	NUM
dpc-3121	543	46	 	 	SPACE
dpc-3121	543	47	years	year	NOUN
dpc-3121	543	48	and	and	CCONJ
dpc-3121	543	49	older	old	ADJ
dpc-3121	543	50	with	with	ADP
dpc-3121	543	51	mild	mild	ADJ
dpc-3121	543	52	-	-	PUNCT
dpc-3121	543	53	to	to	ADP
dpc-3121	543	54	-	-	PUNCT
dpc-3121	543	55	moderate	moderate	ADJ
dpc-3121	543	56	atopic	atopic	NOUN
dpc-3121	543	57	dermatitis	dermatitis	NOUN
dpc-3121	543	58	.	.	PUNCT
dpc-3121	544	1	j	j	PROPN
dpc-3121	544	2	dermatol	dermatol	NOUN
dpc-3121	544	3	.	.	PUNCT
dpc-3121	545	1	2021;48(11):1640	2021;48(11):1640	NUM
dpc-3121	545	2	-	-	SYM
dpc-3121	545	3	1651	1651	NUM
dpc-3121	545	4	.	.	PUNCT
dpc-3121	546	1	doi:10.1111/1346	doi:10.1111/1346	NOUN
dpc-3121	546	2	-	-	PUNCT
dpc-3121	546	3	8138.16120	8138.16120	NUM
dpc-3121	546	4	.	.	PUNCT
dpc-3121	547	1	pmid	pmid	NOUN
dpc-3121	547	2	:	:	PUNCT
dpc-3121	547	3	34435694	34435694	NUM
dpc-3121	547	4	.	.	PUNCT
dpc-3121	548	1	pmcid	pmcid	NOUN
dpc-3121	548	2	:	:	PUNCT
dpc-3121	548	3	pmc9292399	pmc9292399	NOUN
dpc-3121	548	4	.	.	PUNCT
dpc-3121	549	1	65	65	NUM
dpc-3121	549	2	.	.	PUNCT
dpc-3121	550	1	schlessinger	schlessinger	PROPN
dpc-3121	550	2	j	j	PROPN
dpc-3121	550	3	,	,	PUNCT
dpc-3121	550	4	shepard	shepard	NOUN
dpc-3121	550	5	js	js	PROPN
dpc-3121	550	6	,	,	PUNCT
dpc-3121	550	7	gower	gower	PROPN
dpc-3121	550	8	r	r	PROPN
dpc-3121	550	9	,	,	PUNCT
dpc-3121	550	10	et	et	PROPN
dpc-3121	550	11	al	al	PROPN
dpc-3121	550	12	.	.	PROPN
dpc-3121	550	13	safety	safety	PROPN
dpc-3121	550	14	,	,	PUNCT
dpc-3121	550	15	effectiveness	effectiveness	NOUN
dpc-3121	550	16	,	,	PUNCT
dpc-3121	550	17	and	and	CCONJ
dpc-3121	550	18	pharmacokinetics	pharmacokinetic	NOUN
dpc-3121	550	19	of	of	ADP
dpc-3121	550	20	crisaborole	crisaborole	NOUN
dpc-3121	550	21	in	in	ADP
dpc-3121	550	22	infants	infant	NOUN
dpc-3121	550	23	aged	age	VERB